

Structure search in REGISTRY (crossover to CAPLUS, TOXCENTER, USPATFULL, USRATZ, CASREACT, BIOSIS, CAOLD)

Truong 10 088814

10/18/2005

Note: if the authors are present in non-CAPLUS records, they are included here, so long as there is a structure hit. (i.e. they are not included in the author search)

=> file registry

FILE 'REGISTRY' ENTERED AT 09:57:32 ON 18 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 OCT 2005 HIGHEST RN 865410-76-0

DICTIONARY FILE UPDATES: 17 OCT 2005 HIGHEST RN 865410-76-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> file caplus

FILE 'CAPLUS' ENTERED AT 09:57:34 ON 18 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 18 Oct 2005 VOL 143 ISS 17

FILE LAST UPDATED: 17 Oct 2005 (20051017/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L1	STR
----	-----



Page 1-A



NODE ATTRIBUTES:


HCOUNT IS M1 AT 14
HCOUNT IS M1 AT 18
HCOUNT IS M1 AT 19
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3
NSPEC IS R AT 4
NSPEC IS R AT 5
NSPEC IS R AT 6
NSPEC IS R AT 7
NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS R AT 10
NSPEC IS C AT 11
NSPEC IS C AT 12
NSPEC IS C AT 13
NSPEC IS C AT 14
NSPEC IS C AT 15
NSPEC IS C AT 16
NSPEC IS C AT 17
NSPEC IS C AT 18
NSPEC IS C AT 19
NSPEC IS RC AT 20
NSPEC IS C AT 21
NSPEC IS RC AT 22
NSPEC IS C AT 23
NSPEC IS C AT 24
NSPEC IS C AT 25
NSPEC IS C AT 26
NSPEC IS C AT 27
CONNECT IS E2 RC AT 8
CONNECT IS E2 RC AT 10
CONNECT IS E1 RC AT 21
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 12 13 14 15 16 18 19 20 21 22 23 24 25 26
GGCAT IS MCY LOC UNS AT 17
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E6 C AT 17

GRAPH ATTRIBUTES:



RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE

L2 5754 SEA FILE=REGISTRY SSS FUL L1
L4 STR



Page 1-A



Page 2-A

VAR G1=11/13

VPA 23-17/19/20/21/22 U

NODE ATTRIBUTES:

NSPEC	IS	R	AT	1
NSPEC	IS	R	AT	2
NSPEC	IS	R	AT	3
NSPEC	IS	R	AT	4
NSPEC	IS	R	AT	5

NSPEC IS R AT 6
NSPEC IS RC AT 7
NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS R AT 10
NSPEC IS RC AT 11
NSPEC IS C AT 12
NSPEC IS RC AT 13
NSPEC IS RC AT 14
NSPEC IS RC AT 15
NSPEC IS RC AT 16
NSPEC IS R AT 17
NSPEC IS RC AT 18
NSPEC IS R AT 19
NSPEC IS R AT 20
NSPEC IS R AT 21
NSPEC IS R AT 22
NSPEC IS RC AT 23
NSPEC IS RC AT 24
CONNECT IS E2 RC AT 8
CONNECT IS E2 RC AT 10
CONNECT IS E1 RC AT 12
CONNECT IS E2 RC AT 16
CONNECT IS E2 RC AT 23
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 11 12 13 14 15 16 23
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

L6 716 SEA FILE=REGISTRY SUB=L2 SSS FUL L4
L7 19 SEA FILE=CAPLUS ABB=ON PLU=ON L6
L8 296 SEA FILE=CAPLUS ABB=ON PLU=ON KEEN N?/AU
L9 66 SEA FILE=CAPLUS ABB=ON PLU=ON MORTLOCK A?/AU
L10 391 SEA FILE=CAPLUS ABB=ON PLU=ON JUNG F?/AU
L11 74 SEA FILE=CAPLUS ABB=ON PLU=ON BREWSTER A?/AU
L13 14 SEA FILE=CAPLUS ABB=ON PLU=ON (L8 AND (L9 OR L10 OR L11)) OR
(L9 AND (L10 OR L11)) OR (L10 AND L11)
L14 16 SEA FILE=CAPLUS ABB=ON PLU=ON L7 NOT (L13)

*author search
results (previously
printed)*

=> file toxcenter uspatall casreact biosis caold
FILE 'TOXCENTER' ENTERED AT 09:58:40 ON 18 OCT 2005
COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 09:58:40 ON 18 OCT 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:58:40 ON 18 OCT 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CASREACT' ENTERED AT 09:58:40 ON 18 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:58:40 ON 18 OCT 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'CAOLD' ENTERED AT 09:58:40 ON 18 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

```
=> d stat que nos L16
L1          STR
L2          5754 SEA FILE=REGISTRY SSS FUL L1
L4          STR
L6          716 SEA FILE=REGISTRY SUB=L2 SSS FUL L4
L16         30 SEA L6
```

```
=> dup rem L14 L16
DUPLICATE IS NOT AVAILABLE IN 'CAOLD'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
FILE 'CAPLUS' ENTERED AT 10:02:26 ON 18 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE 'TOXCENTER' ENTERED AT 10:02:26 ON 18 OCT 2005
COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 10:02:26 ON 18 OCT 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:02:26 ON 18 OCT 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CASREACT' ENTERED AT 10:02:26 ON 18 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:02:26 ON 18 OCT 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'CAOLD' ENTERED AT 10:02:26 ON 18 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L14
PROCESSING COMPLETED FOR L16

```
L21          30 DUP REM L14 L16 (16 DUPLICATES REMOVED)
              ANSWERS '1-16' FROM FILE CAPLUS
              ANSWERS '17-20' FROM FILE TOXCENTER
              ANSWERS '21-25' FROM FILE USPATFULL
              ANSWERS '26-29' FROM FILE BIOSIS
              ANSWER '30' FROM FILE CAOLD
```

30 answers

```
=> file stnguide
FILE 'STNGUIDE' ENTERED AT 10:02:46 ON 18 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE
```

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Oct 14, 2005 (20051014/UP).

=> d ibib abs hitstr L21 1-16; d iall L21 17-20; d ibib abs hitstr L21 21-25; d
iall 26-30
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, TOXCENTER, USPATFULL, BIOSIS, CAOLD' -
CONTINUE? (Y)/N:y

L21 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2005:902689 CAPLUS
DOCUMENT NUMBER: 143:222463
TITLE: Compounds that inhibit HIV particle formation and Rev
protein-dependent HIV production and screening methods
INVENTOR(S): Rekosh, David; Hammarskjold, Marie-Louis
PATENT ASSIGNEE(S): University of Virginia Patent Foundation, USA
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005076861	A2	20050825	WO 2005-US3165	20050201
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


PRIORITY APPLN. INFO.:
US 2004-541632P P 20040204
US 2004-569354P P 20040507
US 2004-574909P P 20040527
US 2004-583173P P 20040625

AB The present invention describes novel methods of identifying compds. which inhibit HIV particle formation and Rev-dependent HIV production. The present invention also provides methods and compds. for inhibiting HIV particle formation and/or treating patients infected with HIV. Two cell lines were derived from COS cells to determine anti-Rev activity, Rev-dependent 5BD.1 cells and Rev-independent 2A.22 cells. These cell lines constitutively expressed HIV-like particles that contain the HIV core proteins as well as HIV envelope protein. The non-infectious virions created by these cells are secreted into the media, where a simple p24 ELISA can quant. determine virion production. Approx. 40,000 compds. were screened and 192 compds. were identified. The identified compds. were subjected to dose response assays and toxicity assays and 8 compds. were chosen. The eight chosen compds. were tested in a dual luciferase assay for specific inhibition of HIV-1 Rev.

IT 457932-89-7

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lead compound analog, assay of; compds. that inhibit HIV particle

formation and Rev protein-dependent HIV production and screening methods)
 RN 457932-89-7 CAPLUS
 CN Acetamide, N-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



L21 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 2005:29195 CAPLUS
 DOCUMENT NUMBER: 142:127561
 TITLE: Use of aurora kinase inhibitors for reducing the resistance of cancer cells to mitotic spindle assembly inhibitors
 INVENTOR(S): Anand, Shubha; Venkitaraman, Ashok
 PATENT ASSIGNEE(S): Cambridge University Technical Services Ltd., UK
 SOURCE: PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002571	A1	20050113	WO 2003-GB2862	20030703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: WO 2003-GB2862 20030703
 AB The invention discloses the use of anticancer agents that inhibit mitotic spindle assembly in target cells, including taxanes such as paclitaxel, and in particular to methods and means for predicting and/or reducing the resistance of cancer cells to such agents. Over-expression of aurora kinases, such as Aurora A, mediates resistance to such anti-cancer agents and the resistance of a cancer cell may be reduced by inhibiting aurora kinases and/or predicted by measuring the expression or activity of aurora kinases within the cell.

IT 331771-20-1 823807-50-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)(aurora kinase inhibitors for reducing resistance of cancer cells to
mitotic spindle assembly inhibitors)

RN 331771-20-1 CAPLUS

CN Benzenamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-
quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


RN 823807-50-7 CAPLUS

CN Benzenepropanoic acid, β -(benzoylamino)- α -hydroxy-,
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12-bis(acetyloxy)-12-(benzoyloxy)-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
ester, (α R, β S)-, mixt. with N-[4-[[6-methoxy-7-[3-(4-
morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]benzamide (9CI) (CA
INDEX NAME)

CM 1

CRN 331771-20-1

CMF C29 H31 N5 O4




CM 2

CRN 33069-62-4

CMF C47 H51 N O14

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2005:614536 CAPLUS

DOCUMENT NUMBER: 143:115392

TITLE: Preparation of conjugated small molecules for diagnostic and therapeutic use

INVENTOR(S): Grotzfeld, Robert M.; Milanov, Zdravko V.; Patel, Hitesh K.; Lai, Andiliy G.; Mehta, Shamal A.; Lockhart, David J.

PATENT ASSIGNEE(S): Ambit Biosciences Corp., USA

SOURCE: U.S. Pat. Appl. Publ., 63 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005153371	A1	20050714	US 2005-31638	20050107
WO 2005067644	A2	20050728	WO 2005-US456	20050107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2004-535173P P 20040107

GI



AB Provided herein are linker compds. and conjugates that include the linker compds. In one embodiment, the linker compds. comprise 2 or 3 residues of 6-aminohexanoic acid and optionally 7-10 residues of polyethyleneglycol (PEG). The linker compds. are useful in forming conjugates with one or more components useful in biopharmaceutical or bioanal. applications. In particular, the biopharmaceutically useful compds. are kinase inhibitors. The conjugates described herein have utility in a variety of diagnostic, separation, and therapeutic applications. Thus, I was prepared from SB 202190, PEG-azide and the biotin-linker compound

IT 857892-01-4P

RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of conjugated biotins for diagnostic and therapeutic use)

RN 857892-01-4 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[42-[4-[[[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]amino]carbonyl]phenyl]-6,13-dioxo-17,20,23,26,29,32,35,38-octaoxa-7,14,41-triazadotetracont-1-yl]-2-oxo-, (3aS,4S,6aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CNCCc1ccc(cc1)C(=O)Nc2ccc(cc2)Nc3cc(OC)c(OCCCCN4CCOCC4)cc3n5ccncc5

The diagram shows a single polymer chain with four repeating units. Each unit consists of a zigzag line segment representing a hydrocarbon chain, with an oxygen atom (O) at the vertex where the chain continues. The units are connected in a linear fashion, forming a continuous zigzag backbone.

PAGE 3-A



PAGE 3-B



PAGE 4-A



L21 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4
 ACCESSION NUMBER: 2005:220855 CAPLUS
 DOCUMENT NUMBER: 143:301206
 TITLE: Aurora kinase inhibitor ZM447439 blocks
 chromosome-induced spindle assembly, the completion of
 chromosome condensation, and the establishment of the
 spindle integrity checkpoint in Xenopus egg extracts

AUTHOR(S): Gadea, Bedrick B.; Ruderman, Joan V.
 CORPORATE SOURCE: Department of Cell Biology, Harvard Medical School,
 Boston, MA, 02115, USA
 SOURCE: Molecular Biology of the Cell (2005), 16(3), 1305-1318
 CODEN: MBCEEV; ISSN: 1059-1524
 PUBLISHER: American Society for Cell Biology
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB The Aurora family kinases contribute to accurate progression through several mitotic events. ZM447439 ("ZM"), the first Aurora family kinase inhibitor to be developed and characterized, was previously found to interfere with the mitotic spindle integrity checkpoint and chromosome segregation. Here, we have used exts. of *Xenopus* eggs, which normally proceed through the early embryonic cell cycles in the absence of functional checkpoints, to distinguish between ZM's effects on the basic cell cycle machinery and its effects on checkpoints. ZM clearly had no effect on either the kinetics or amplitude in the oscillations of activity of several key cell cycle regulators. It did, however, have striking effects on chromosome morphol. In the presence of ZM, chromosome condensation began on schedule but then failed to progress properly; instead, the chromosomes underwent premature decondensation during mid-mitosis. ZM strongly interfered with mitotic spindle assembly by inhibiting the formation of microtubules that are nucleated/stabilized by chromatin. By contrast, ZM had little effect on the assembly of microtubules by centrosomes at the spindle poles. Finally, under conditions where the spindle integrity checkpoint was exptl. induced, ZM blocked the establishment, but not the maintenance, of the checkpoint, at a point upstream of the checkpoint protein Mad2. These results show that Aurora kinase activity is required to ensure the maintenance of condensed chromosomes, the generation of chromosome-induced spindle microtubules, and activation of the spindle integrity checkpoint.

IT 331771-20-1, ZM447439

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of spindle integrity checkpoint in *Xenopus* egg exts.)

RN 331771-20-1 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 2004:1059178 CAPLUS
DOCUMENT NUMBER: 142:38270
TITLE: A preparation of macrocyclic quinazoline derivatives,
useful as antiproliferative agents
INVENTOR(S): Freyne, Eddy Jean Edgard; Perera, Timothy Pietro
Suren; Buijnsters, Peter Jacobus Johannes Antonius;
Willems, Marc; Diels, Gaston Stanislas Marcella;
Embrechts, Werner Constant Johan; Ten Holte, Peter
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 196 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004105765	A1	20041209	WO 2004-EP5621	20040525
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: WO 2003-EP5723 A 20030527
WO 2003-EP10266 A 20030915
WO 2003-EP51061 A 20031218


OTHER SOURCE(S): MARPAT 142:38270
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to a preparation of macrocyclic derivs. of formula I [wherein: Z is O, CH₂, NH, or S; Y is alk(en/yn)yl, alkyl-C(O)NH, C(O)alkyl, or C(O)NH-alkyl, etc.; X1 and X2 are independently selected from a direct bond, O, O-alkyl, CH₂, or ON:CH, etc.; R1 is H, CN, halogen, OH, CHO, or alkyl, etc.; R2 is H, CN, OH, alkylcarbonyl, or aminocarbonyl, etc.; R3 is H or alkyl; R4 is H, OH, aryloxy, alkoxy, or alkenyloxy, etc.], useful as antiproliferative agents. For instance, pyrimidobenzodioxazacyclopentadecine derivative II [kinase activity: pIC₅₀ = 7.8, A431 cell (C5): pIC₅₀ < 6] was prepared via intramol. heterocyclization/etherification of the prepared quinazoline derivative III.

IT 807640-31-9P 807640-32-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of macrocyclic quinazoline derivs. useful as antiproliferative agents)

RN 807640-31-9 CAPLUS
 CN Benzamide, N-[3-[[6-(acetyloxy)hexyl]oxy]-4-[[6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 807640-32-0 CAPLUS
 CN Benzamide, 4-fluoro-N-[3-[(6-hydroxyhexyl)oxy]-4-[(6-hydroxy-7-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 6
ACCESSION NUMBER: 2004:182368 CAPLUS
DOCUMENT NUMBER: 140:229401
TITLE: Three hybrid assay system for isolating ligand-binding
polypeptides and for isolating small mol. ligands
INVENTOR(S): Come, Jon H.; Becker, Frank; Kley, Nikolai A.;
Reichel, Christoph
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S.
Ser. No. 91,177.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2004043388	A1	20040304	US 2002-234985	20020903
US 2003165873	A1	20030904	US 2002-91177	20020304
US 2004266854	A1	20041230	US 2004-820453	20040407
PRIORITY APPLN. INFO.:			US 2001-272932P	P 20010302
			US 2001-278233P	P 20010323
			US 2001-329437P	P 20011015
			US 2002-91177	A2 20020304
			US 2001-336962P	P 20011203
			WO 2002-US6677	A2 20020304
			US 2002-234985	A2 20020903
			WO 2002-US33052	A2 20021015
			US 2003-460921P	P 20030407
			US 2003-531872P	P 20031223
AB	The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g a methotrexate moiety linked by a polyethylene glycol moiety to dexamethasone, is described.			
IT	666837-95-2D, conjugates RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)			
RN	666837-95-2 CAPLUS			
CN	Benzamide, 3-(dimethylamino)-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]- (9CI) (CA INDEX NAME)			



L21 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 2004:791974 CAPLUS

DOCUMENT NUMBER: 141:342890

TITLE: Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase

AUTHOR(S): Cumming, John G.; McKenzie, Caroline L.; Bowden, Stuart G.; Campbell, Douglas; Masters, David J.; Breed, Jason; Jewsbury, Philip J.

CORPORATE SOURCE: Mereside, Alderley Park, AstraZeneca, Macclesfield, Cheshire, SK10 4TG, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(21), 5389-5394

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:342890

AB SAR studies led to the identification of 4-(3-benzoylamino-6-methyl-anilino)quinazolines as potent and selective inhibitors of p38 MAP kinase. Further optimization led to the identification of a series of 4-(3-benzoylamino-6-methyl-anilino)pyrimidines as potent inhibitors of the p38 MAP kinase signalling pathway in vitro and in vivo.

IT 153437-75-3P 263400-21-1P 263400-23-3P

263400-28-8P 263400-29-9P 263400-30-2P

721881-54-5P 742684-90-8P 743409-28-1P

748120-10-7P 750558-62-4P 774597-59-0P

774597-60-3P 774597-61-4P 774597-62-5P


774597-63-6P 774597-64-7P 774597-65-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase: preparation and SAR)


RN 153437-75-3 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 263400-21-1 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)ethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-23-3 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-[bis(1-methylethyl)amino]ethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-28-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-29-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-piperidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-30-2 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 721881-54-5 CAPLUS

CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2,4-difluorophenyl]- (9CI) (CA INDEX NAME)




RN 742684-90-8 CAPLUS

CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenyl]-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 743409-28-1 CAPLUS

CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 748120-10-7 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 750558-62-4 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-(9CI) (CA INDEX NAME)




RN 774597-59-0 CAPLUS

CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-(9CI) (CA INDEX NAME)




RN 774597-60-3 CAPLUS

CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-(9CI) (CA INDEX NAME)




RN 774597-61-4 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl] -
(9CI) (CA INDEX NAME)



RN 774597-62-5 CAPLUS


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl] -
(9CI) (CA INDEX NAME)



RN 774597-63-6 CAPLUS


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl] -3-

(dimethylamino)- (9CI) (CA INDEX NAME)




RN 774597-64-7 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 774597-65-8 CAPLUS

CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



IT 687995-79-5


RL: RCT (Reactant); RACT (Reactant or reagent)

(anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase:

preparation and SAR)

RN 687995-79-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 8

ACCESSION NUMBER: 2003:590835 CAPLUS

DOCUMENT NUMBER: 139:149651

TITLE: Preparation of 4-phenylaminoquinazoline derivatives as fructose 1,6-bisphosphatase inhibitors

INVENTOR(S): Bauer, Paul H.; Wright, Stephen W.; Schnur, Rodney C.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 23 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003144308	A1	20030731	US 2002-251073	20020920
PRIORITY APPLN. INFO.:			US 2001-324751P	P 20010924
OTHER SOURCE(S):	MARPAT	139:149651		

GI



I

AB The present invention relates to certain quinazoline compds. (I), prodrugs thereof, or pharmaceutically acceptable salts of said compds. or said prodrugs, [wherein Q = pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, furyl, quinolyl, imidazolyl, pyridyl pyrimidyl; T1 = H, Me, Et, OR10, SR10, cyano, cyclopropyl, cyclobutyl, NH2, NHR10, N(R10)2, NHH2, CHR10OH, CH2R10, COCH3, CON(R10)2; R1, R2, R3, R4 = H, halo, trifluoromethyl, C1-4 alkyl, C1-4 alkoxy; R5, R8 = H, F, Cl, HO, Me; R6, R7 = C1-4 alkyl, C1-4 alkoxy; R9 = H, cyclopropyl, cyclobutyl, C1-4 alkyl, (CH2)m-Y; R10 = H, Me, Et; m = 1, 2, 3, or 4; Y = F, Cl, Br, HO, N(R11)2, N-methylpiperazin-1-yl, thiazolidin-3-yl, thiomorpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, imidazol-1-yl, C1-4 alkoxy, SR11, SOR11, SO2R11, CO2H, CO2(C1-C4)alkyl or CON(R11)2; R11 = H, C1-4 alkyl] which are fructose 1,6-bisphosphatase inhibitors (no data) and have utility in the treatment of diabetes mellitus, hypercholesterolemia, hyperlipidemia, diabetic complications, and cancer. The invention also relates to pharmaceutical compns. and kits comprising such quinazoline compds. I and to methods of using such compds. in the treatment of diabetes mellitus, hypercholesterolemia, hyperlipidemia, diabetic complications, and cancer. Thus, a solution of 0.157 g (0.62 mmol) of 4-chloro-6,7-diethoxyquinazoline in 2.5 mL of ethanol was heated at reflux, treated with 0.136 g (0.62 mmol) of 4-(3-aminophenyl)thiazole-2-carboxylic acid amide dissolved in 4 mL of ethanol added in a single portion, and heated at reflux for 30 min, after which the reaction mixture was allowed to cool and the precipitated product was filtered, washed with ethanol, and dried to afford 0.152 g (56 %) of 4-[3-(6,7-diethoxyquinazolin-4-ylamino)phenyl]thiazole-2-carboxylic acid amide hydrochloride.


IT **570431-19-5P**, [3-[[6-Ethoxy-7-isopropoxy-2-(methoxymethyl)quinazolin-4-yl]amino]phenyl]thiazole-2-carboxylic acid amide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylaminoquinazoline derivs. as fructose bisphosphatase inhibitors for treatment of diabetes mellitus, hypercholesterolemia, hyperlipidemia, diabetic complications and cancer)

RN 570431-19-5 CAPLUS

CN 2-Thiazolecarboxamide, N-[3-[[6-ethoxy-2-(methoxymethyl)-7-(1-methylethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1998:105843 CAPLUS
 DOCUMENT NUMBER: 128:136497
 TITLE: Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
 INVENTOR(S): Myers, Michael R.; Spada, Alfred P.; Maguire, Martin P.; Persons, Paul E.
 PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
 SOURCE: U.S., 19 pp., Cont.-in-part of U.S. 5,480,883.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5710158	A	19980120	US 1994-229886	19940419
US 5480883	A	19960102	US 1993-166199	19931210
WO 9515758	A1	19950615	WO 1994-US14180	19941208
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9513050	A1	19950627	AU 1995-13050	19941208
EP 871448	A1	19981021	EP 1995-904308	19941208
EP 871448	B1	20050302		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
EP 1488792	A2	20041222	EP 2004-19772	19941208
EP 1488792	A3	20050105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 289814	E	20050315	AT 1995-904308	19941208
PT 871448	T	20050531	PT 1995-904308	19941208
ES 2236701	T3	20050716	ES 1995-904308	19941208
US 5656643	A	19970812	US 1995-385258	19950208
US 6645969	B1	20031111	US 1995-521852	19950518
US 5714493	A	19980203	US 1996-652444	19960604
US 37650	E	20020409	US 2000-496399	20000202
US 2004014774	A1	20040122	US 2003-617342	20030710
PRIORITY APPLN. INFO.:				
			US 1991-698420	B2 19910510
			US 1992-988515	B2 19921210
			US 1993-166199	A2 19931210
			WO 1992-US3736	A2 19920506
			US 1993-146072	A3 19931108
			US 1994-229886	A 19940419
			EP 1995-904308	A3 19941208
			WO 1994-US14180	W 19941208
			US 1995-521852	A3 19950518
			US 1996-652444	A5 19960604

OTHER SOURCE(S): MARPAT 128:136497

AB This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compds. in inhibiting cell proliferation, including compds. which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation using said quinazoline compds. and their use in pharmaceutical compns. is described. A number of compds. were tested for

inhibition of PDGF receptor cell-free antophosphorylation procedure.


IT 202475-66-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(aryl and heteroaryl quinazoline compds. which inhibit EGF and/or PDGF receptor tyrosine kinase)

RN 202475-66-9 CAPLUS

CN Acetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 12

ACCESSION NUMBER: 1996:483485 CAPLUS

DOCUMENT NUMBER: 125:142741

TITLE: Preparation of N-phenyl-4-quinazolinamines for the treatment of proliferative diseases

INVENTOR(S): Brown, Dearg Sutherland; Morris, Jeffrey James; Thomas, Andrew Peter

PATENT ASSIGNEE(S): Zeneca Limited, UK

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9615118	A1	19960523	WO 1995-GB2606	19951108
W:	AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2200871	AA	19960523	CA 1995-2200871	19951108
AU 9538130	A1	19960606	AU 1995-38130	19951108
AU 703328	B2	19990325		
EP 790986	A1	19970827	EP 1995-936044	19951108

EP 790986	B1	19990120		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10508616	T2	19980825	JP 1995-515816	19951108
AT 175962	E	19990215	AT 1995-936044	19951108
ES 2128092	T3	19990501	ES 1995-936044	19951108
ZA 9509572	A	19960513	ZA 1995-9572	19951110
IL 115959	A1	20040620	IL 1995-115959	19951112
FI 9701970	A	19970507	FI 1997-1970	19970507
NO 9702152	A	19970512	NO 1997-2152	19970509
NO 307178	B1	20000221		
US 5821246	A	19981013	US 1997-836362	19970521
PRIORITY APPLN. INFO.:			GB 1994-22866	A 19941112
			GB 1995-7308	A 19950407
			WO 1995-GB2606	W 19951108
OTHER SOURCE(S):		MARPAT 125:142741		
GI				




Proton 30 out

AB The title compds. I (m = 1-3; R1 = halo, hydroxy, amino, ureido, etc.; n = 0-3; R2 = halo, trifluoromethyl, hydroxy, amino, nitri, cyano, alkyl; X = carbonyl, methine, O,S, etc.) were disclosed. I were claimed for the use as receptor tyrosine kinase inhibitors and for treatment of proliferative disease such as cancer. An example compound is the chlorophenyl [(quinazolinyl)aminolphenyl] methanone II.

IT **179687-48-0P**
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-phenylquinazolinamines as tyrosine kinase inhibitors)

RN 179687-48-0 CAPLUS

CN Benzenesulfonamide, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)aminolphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L21 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 13
 ACCESSION NUMBER: 1994:217715 CAPLUS
 DOCUMENT NUMBER: 120:217715
 TITLE: Quinazoline tyrosine kinase-inhibiting anticancer agents
 INVENTOR(S): Barker, Andrew J.
 PATENT ASSIGNEE(S): Zeneca Ltd., UK
 SOURCE: Can. Pat. Appl., 99 pp.
 CODEN: CPXXEB
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2086968	AA	19930721	CA 1993-2086968	19930108
CA 2086968	C	19980623		
ZA 9300015	A	19930720	ZA 1993-15	19930104
AU 9331010	A1	19930722	AU 1993-31010	19930104
AU 661533	B2	19950727		
HU 63153	A2	19930728	HU 1993-94	19930115
EP 566226	A1	19931020	EP 1993-300270	19930115
EP 566226	B1	19951108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 130000	E	19951115	AT 1993-300270	19930115
ES 2078798	T3	19951216	ES 1993-300270	19930115
CZ 282038	B6	19970416	CZ 1993-43	19930118
NO 9300178	A	19930721	NO 1993-178	19930119
NO 301541	B1	19971110		
RU 2127263	C1	19990310	RU 1993-4423	19930119
SK 281551	B6	20010510	SK 1993-16	19930119
FI 111631	B1	20030829	FI 1993-208	19930119
KR 229294	B1	19991101	KR 1993-645	19930120
IL 104479	A1	19991222	IL 1993-104479	19930121
JP 06073025	A2	19940315	JP 1993-26577	19930216
JP 2994165	B2	19991227		

US 5457105	A	19951010	US 1994-284293	19940802
US 5616582	A	19970401	US 1995-490666	19950615
PRIORITY APPLN. INFO.:			GB 1992-1095	A 19920120
			GB 1992-13572	A 19920626
			GB 1992-23735	A 19921112
			US 1993-5280	B1 19930119
			US 1994-284293	A1 19940802

OTHER SOURCE(S) : MARPAT 120:217715
GI




AB The title compds. I [R1 = HO, (un)substituted amino, carboxy, carbamoyl, ureido, etc.; R2 = H, HO, halogen, CF3, NH2, NO2, CN, (un)substituted C1-4 alkyl, etc.; m = 1-3; n = 1, 2], useful as tyrosine kinase-inhibiting anticancer agents (no data), are prepared and I-containing formulations presented. Thus, 4-chloro-6,7-dimethoxyquinazoline was condensed with 3-MeC6H4NH2, producing 6,7-dimethoxy-4-(3'-methylanilino)quinazoline hydrochloride, m.p. 248-249°.

IT 153437-74-2P 153437-75-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of, as tyrosine kinase-inhibiting anticancer agent)


RN 153437-74-2 CAPLUS

CN Acetamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 153437-75-3 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



L21 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 14

ACCESSION NUMBER: 1962:463342 CAPLUS

DOCUMENT NUMBER: 57:63342

ORIGINAL REFERENCE NO.: 57:12670a-e

TITLE: Azo dyes

INVENTOR(S): Barker, Peter W.; Hunter, James S.; Waite, Frederick A.

PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd.

SOURCE: 11 pp.

DOCUMENT TYPE: Patent

LANGUAGE: Unavailable

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 892323		19620328	GB	19590814

GI For diagram(s), see printed CA Issue.


AB Sulfamic acid derivs. of the general formula I are diazotized and treated with coupling components to give yellow to red dyes for cotton. Thus, 18.8 parts 4-H₂NC₆H₄NHSO₃H (II) is condensed with 18.6 parts cyanuric chloride (III) at pH 7. A solution of HN(CH₂CH₂OH)₂ 10.5 in H₂O 50 is added, the mixture is stirred for 2 hrs. at 35-40°, then for 20 hrs. at 45-50° at pH 7 to give I, X = N(CH₂CH₂OH)₂, R = Y = Z = H (IV). Similarly, I are prepared (compound number, X, Y, Z, R given): V, Cl, H, H, H; VI, MeO, H, H, H; VII, Cl, Cl, H, H; VIII, PhNH, H, H, H; IX, benzothiazol-2-yl-thio, H, H, H; X, Cl, MeO, Me, H; XI, Cl, H, H, Me. An isomer (XII) of V is prepared from III and 3-H₂NC₆H₄NHSO₃H. Analogs of I (XIII, XIV, and XV) are prepared from II and 2,4,6-trichloropyrimidine, 2,4-dichloro-5-cyanopyrimidine, and 2,4-dichloroquinazoline, resp. Diazotized IV coupled with p-MeC₆H₄OH (XVI) gave a 37.3% yield of yellow dye [82.2% yield when IV was diazotized in the presence of poly(glycerol ricinoleate)]. Similarly, other dyes were prepared (diazo component, coupling component, % yield, and shade given): XIII, XVI, 66.7, yellow; V, 1-ClO₂H₇NHCH₂CH₂OH, 47, red; V, m-C₆H₄(OH)₂, 50.3, orange; V, 2,6-ClCH₂COC₁₀H₆OH, 43.3, red; VI, XVI, 58, yellow; XII, 1,8,3,6-AcNH(HO)C₁₀H₄(SO₃H)₂ (XVII), 73.4, red; VII, 1-phenyl-3-methyl-5-pyrazolone, (XVIII), 70.5, yellow; XIV, XVI, 32.7, yellow; VIII, 1,2,6-H₂N(MeO)C₁₀H₅SO₃H, 59.3, red; IX, 4'-SO₃H derivative of XVIII, 63.2, yellow; XV, XVII, 44.5, red; X, PhNHCOCH₂Ac, 60.8, greenish yellow; XI, XVI, 54.9, yellow; IV, m-MeC₆H₄N(CH₂CH₂OH)₂, 62.9, orange; IV, 2,5,7,1-H₂N(HO)(HO₃S)C₁₀H₄N: NC₆H₄SO₃H-2, 63.3, brown.

IT 93309-34-3, Sulfamic acid, [p-[(2-chloro-4-quinazolinyl)amino]phenyl]-

(preparation of)

RN 93309-34-3 CAPLUS

CN Sulfamic acid, [p-[(2-chloro-4-quinazolinyl)amino]phenyl]- (7CI) (CA INDEX NAME)



L21 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:470256 CAPLUS

DOCUMENT NUMBER: 143:20052

TITLE: Urea derivatives as kinase modulators

INVENTOR(S): Milanov, Zdravko V.; Patel, Hitesh K.; Grotzfeld, Robert M.; Mehta, Shamal A.; Andiliy, Lai G.; Lockhart, David J.

PATENT ASSIGNEE(S): Ambit Biosciences Corporation, USA

SOURCE: PCT Int. Appl., 350 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005048948	A2	20050602	WO 2004-US38288	20041115
WO 2005048948	A3	20050728		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005148605	A1	20050707	US 2004-989745	20041115
US 2005165031	A1	20050728	US 2004-989814	20041115
US 2005165024	A1	20050728	US 2004-989824	20041115
US 2005165074	A1	20050728	US 2004-990007	20041115
US 2005171171	A1	20050804	US 2004-989766	20041115
US 2005171172	A1	20050804	US 2004-989823	20041115
US 2005192314	A1	20050901	US 2004-990195	20041115

US 2005197371 A1 20050908 US 2004-990194 20041115
PRIORITY APPLN. INFO.: US 2003-520273P P 20031113
US 2003-527094P P 20031203
US 2003-531082P P 20031218
US 2003-531243P P 20031218

OTHER SOURCE(S): MARPAT 143:20052

AB The invention provides methods and compns. for treating conditions mediated by various kinases wherein derivs. of urea compds. are employed. The invention also provides methods of using the compds. and/or compns. in the treatment of a variety of diseases and unwanted conditions in subjects such as cellular proliferative disorders.

IT 852668-40-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(urea derivs. as kinase modulators for treatment of cellular proliferative disorders)

RN 852668-40-7 CAPLUS

CN Urea, N-[4-[(2-chloro-6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

/
t-Bu

IT 852668-55-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(urea derivs. as kinase modulators for treatment of cellular
proliferative disorders)

RN 852668-55-4 CAPLUS

CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N'-[5-(1,1-
dimethylethyl)-3-isoxazolyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

/
t-Bu

L21 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:395277 CAPLUS

DOCUMENT NUMBER: 142:423807

TITLE: Phenyl(quinazolinyl)amines as UL 97-kinase inhibitors
for the treatment of human cytomegaloviral and other
herpesviral infections

INVENTOR(S): Herget, Thomas

PATENT ASSIGNEE(S): Axxima Pharmaceuticals A.-G., Germany

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040125	A1	20050506	WO 2004-EP11118	20041005
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:


EP 2003-22647

A 20031006

OTHER SOURCE(S):

MARPAT 142:423807

GI




AB The present invention relates to phenyl(quinazolinyl)amine derivs. (shown as I; variables defined below; e.g. (3,4-dichlorophenyl)(6-methylquinazolin-4-yl)amine) and pharmaceutically acceptable salts thereof and pharmaceutical compns. comprising at least one of these derivs. and/or pharmaceutically salts thereof, as well as the use of these derivs. for the prophylaxis and/or treatment of herpesviral induced infections, including opportunistic infections, especially for the prophylaxis and/or treatment of infections and diseases induced by human cytomegalovirus (HCMV, a highly specific β -herpesvirus). For I: R1 = H and C1-C6-alkyl, aryl, or 4-R18piperazin-1-yl (R18 = 2,4,6-R193phenyl (R19 = H, F, Cl, Br, I, NO₂, NH₂ or CF₃) or furan-2-ylcarbonyl); R2 = H and C1-C6-alkyl; R3, R4, R5 and R6 = H, C1-C6-alkyl, C1-C6-alkoxy, phenoxy, F, Cl, Br, I, OH, CN, NR₁₂R₁₂', N:NR₁₃, NHC(O)R₁₄, NO₂, C.tplbond.CR₁₅, C(R₂₀)₃, or -CH(R₂₀)₂ or O(CH₂)omorpholino (o = 0-6), or R4 and R5 together form dioxolan-4,5-diyl or 1H-imidazol-4,5-diyl. R7, R8, R9, R10, and R11 = H, C1-C6-alkyl, C1-C6-alkoxy, F, Cl, Br, I, OH, CN, NR₁₂R₁₂', N:NR₁₃, NHC(O)R₁₄, NO₂, C.tplbond.CR₁₅, C(R₂₀)₃, or CH(R₂₀)₂ or O(CH₂)omorpholino (o = 0-6) or R8 and R9 together form dioxolan-4,5-diyl or 1H-imidazol-4,5-diyl; addnl. details are given in the claims. Methods of preparation are not claimed and no example prepns. are included. UL 97-kinase inhibitory and HCMV antiviral activity of some I are reported.

IT 331770-22-0, Furan-2-carboxylic acid N-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]amide 331770-31-1, 2-Cyano-N-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]acetamide

457932-98-8, N-[4-(Quinazolin-4-ylamino)phenyl]acetamide
 749836-55-3, Furan-2-carboxylic acid N-[3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]amide 851016-98-3,
 2-Cyano-N-[3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]acetamide
 851017-13-5, N-[4-(6-Methylquinazolin-4-ylamino)phenyl]acetamide
 851017-14-6, N-[4-(8-Methylquinazolin-4-ylamino)phenyl]acetamide
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (drug candidate; phenyl(quinazolinyl)amines as UL 97-kinase inhibitors
 for treatment of human cytomegaloviral and other herpesviral
 infections)


RN 331770-22-0 CAPLUS

CN 2-Furancarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl] -
 (9CI) (CA INDEX NAME)




RN 331770-31-1 CAPLUS

CN Acetamide, 2-cyano-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl] -
 (9CI) (CA INDEX NAME)




RN 457932-98-8 CAPLUS

CN Acetamide, N-[4-(4-quinazolinylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 749836-55-3 CAPLUS

CN 2-Furancarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl) amino]phenyl]- (9CI) (CA INDEX NAME)




RN 851016-98-3 CAPLUS

CN Acetamide, 2-cyano-N-[3-[(6,7-dimethoxy-4-quinazolinyl) amino]phenyl]- (9CI) (CA INDEX NAME)




RN 851017-13-5 CAPLUS

CN Acetamide, N-[4-[(6-methyl-4-quinazolinyl)amino]phenyl] - (9CI) (CA INDEX NAME)



RN 851017-14-6 CAPLUS

CN Acetamide, N-[4-[(8-methyl-4-quinazolinyl)amino]phenyl] - (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:241203 CAPLUS

DOCUMENT NUMBER: 132:265207

TITLE: Preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease

INVENTOR(S): Cumming, John Graham

PATENT ASSIGNEE(S): Zeneca Limited, UK

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

Call

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000020402	A1	20000413	WO 1999-GB3220	19990927
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2341374	AA	20000413	CA 1999-2341374	19990927
AU 9961064	A1	20000426	AU 1999-61064	19990927
AU 761552	B2	20030605		
BR 9914162	A	20010626	BR 1999-14162	19990927
EP 1117653	A1	20010725	EP 1999-947686	19990927
EP 1117653	B1	20030205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526538	T2	20020820	JP 2000-574519	19990927
AT 232205	E	20030215	AT 1999-947686	19990927
NZ 510210	A	20030630	NZ 1999-510210	19990927
PT 1117653	T	20030630	PT 1999-947686	19990927
ES 2191462	T3	20030901	ES 1999-947686	19990927
ZA 2001002187	A	20020618	ZA 2001-2187	20010315
US 6593333	B1	20030715	US 2001-787883	20010323
NO 2001001631	A	20010521	NO 2001-1631	20010330
HK 1037367	A1	20030822	HK 2001-108138	20011119
US 2003216417	A1	20031120	US 2003-441084	20030520
US 6716847	B2	20040406		
PRIORITY APPLN. INFO.:			GB 1998-21338	A 19981001
			GB 1999-6564	A 19990323
			WO 1999-GB3220	W 19990927
			US 2001-787883	A3 20010323
OTHER SOURCE(S):	MARPAT 132:265207			
GI				



I



II


AB The title compds. [I; G = N, CH; R1 = OH, halo, CF3, etc.; R2, R3 = H, halo, alkyl, etc.; R4 = H, OH, alkyl, etc.; R5 = H, halo, CF3; m = 1-3; q = 0-4] and their pharmaceutically acceptable salts or in vivo cleavable esters, useful in the treatment of diseases or medical conditions mediated by cytokines, were prepared and formulated. E.g., a multi-step synthesis of II which showed IC50 of 0.2 μ M against p38 α kinase and IC50 of 5.2 μ M against TNF α production, was given.

IT 263400-17-5P 263400-18-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)


RN 263400-17-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-18-6 CAPLUS
 CN 4-Pyridinecarboxamide, N-[3-[(6-hydroxy-7-methoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



IT 263399-67-3P 263399-68-4P 263399-70-8P
 263399-71-9P 263399-72-0P 263399-74-2P
 263399-75-3P 263399-76-4P 263399-77-5P
 263399-78-6P 263399-79-7P 263399-80-0P
 263399-81-1P 263399-82-2P 263399-83-3P
 263399-84-4P 263399-85-5P 263399-86-6P
 263399-87-7P 263399-88-8P 263399-89-9P
 263399-90-2P 263399-91-3P 263399-92-4P
 263399-93-5P 263399-94-6P 263399-95-7P
 263399-96-8P 263399-97-9P 263399-98-0P
 263399-99-1P 263400-00-6P 263400-01-7P
 263400-03-9P 263400-04-0P 263400-05-1P
 263400-06-2P 263400-07-3P 263400-08-4P
 263400-09-5P 263400-10-8P 263400-11-9P
 263400-12-0P 263400-13-1P 263400-19-7P
 263400-20-0P 263400-21-1P 263400-22-2P
 263400-23-3P 263400-25-5P 263400-26-6P
 263400-27-7P 263400-28-8P 263400-29-9P
 263400-30-2P 263400-31-3P 263400-32-4P
 263400-33-5P 263400-34-6P 263400-35-7P
 263400-36-8P 263400-37-9P 263400-38-0P


263400-39-1P 263400-40-4P 263400-41-5P
 263400-42-6P 263400-43-7P 263400-44-8P
 263400-45-9P 263400-46-0P 263400-48-2P
 263400-50-6P 263400-51-7P 263400-52-8P
 263400-53-9P 263400-94-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)

RN 263399-67-3 CAPLUS


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-68-4 CAPLUS


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,4-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-70-8 CAPLUS


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-71-9 CAPLUS


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-72-0 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-74-2 CAPLUS
 CN Benzamide, 4-cyano-N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-75-3 CAPLUS
 CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263399-76-4 CAPLUS


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-77-5 CAPLUS


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263399-78-6 CAPLUS


CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-79-7 CAPLUS


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263399-80-0 CAPLUS


CN Acetamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-81-1 CAPLUS


CN Propanamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-82-2 CAPLUS


CN Acetamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-83-3 CAPLUS


CN Propanamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-84-4 CAPLUS


CN Acetamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-85-5 CAPLUS

CN Acetamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-86-6 CAPLUS
 CN Acetamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-87-7 CAPLUS
 CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-88-8 CAPLUS
 CN 2-Furancarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-89-9 CAPLUS
 CN 3-Pyridinecarboxamide, 6-chloro-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-90-2 CAPLUS


CN 5-Isioxazolecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-91-3 CAPLUS

CN Benzamide, 3-(dimethylamino)-N-[4-methyl-3-[(6,7,8-trimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 263399-92-4 CAPLUS

CN Carbamic acid, [5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 263399-93-5 CAPLUS


CN Benzamide, 4-cyano-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-94-6 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 263399-95-7 CAPLUS


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-96-8 CAPLUS


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-97-9 CAPLUS


CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-98-0 CAPLUS

CN Benzamide, 4-cyano-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-99-1 CAPLUS
 CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-00-6 CAPLUS
 CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-01-7 CAPLUS
 CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-03-9 CAPLUS
 CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2,4-difluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-04-0 CAPLUS
 CN Benzamide, N-[4-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-05-1 CAPLUS
 CN Benzamide, 3-(dimethylamino)-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-06-2 CAPLUS
 CN Acetamide, N-[4-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-07-3 CAPLUS
 CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[3-(3-pyridinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-08-4 CAPLUS


CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-09-5 CAPLUS


CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[2-(4-morpholinyl)ethoxy]]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-10-8 CAPLUS


CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-11-9 CAPLUS


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-12-0 CAPLUS


CN 4-Pyridinecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-13-1 CAPLUS


CN Benzamide, N-[2-fluoro-5-[(6,7,8-trimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-19-7 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(diethylamino)-2-oxoethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-20-0 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)-2-oxoethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-21-1 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)ethoxy]-7-methoxy-4-quinazoliny]]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-22-2 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(diethylamino)ethoxy]-7-methoxy-4-quinazoliny]]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-23-3 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-[bis(1-methylethyl)amino]ethoxy]-7-methoxy-4-quinazoliny]]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-25-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[3-(dimethylamino)propoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-26-6 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[3-(diethylamino)propoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-27-7 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)-2-methylpropoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-28-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-29-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-piperidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-30-2 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-31-3 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-32-4 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-33-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-34-6 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-methyl-2-pyrrolidinyloxy)]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-(9CI) (CA INDEX NAME)




RN 263400-35-7 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[(1-methyl-2-piperidinyloxy)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-(9CI) (CA INDEX NAME)




RN 263400-36-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[(1-methyl-3-piperidinyloxy)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-(9CI) (CA INDEX NAME)




RN 263400-37-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[(1-methyl-5-oxo-2-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-38-0 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(2-oxo-1-imidazolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-39-1 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-40-4 CAPLUS

CN Benzamide, 4-cyano-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 263400-41-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-42-6 CAPLUS


CN 4-Pyridinecarboxamide, N-[3-[(7-fluoro-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 263400-43-7 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[3-(methylsulfonyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-44-8 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-45-9 CAPLUS
 CN 2-Thiophenecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-46-0 CAPLUS
 CN Cyclopropanecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-48-2 CAPLUS


CN Acetamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-50-6 CAPLUS

CN Carbamic acid, [5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 263400-51-7 CAPLUS

CN Benzamide, 4-cyano-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 263400-52-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-53-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-94-8 CAPLUS

CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl] - (9CI) (CA INDEX NAME)




IT 263400-86-8P 263400-87-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)

RN 263400-86-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[(7-hydroxy-6-methoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl) - (9CI) (CA INDEX NAME)



RN 263400-87-9 CAPLUS
 CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:462220 CAPLUS

DOCUMENT NUMBER: 125:114665

TITLE: Preparation of quinoline and quinazoline protein tyrosine kinase inhibitors

INVENTOR(S): Hudson, Alan Thomas; Vile, Sadie; Barraclough, Paul; Franzmann, Karl Witold; McKeown, Stephen Carl; Page, Martin John

PATENT ASSIGNEE(S): Wellcome Foundation Limited, UK

SOURCE: PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9609294	A1	19960328	WO 1995-GB2202	19950918
W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM			
RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9534824	A1	19960409	AU 1995-34824	19950918
ZA 9507853	A	19970318	ZA 1995-7853	19950918
EP 782570	A1	19970709	EP 1995-931351	19950918
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
JP 10505600	T2	19980602	JP 1995-509740	19950918


PRIORITY APPLN. INFO.:

GB 1994-18852	A 19940919
GB 1995-7788	A 19950413
GB 1995-10757	A 19950526
WO 1995-GB2202	W 19950918

OTHER SOURCE(S):

MARPAT 125:114665

GI




AB The title compds. [I; X = N, CH; Y = W(CH₂), (CH₂)W, W; W = O, S(O)_m, (un)substituted NH; R₁ = NH₂, H, halogen, OH, NO₂, CO₂H, CF₃, CF₃O, ureido, etc.; R₄ = H, OH, halogen, alkyl, alkoxy, alkylthio, CN, NO₂, CF₃, etc.; n = 1-3; R₅ = H, halogen, CF₃, alkyl, alkoxy; R₆ = substituted hydrocarbyl, etc.], which are protein tyrosine kinase inhibitors, are prepared. Thus, 4-chloroquinoline was reacted with 4-methoxyaniline in the presence of HCl, producing 4-(4-phenoxyanilino)quinoline hydrochloride, m.p. 216-218°, which demonstrated a IC₅₀ against p56lck protein tyrosine kinase of 5 μM.

IT 179247-41-7P 179247-42-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoline and quinazoline protein tyrosine kinase inhibitors)

RN 179247-41-7 CAPLUS


CN Benzamide, N-[4-(4-quinazolinylamino)phenyl]-, monohydrochloride (9CI)
(CA INDEX NAME)



*proviso
out*

● HCl

RN 179247-42-8 CAPLUS
CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



*proviso
out*

● HCl

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, TOXCENTER, USPATFULL, BIOSIS, CAOLD' -
CONTINUE? (Y)/N:y

L21 ANSWER 17 OF 30 TOXCENTER COPYRIGHT 2005 ACS on STN DUPLICATE 10
ACCESSION NUMBER: 2003:191549 TOXCENTER
COPYRIGHT: Copyright 2005 ACS
DOCUMENT NUMBER: CA13910143528C

TITLE: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores
AUTHOR(S): Ditchfield, Claire; Johnson, Victoria L.; Tighe, Anthony; Ellston, Rebecca; Haworth, Carolyn; Johnson, Trevor; Mortlock, Andrew; Keen, Nicholas; Taylor, Stephen S.
CORPORATE SOURCE: School of Biological Sciences, University of Manchester, Manchester, M13 9PT, UK.
SOURCE: Journal of Cell Biology, (2003) Vol. 161, No. 2, pp. 267-280.
CODEN: JCLBA3. ISSN: 0021-9525.
COUNTRY: UNITED KINGDOM
DOCUMENT TYPE: Journal
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2003:339130
LANGUAGE: English
ENTRY DATE: Entered STN: 20030805
Last Updated on STN: 20031014

ABSTRACT:

The Aurora/Ipl1 family of protein kinases plays multiple roles in mitosis and cytokinesis. Here, we describe ZM447439, a novel selective Aurora kinase inhibitor. Cells treated with ZM447439 progress through interphase, enter mitosis normally, and assemble bipolar spindles. However, chromosome alignment, segregation, and cytokinesis all fail. Despite the presence of maloriented chromosomes, ZM447439-treated cells exit mitosis with normal kinetics, indicating that the spindle checkpoint is compromised. Indeed, ZM447439 prevents mitotic arrest after exposure to paclitaxel. RNA interference expts. suggest that these phenotypes are due to inhibition of Aurora B, not Aurora A or some other kinase. In the absence of Aurora B function, kinetochore localization of the spindle checkpoint components BubR1, Mad2, and Cenp-E is diminished. Furthermore, inhibition of Aurora B kinase activity prevents the rebinding of BubR1 to metaphase kinetochores after a reduction in centromeric tension. Aurora B kinase activity is also required for phosphorylation of BubR1 on entry into mitosis. Finally, we show that BubR1 is not only required for spindle checkpoint function, but is also required for chromosome alignment. Together, these results suggest that by targeting checkpoint proteins to kinetochores, Aurora B couples chromosome alignment with anaphase onset.

CLASSIFICATION CODE: 1-6

SUPPLEMENTARY TERMS: Miscellaneous Descriptors
Aurora kinase anaphase targeting kinetochore chromosome
ZM447439 antitumor

REGISTRY NUMBER: 114051-78-4 (Protein kinase LCK)
141349-86-2 (Protein kinase CDK2)
141349-89-5 (SRC kinase)
142805-58-1 (Protein kinase MEK)
143375-65-9 (Protein kinase CDK1)
144114-16-9 (FAK kinase)
147014-97-9 (Protein kinase CDK4)
148047-34-1 (Protein kinase zap-70)
154907-65-0 (Protein kinase CHK1)
165245-99-8 (Protein kinase PLK)
195740-69-3 (Aurora B kinase)
212566-53-5 (Protein kinase BubR1)
362516-16-3 (IKK1 kinase)
362517-43-9 (IKK2 kinase)
458560-40-2 (Aurora A)
331771-20-1 (ZM 447439)

L21 ANSWER 18 OF 30 TOXCENTER COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:95462 TOXCENTER
COPYRIGHT: Copyright 2005 ACS
DOCUMENT NUMBER: CA13419266317N
TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors
AUTHOR(S): Mortlock, Andrew Austen; Keen, Nicholas John; Jung, Frederic Henri; Brewster, Andrew George
CORPORATE SOURCE: ASSIGNEE: Astrazeneca UK Limited
PATENT INFORMATION: WO 2001021596 A1 29 Mar 2001
SOURCE: (2001) PCT Int. Appl., 306 pp.
CODEN: PIXXD2.
COUNTRY: SWEDEN
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2001:228866
LANGUAGE: English
ENTRY DATE: Entered STN: 20011116
Last Updated on STN: 20050823

ABSTRACT:

Title compds. (I) [wherein X = O, S, SO, SO₂, NH, or NR₁₂; R₁₂ = H or alkyl; R₁-R₄ = independently halo, CN, NO₂, alkylsulfanyl, N(OH)R₁₃, or R₁₅X₁; R₁₃ = H or alkyl; X₁ = a direct bond, O, CH₂, OC(O), CO, CO₂, S, SO, SO₂, or (un)substituted NHCO, CONH, SO₂NH, NHSO₂, or NH; R₁₅ = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; R₅ = NHCO₂R₉, NHCOR₉, NHSO₂R₉, COR₉, CO₂R₉, SOR₉, SO₂OR₉, CONR₁₀R₁₁, SONR₁₀R₁₁, or SO₂NR₁₀R₁₁; R₉-R₁₁ = independently H or (un)substituted hydrocarbyl or heterocyclyl; or R₁₀ and R₁₁ together with the N to which they are attached = (un)substituted heterocyclyl; R₆ = H or (un)substituted hydrocarbyl or heterocyclyl; R₇ and R₈ = independently H, halo, alkyl, (di)alkoxy(methyl), alkanoyl, CF₃, CN, NHY₂, alkenyl, alkynyl, or (un)substituted Ph, PhCH₂, or heterocyclyl; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, a 7-step sequence involving (1) alkylation of morpholine with 1-bromo-3-chloropropane (49%), (2) addition of Et vanillate to yield Et 3-methoxy-4-(3-morpholinopropoxy)benzoate (100%), (3) nitration (86%), (4) reduction to the amine using 10% Pd/C (100%), (5) cycloaddn. with formamide to form the quinazoline (68%), (6) chlorination to give 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (60%), and (7) amination with N-benzoyl-4-aminoaniline (58%) yielded II. The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.0193 μ M. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 1.06 μ M and reduced BrdU incorporation into cellular DNA by 50% at 0.159-0.209 μ M.

CLASSIFICATION CODE: 28-16

SUPPLEMENTARY TERMS: Miscellaneous Descriptors
quinazoline prepn aurora 2 kinase inhibitor; anticancer antiproliferative quinazoline prepnREGISTRY NUMBER: 736-02-7 (N-Benzoyl-3-(trifluoromethyl)-4-aminoaniline)
7357-67-7 (N-(3-Chloropropyl)-morpholine)
13790-39-1 (4-Chloro-6,7-dimethoxyquinazoline)
13794-72-4 (6,7-Dimethoxy-3,4-dihydroquinazolin-4-one)
15457-50-8 (N-Benzoyl-4-hydroxyaniline)
17625-83-1 (N-Benzoyl-4-aminoaniline)
63565-22-0 (N-Benzoyl-2-chloro-4-aminoaniline)
64160-38-9 (N-Benzoyl-2-chloro-4-nitroaniline)
84197-48-8 (N-Benzoyl-2-cyano-4-nitroaniline)
104478-92-4 (N-Benzoyl-2-methyl-4-nitroaniline)
104478-97-9 (N-Benzoyl-2-methoxy-4-aminoaniline)
108479-25-0 (Ethyl 3-methoxy-4-(3-morpholinopropoxy)benzoate)

117367-10-9 (N-Benzoyl-3-(trifluoromethyl)-4-nitroaniline)
123855-51-6 (4-Hydroxymethyl-1-tert-butylloxycarbonylpiperidine)
129912-30-7 (4-Chloro-6,7-dimethoxyquinazoline hydrochloride)
142851-03-4 (Ethyl 1-(tert-butoxycarbonyl)-4-piperidinecarboxylate)
166815-96-9 (4-(4-Methylphenylsulphonyloxymethyl)-1-tert-butylloxycarbonylpiperidine)
179688-01-8 (7-Benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one)
179688-53-0 (6-Acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one)
179688-54-1 (4-Chloro-6-acetoxy-7-methoxyquinazoline hydrochloride)
183322-18-1 (4-Chloro-6,7-di(2-methoxyethoxy)quinazoline)
196194-62-4 (6-Methoxy-7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one)
196195-13-8 (4-Chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline)
229958-93-4 (1-(3-Bromopropyl)-4,5-dihydroimidazole)
230955-75-6 (4-Chloro-6-acetoxy-7-methoxyquinazoline)
264208-58-4 (Ethyl 3-methoxy-4-(1-tert-butylloxycarbonylpiperidin-4-ylmethoxy)benzoate)
264208-60-8 (Ethyl 3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)benzoate)
264208-63-1 (Ethyl 3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)-6-nitrobenzoate)
264208-66-4 (Ethyl 6-amino-3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)benzoate)
264208-69-7 (6-Methoxy-7-((1-methylpiperidin-4-yl)methoxy)-3,4-dihydroquinazolin-4-one)
264208-72-2 (4-Chloro-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline)
330999-62-7 (4-(4-Aminoanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline)
330999-81-0 (Ethyl 3-methoxy-4-(2,2,2-trifluoroethoxy)-6-nitrobenzoate)
330999-82-1 (Ethyl 3-methoxy-4-(2,2,2-trifluoroethoxy)-6-aminobenzoate)
330999-83-2 (6-Methoxy-7-(2,2,2-trifluoroethoxy)-3,4-dihydroquinazolin-4-one)
330999-84-3 (Ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-nitrobenzoate)
330999-85-4 (Ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-aminobenzoate)
331776-47-7 (N-Benzoyl-2-cyano-4-aminoaniline)
331776-48-8 (N,N-Di(benzoyl)-2-methyl-4-nitroaniline)
331776-50-2 (N-Benzoyl-2-chloro-4-hydroxyaniline)
331776-51-3 (4-(4-Aminoanilino)-6-methoxy-7-(2,2,2-trifluoroethoxy)quinazoline)
331776-54-6 (2-(4-Morpholino)-4-chloro-6,7-dimethoxyquinazoline)
331776-64-8 (4-(Methylthio)-6-methoxy-7-(cyanomethoxy)quinazoline)
331776-72-8 (4-(Methylthio)-6-methoxy-7-(3-hydroxyprop-1-enyl)quinazoline)
331776-73-9 (6-Methoxy-7-benzyloxy-3,4-dihydroquinazolin-4-thione)

331776-74-0 (4-(Methylthio)-6-methoxy-7-benzyloxyquinazoline)
331776-75-1 (4-(Methylthio)-6-methoxy-7-(trifluoromethanesulphonyloxy)-quinazoline)
331776-76-2 (4-(Methylthio)-7-(3-hydroxy-3-methylbut-1-ynyl)quinazoline)
331776-77-3 (4-(Methylthio)-7-(trifluoromethanesulphonyloxy)quinazoline)
331776-78-4 (4-(Methylthio)-6-methoxy-7-(3-hydroxyprop-1-ynyl)quinazoline)
331776-82-0 (4-(Methylthio)-7-aminoquinazoline)
331776-83-1 (N-(2-Cyanophenyl)-4-amino-2-chlorobenzamide)
331776-84-2 (N-(2-Cyanophenyl)-2-chloro-4-nitrobenzamide)
331776-87-5 (4-((4-Carbomethoxy)anilino)-6,7-dimethoxyquinazoline)
9026-43-1 (Serine/threonine kinase)
458560-40-2 (Protein kinase aurora 2)
50-79-3 (2,5-Dichlorobenzoic acid)
59-51-8 (Methionine)
59-67-6 (Nicotinic acid)
62-23-7 (4-Nitrobenzoic acid)
63-74-1 (Sulphanilamide)
77-86-1 (Tris-(hydroxymethyl)methylamine)
79-41-4 (Methacrylic acid)
79-44-7 (N,N-Dimethyl-carbamoyl chloride)
88-14-2 (Furan-2-carboxylic acid)
89-41-8 (4-Methoxy-3-nitrobenzoic acid)
94-25-7 (n-Butyl 4-aminobenzoate)
94-53-1 (3,4-Methylenedioxybenzoic acid)
96-33-3 (Methyl acrylate)
96-98-0 (4-Methyl-3-nitrobenzoic acid)
97-52-9 (2-Methoxy-4-nitroaniline)
98-09-9 (Benzenesulfonyl chloride)
98-16-8 (3-(Trifluoromethyl)aniline)
98-89-5 (Cyclohexanecarboxylic acid)
99-34-3 (3,5-Dinitrobenzoic acid)
99-60-5 (2-Chloro-4-nitrobenzoic acid)
100-09-4 (4-Methoxybenzoic acid)
100-36-7 (N,N-Diethyl-ethylenediamine)
103-76-4 (N-(2-Hydroxyethyl)piperazine)
104-01-8 (4-Methoxyphenylacetic acid)
104-78-9 (3-(Diethylamino)-propylamine)
106-50-3 (1,4-Phenylenediamine)
107-19-7 (Propargyl alcohol)
108-00-9 (N,N-Dimethylethylenediamine)
108-01-0 (N,N-Dimethylethanolamine)
108-09-8 (1,3-Dimethylbutylamine)
108-91-8 (Cyclohexylamine)
109-01-3 (N-Methyl piperazine)
109-05-7 (2-Methylpiperidine)
109-55-7 (3-Dimethylamino-propylamine)
109-70-6 (1-Bromo-3-chloropropane)
109-76-2 (1,3-Propanediamine)
109-83-1 (N-Methyl ethanolamine)
109-85-3 (2-Methoxyethyl-amine)
109-96-6 (3-Pyrroline)
110-57-6 (trans-1,4-Dichloro-2-butene)
110-73-6 (N-Ethyl ethanolamine)
110-91-8 (Morpholine)

111-26-2 (Hexylamine)
111-42-2 (Diethanolamine)
111-68-2 (n-Heptylamine)
115-19-5 (2-Methyl-3-butyn-2-ol)
115-69-5 (2-Amino-2-methyl-1,3-propanediol)
115-70-8 (2-Amino-2-ethyl-1,3-propanediol)
118-41-2 (3,4,5-Trimethoxybenzoic acid)
118-91-2 (2-Chlorobenzoic acid)
120-13-8 ((4-Ethoxy-3-methoxyphenyl)acetic acid)
121-05-1 (N,N-Diisopropyl-ethylenediamine)
121-32-4 (3-Ethoxy-4-hydroxybenzaldehyde)
121-87-9 (2-Chloro-4-nitroaniline)
121-92-6 (3-Nitrobenzoic acid)
123-00-2 (4-(3-Aminopropyl)-morpholine)
123-30-8 (4-Aminophenol)
123-90-0 (Thiomorpholine)
124-07-2 (Octanoic acid)
124-68-5 (2-Amino-2-methyl-1-propanol)
140-75-0 (4-Fluorobenzylamine)
140-77-2 (3-(Cyclopentyl)-propanoic acid)
141-91-3 (2,6-Dimethylmorpholine)
142-25-6 (N,N,N'-Trimethyl ethylenediamine)
150-13-0 (4-Aminobenzoic acid)
156-57-0 (2-Mercaptoethylamine hydrochloride)
156-87-6 (3-Amino-1-propanol)
351-35-9 (3-(Trifluoromethyl)-phenylacetic acid)
372-09-8 (Cyanoacetic acid)
373-88-6 (2,2,2-Trifluoroethylamine hydrochloride)
393-11-3 (3-(Trifluoromethyl)-4-nitroaniline)
399-76-8 (5-Fluoroindole-2-carboxylic acid)
403-16-7 (3-Chloro-4-fluorobenzoic acid)
405-50-5 (4-Fluorophenylacetic acid)
445-29-4 (2-Fluorobenzoic acid)
451-82-1 ((2-Fluorophenyl)acetic acid)
453-71-4 (4-Fluoro-3-nitrobenzoic acid)
455-24-3 (4-(Trifluoromethyl)-benzoic acid)
455-38-9 (3-Fluorobenzoic acid)
456-22-4 (4-Fluorobenzoic acid)
462-08-8 (3-Aminopyridine)
462-94-2 (1,5-Pentanediamine)
504-03-0 (2,6-Dimethyl-piperidine)
504-29-0 (2-Aminopyridine)
504-75-6 (Imidazoline)
527-69-5 (2-Furoyl chloride)
527-72-0 (Thiophene-2-carboxylic acid)
530-57-4 (3,5-Dimethoxy-4-hydroxybenzoic acid)
534-03-2 (2-Amino-1,3-propanediol)
535-80-8 (3-Chlorobenzoic acid)
540-51-2 (2-Bromoethanol)
552-16-9 (2-Nitrobenzoic acid)
579-75-9 (2-Methoxybenzoic acid)
585-70-6 (5-Bromo-2-furoic acid)
592-55-2 (2-Bromoethyl ethyl ether)
610-30-0 (2,4-Dinitrobenzoic acid)
616-30-8 (3-Amino-1,2-propanediol)
617-05-0 (Ethyl vanillate)
617-89-0 (Furfurylamine)
619-45-4 (Methyl 4-aminobenzoate)
621-82-9 (Cinnamic acid)

622-26-4 (4-(2-Hydroxyethyl)-piperidine)
622-40-2 (N-(2-Hydroxyethyl)morpholine)
626-58-4 (4-Methylpiperidine)
626-67-5 (N-Methylpiperidine)
627-00-9 (4-Chlorobutyric acid)
627-37-2 (N-Methyl allylamine)
627-42-9 (Methyl 2-chloroethyl ether)
645-12-5 (5-Nitro-2-furoic acid)
646-01-5 (3-(Methylthio)propanoic acid)
646-07-1 (4-Methylpentanoic acid)
693-05-0 (N-Methyl 2-cyano-ethylamine)
694-05-3 (1,2,3,6-Tetrahydropyridine)
701-97-3 (3-(Cyclohexyl)-propanoic acid)
765-30-0 (Cyclopropylamine)
765-38-8 (2-Methylpyrrolidine)
782-45-6 (4-Aminobenzanilide)
825-99-0 (3-(Methylthio)-benzoic acid)
882-06-4 ((E)-4-Nitrocinnamic acid)
929-06-6 (2-(2-Aminoethoxy)ethanol)
930-52-9 (2-Ethylimidazoline)
940-31-8 (2-Phenoxypropanoic acid)
940-62-5 ((E)-4-Chlorocinnamic acid)
1001-53-2 (N-Acetyl ethylenediamine)
1003-03-8 (Cyclopentylamine)
1013-96-3 ((E)-2-Nitrocinnamic acid)
1122-58-3 (4-(Dimethylamino)-pyridine)
1123-00-8 (Cyclopentylacetic acid)
1126-09-6 (Ethyl 4-piperidinecarboxylate)
1137-41-3 (4-Aminobenzophenone)
1137-42-4 (4-Hydroxybenzophenone)
1199-77-5 (α -Methylcinnamic acid)
1476-11-5 (cis-1,4-Dichloro-2-butene)
1477-50-5 (Indole-2-carboxylic acid)
1484-84-0 (2-(2-Hydroxyethyl)-piperidine)
1501-05-9 (4-Benzoylbutyric acid)
1521-38-6 (2,3-Dimethoxybenzoic acid)
1532-84-9 (1-Aminoisoquinoline)
1575-74-2 (2-Methyl-4-pentenoic acid)
1583-58-0 (2,4-Difluorobenzoic acid)
1759-53-1 (Cyclopropane carboxylic acid)
1772-76-5 ((E)-3-Nitrocinnamic acid)
1821-12-1 (4-Phenylbutyric acid)
1866-38-2 (3-Chlorocinnamic acid)
1877-72-1 (3-Cyanobenzoic acid)
1877-73-2 (3-Nitrophenylacetic acid)
1878-66-6 (4-Chlorophenylacetic acid)
1885-29-6 (2-Aminobenzonitrile)
1918-77-0 (2-Thiopheneacetic acid)
1967-31-3 (3-Chloro-4-carboxybenzoic acid)
1975-50-4 (2-Methyl-3-nitrobenzoic acid)
2038-03-1 (4-(2-Aminoethyl)morpholine)
2107-70-2 (3-(3,4-Dimethoxy-phenyl)propanoic acid)
2252-63-3 (N-(4-Fluorophenyl)piperazine)
2345-34-8 (4-Acetoxybenzoic acid)
2345-51-9 (3-Butynoic acid)
2439-57-8 (N-Methyl tetrahydrofurfurylamine)
2508-29-4 (5-Amino-1-pentanol)
2516-34-9 (Cyclobutylamine)
2516-47-4 (Cyclopropane-methylamine)

REGISTRY NUMBER:

2516-96-3 (2-Chloro-5-nitrobenzoic acid)
2544-06-1 (3-Methoxy-propionic acid)
2799-21-5 ((R)-3-Pyrrolidinol)
2835-68-9 (4-Aminobenzamide)
2857-97-8 (Trimethylsilyl bromide)
2861-28-1 ((3,4-Methylenedioxy-phenyl)acetic acid)
2942-59-8 (2-Chloronicotinic acid)
2975-41-9 (2-Aminoindan)
2991-28-8 (2,5-Difluorobenzoic acid)
3025-95-4 (N-Acetyl-3-aminopropanoic acid)
3153-44-4 (3-(4-Methoxybenzoyl)-propanoic acid)
3179-63-3 (3-(Dimethylamino)-propanol)
3218-02-8 (Cyclohexanemethyl-amine)
3222-47-7 (6-Methylnicotinic acid)
3273-14-1 (1-(2-Hydroxyethyl)-1,2,4-triazole)
3350-06-9 (3-Aminocyclopent-1-ene)
3378-71-0 (2,5-Dimethyl-pyrrolidine)
3399-73-3 (1-Cyclohexene-1-ethanamine)
3400-45-1 (Cyclopentane carboxylic acid)
3433-37-2 (2-Piperidinemethanol)
3529-09-7 (2-Dibutylamino-ethylamine)
3644-18-6 (1-(2-Dimethylaminoethyl)piperazine)
3721-95-7 (Cyclobutanecarboxylic acid)
3724-10-5 (2-(Methylthio)benzoic acid)
3731-53-1 (4-(Aminomethyl)-pyridine)
3970-35-2 (2-Chloro-3-nitrobenzoic acid)
4000-72-0 (1-(Aminomethyl)-1-cyclohexanol)
4005-51-0 (2-Amino-1,3,4-thiadiazole)
4104-45-4 (3-(Methylthio)propylamine)
4318-37-0 (1-Methyl homopiperazine)
4318-42-7 (1-Isopropyl-piperazine)
4324-38-3 (3-Ethoxypropanoic acid)
4441-30-9 (N-(3-Hydroxypropyl)morpholine)
4441-63-8 (4-(Cyclohexyl)butyric acid)
4519-39-5 (2,3-Difluorobenzoic acid)
4547-57-3 (4-(n-Butoxy)phenylacetic acid)
4572-03-6 (1-(3-Aminopropyl)-4-methylpiperazine)
4606-65-9 (3-Piperidine-methanol)
4653-11-6 (4-(2-Thienyl)butyric acid)
4785-66-4 (3-Sulpholanyl acetic acid)
4795-29-3 (Tetrahydrofurfurylamine)
4897-50-1 (4-Piperidino-piperidine)
4920-80-3 (3-Methoxy-2-nitrobenzoic acid)
4998-07-6 (3,4-Dimethoxy-6-nitrobenzoic acid)
5004-07-9 (4-(1-Pyrrolidinyl)-piperidine)
5036-48-6 (1-(3-Aminopropyl)-imidazole)
5292-21-7 (Cyclohexaneacetic acid)
5308-25-8 (N-Ethylpiperazine)
5317-32-8 (N-(3-Hydroxypropyl)piperazine)
5326-23-8 (6-Chloronicotinic acid)
5332-73-0 (3-Methoxypropylamine)
5350-93-6 (5-Amino-2-chloropyridine)
5382-16-1 (4-Hydroxy piperidine)
5407-04-5 (3-(Dimethylamino)-1-chloropropane hydrochloride)
5521-55-1 (2-Methylpyrazine-5-carboxylic acid)
5625-67-2 (2-Oxopiperazine)
5653-40-7 (4,5-Dimethoxyanthranilic acid)
5728-52-9 (4-Biphenylacetic acid)

5744-59-2 (1,5-Dimethyl-1H-pyrazole-3-carboxylic acid)
5856-63-3 (D-2-Amino-1-butanol)
5930-93-8 (4-Nitropyrrole-2-carboxylic acid)
6168-72-5 (2-Amino-1-propanol)
6284-84-0 (cis-2,5-Dimethyl-piperazine)
6291-85-6 (3-Ethoxypropylamine)
6303-58-8 (4-Phenoxybutyric acid)
6304-89-8 (3-Acetoxybenzoic acid)
6338-70-1 (Tetrahydro-3-thiophenamine 1,1-dioxide)
6482-24-2 (2-Bromoethyl methyl ether)
6547-53-1 (4-Benzyloxyphenyl-acetic acid)
6850-35-7 (3-Methylcyclohexylamine)
6850-65-3 (4-Aminocyclo-hexanol)
6859-99-0 (3-Hydroxypiperidine)
6959-48-4 (3-Picolyl chloride hydrochloride)
6964-21-2 (3-Thiopheneacetic acid)
7051-34-5 (Cyclopropylmethyl bromide)
7154-73-6 (1-(2-Aminoethyl)-pyrrolidine)
7170-38-9 (3-Phenoxypropanoic acid)
7304-32-7 (2-Fluoro-5-nitrobenzoic acid)
7311-63-9 (5-Bromothiophene-2-carboxylic acid)
7531-52-4 (L-Prolinamide)
7663-77-6 (1-(3-Aminopropyl)-2-pyrrolidinone)
10517-21-2 (5-Chloro indole-2-carboxylic acid)
13156-06-4 (N-Isopropyl-3-hydroxyazetidine)
13325-10-5 (4-Amino-1-butanol)
13364-16-4 (2-Methyl-pentylamine)
13484-40-7 (1-(2-Methoxyethyl)piperazine)
13831-31-7 (Acetoxyacetyl chloride)
13889-98-0 (N-Acetyl piperazine)
14003-16-8 (5-Methyl-2-furanmethanamine)
14290-86-9 ((E)-4-Fluorocinnamic acid)
16397-19-6 (2-Amino-1-hexanol)
16499-88-0 (3-Butoxypropyl-amine)
16874-33-2 (Tetrahydro-2-furoic acid)
16957-70-3 (trans-2-Methylpent-2-enoic acid)
17247-58-4 (Cyclobutylmethyl bromide)
17420-30-3 (2-Cyano-4-nitroaniline)
18278-34-7 (4-Hydroxy-2-methoxybenzaldehyde)
18542-42-2 (2-(Methylthio)ethylamine)
18600-42-5 (4-Nitrobenzylamine hydrochloride)
19815-17-9 (4-Chloro-7-nitroquinazoline)
19961-27-4 (N-Ethyl isopropylamine)
19968-85-5 (1-Aminomethyl-1-cyclohexanol hydrochloride)
20327-23-5 (N-Cyclopropyl piperazine)
21211-22-3 (3-Chlorobenzothiophene-2-carboxylic acid)
23356-96-9 ((S)-2-Pyrrolidinemethanol)
25850-22-0 (4-Amino-2,2-dimethyltetrahydropyran)
25952-53-8 (1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride)
26116-12-1 (2-(Aminomethyl)-1-ethylpyrrolidine)
26371-07-3 (1-Piperidine propanoic acid)
26690-80-2 (N-(tert-Butoxycarbonyl)-ethanolamine)
26734-09-8 (3-Amino-2,2-dimethyl-1-propanol)
27578-60-5 (2-Piperidino-ethylamine)
27631-29-4 (2,4-Dichloro-6,7-dimethoxyquinazoline)
27757-85-3 (Thiophene-2-methylamine)
30433-91-1 (2-Thiophene ethylamine)
30964-00-2 (6-Heptynoic acid)

31230-17-8 (3-Amino-5-methylpyrazole)
32852-81-6 (3-Phenoxyphenylacetic acid)
33208-99-0 (L-Alaninamide hydrochloride)
34698-41-4 (1-Aminoindan)
35794-11-7 (3,5-Dimethyl-piperidine)
36489-03-9 (2-(Ethylthio)ethylamine)
37143-54-7 (2-Amino-1-methoxypropane)
38196-09-7 (3-(4-Hydroxy-3-nitrophenyl)propanoic acid)
39178-35-3 (Isonicotinoyl chloride hydrochloride)
39546-32-2 (Isonipecotamide)
40499-83-0 (3-Hydroxy pyrrolidine)
42514-50-1 (3-Amino-3-methyl-1-butanol)
45347-82-8 (3-Hydroxy azetidine)
51387-90-7 (2-(2-Aminoethyl)-1-methylpyrrolidine)
52671-64-4 (3-Chloro-4-aminophenol hydrochloride)
53293-00-8 (5-Hexynoic acid)
54872-83-2 (1-Piperidinepropanoyl chloride)
58859-46-4 (Ethyl-4-amino-1-piperidinecarboxylate)
60547-98-0 (2-Amino-4-benzyloxy-5-methoxybenzamide)
62937-45-5 (D-Prolinamide)
64021-83-6 (N,N'-Dimethyl-3-aminopyrrolidine)
64415-15-2 (4-Aminosulphonyl-1-hydroxy-2-naphthoic acid)
67515-55-3 (4-Fluoro-3-(trifluoromethyl)benzoic acid)
67801-07-4 ((E)-3-(Trifluoromethyl)-cinnamic acid)
68453-63-4 (1-(3-Hydroxypropyl)-4,5-dihydroimidazole)
70987-78-9 ((2S)-(+)-Glycidyl tosylate)
71026-66-9 (N-(t-Butoxycarbonyl)-4-aminoaniline)
72934-37-3 (1-(4-Chlorophenyl)-cyclopropane carboxylic acid)
73579-08-5 (1-Methyl-4-(methylamino)piperidine)
74141-12-1 (E-3-(Tributylstannyl)-2-propen-1-ol)
81018-64-6 (Thiazoline-2-carboxylic acid)
81029-08-5 (4-(Methylsulphonyl)-3-nitrobenzoic acid)
85068-28-6 (2,6-Difluorophenyl-acetic acid)
89895-06-7 (4-Acetyl piperidine hydrochloride)
103057-44-9 (N-(tert-Butoxycarbonyl)-3-hydroxypyrrolidine)
104587-51-1 ((2S,4R)-2-(Hydroxymethyl)-4-hydroxypyrrolidine)
105184-38-1 (3,5-Difluorophenyl-acetic acid)
133659-14-0 (2-Chloro-3-methoxythiophene-4-carboxylic acid)
141699-57-2 (N-(tert-Butoxycarbonyl)-3-hydroxypyrrolidine methanesulphonate)
143128-39-6 (4-Amino-2-chloro-4'-fluorobenzophenone)
162364-72-9 (4-Chloro-6-methoxy-7-benzyloxyquinazoline)
162848-23-9 (2-Bromo-3-methoxythiophene-4-carboxylic acid)
179688-29-0 (6,7-Di(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one)
205194-33-8 (4-(3-Hydroxypropyl)-thiomorpholine-1,1-dioxide)
220141-72-0 (3,4,5-Trifluorobenzyl bromide)
220896-01-5 (7-Benzyloxy-3,4-dihydroquinazolin-4-thione)
330999-50-3 (4-(4-Aminoanilino)-6,7-dimethoxyquinazoline)
330999-74-1 (4-(4-(N-Boc-amino)anilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline dihydrochloride)
330999-79-6 (4-Chloro-6-methoxy-7-(2,2,2-trifluoroethoxy)quinazoline)
330999-80-9 (Ethyl 4-(2,2,2-trifluoroethoxy)-3-

methoxybenzoate)
331734-30-6 (3-Aminotetrahydrothiophene-S,S-dioxide dihydrochloride)
331776-45-5 ((E)-2,3,4-Trifluorocinnamic acid)
331776-49-9 (N-(4-Amino-2-(trifluoromethyl)phenyl)benzamide)
331776-52-4 (4-(4-(N-Boc-amino)anilino)-6-methoxy-7-(2,2,2-trifluoroethoxy)quinazoline)
331776-57-9 (4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-hydroxyquinazoline trifluoroacetate)
331776-58-0 (4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-benzyloxyquinazoline trifluoroacetate)
331776-61-5 (4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-(4-piperidinoxy)quinazoline)
331776-62-6 (4-(Methylthio)-6-methoxy-7-((4,5-dihydro-2-imidazolyl)methoxy)quinazoline)
331776-63-7 (4-(Methylthio)-6-methoxy-7-hydroxyquinazoline)
331776-65-9 (4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-(2-bromoethoxy)quinazoline)
331776-66-0 (3-(Aminomethyl)-thiophene dihydrochloride)
331776-68-2 ((R)-4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-(glycidyl)quinazoline)
331776-79-5 (4-((4-(N-Benzoyl)amino)anilino)-7-nitroquinazoline)
331776-81-9 (4-(Methylthio)-7-nitroquinazoline)
331776-85-3 (4-Amino-2,4'-difluorobenzophenone)
331776-89-7 (4-(4-Carboxyphenyl)-6-methoxy-7-(3-morpholinopropoxy)quinazoline)
331776-90-0 (4-(4-Carboxyanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline dihydrochloride)
6737-42-4; 38259-78-8; 104478-99-1; 331776-46-6;
331776-70-6; 331776-86-4; 331776-88-6; 331776-91-1;
331770-21-9; 331771-20-1; 331775-74-7;
331772-11-3; 331772-14-6;
331772-33-9; 331772-44-2;
331772-45-3; 331772-47-5;
331772-51-1; 331772-52-2;
331772-53-3; 331774-61-9;
331775-47-4; 331775-48-5;
331775-49-6; 331775-55-4; 202475-67-0;
331770-22-0; 331770-23-1;
331770-24-2; 331770-25-3;
331770-26-4; 331770-27-5;
331770-28-6; 331770-29-7;
331770-30-0; 331770-31-1;
331770-32-2; 331770-33-3;
331770-34-4; 331770-35-5;
331770-36-6; 331770-37-7;
331770-38-8; 331770-39-9;
331770-40-2; 331770-41-3;
331770-42-4; 331770-43-5;
331770-44-6; 331770-45-7;
331770-46-8; 331770-47-9;
331770-48-0; 331770-49-1;
331770-50-4; 331770-51-5;
331770-52-6; 331770-53-7;
331770-54-8; 331770-55-9;
331770-56-0; 331770-57-1;

REGISTRY NUMBER:

331770-58-2; 331770-59-3;
331770-60-6; 331770-61-7;
331770-62-8; 331770-63-9;
331770-64-0; 331770-65-1;
331770-66-2; 331770-67-3;
331770-68-4; 331770-69-5;
331770-70-8; 331770-71-9;
331770-72-0; 331770-73-1;
331770-74-2; 331770-75-3;
331770-76-4; 331770-77-5;
331770-78-6; 331770-79-7;
331770-80-0; 331770-81-1;
331770-82-2; 331770-83-3;
331770-84-4; 331770-85-5;
331770-86-6; 331770-87-7;
331770-88-8; 331770-89-9;
331770-90-2; 331770-91-3;
331770-92-4; 331770-93-5;
331770-94-6; 331770-95-7;
331770-96-8; 331770-97-9;
331770-98-0; 331770-99-1;
331771-00-7; 331771-01-8;
331771-02-9; 331771-03-0;
331771-04-1; 331771-05-2;
331771-06-3; 331771-07-4;
331771-08-5; 331771-09-6;
331771-10-9; 331771-11-0;
331771-12-1; 331771-13-2;
331771-14-3; 331771-15-4;
331771-16-5; 331771-17-6; 331771-18-7;
331771-19-8; 331771-21-2; 331771-22-3;
331771-23-4; 331771-24-5;
331771-25-6; 331771-26-7;
331771-27-8; 331771-28-9;
331771-29-0; 331771-30-3;
331771-31-4; 331771-32-5;
331771-33-6; 331771-34-7;
331771-35-8; 331771-36-9;
331771-37-0; 331771-38-1;
331771-39-2; 331771-40-5;
331771-41-6; 331771-42-7;
331771-43-8; 331771-44-9;
331771-45-0; 331771-46-1;
331771-47-2; 331771-48-3;
331771-49-4; 331771-50-7;
331771-51-8; 331771-52-9;
331771-53-0; 331771-54-1;
331771-55-2; 331771-56-3;
331771-57-4; 331771-58-5;
331771-59-6; 331771-60-9;
331771-61-0; 331771-62-1;
331771-63-2; 331771-64-3;
331771-65-4; 331771-66-5;
331771-67-6; 331771-68-7;
331771-69-8; 331771-70-1;
331771-71-2; 331771-72-3;
331771-73-4; 331771-74-5;
331771-75-6; 331771-76-7;
331771-77-8; 331771-78-9;

REGISTRY NUMBER:

331771-79-0; 331771-80-3;
331771-81-4; 331771-82-5;
331771-83-6; 331771-84-7;
331771-85-8; 331771-86-9;
331771-87-0; 331771-88-1;
331771-89-2; 331771-90-5;
331771-91-6; 331771-92-7;
331771-93-8; 331771-94-9;
331771-95-0; 331771-96-1;
331771-97-2; 331771-98-3;
331771-99-4; 331772-00-0;
331772-01-1; 331772-02-2;
331772-03-3; 331772-04-4;
331772-05-5; 331772-06-6;
331772-07-7; 331772-08-8;
331772-09-9; 331772-10-2;
331772-12-4; 331772-13-5;
331772-15-7; 331772-16-8;
331772-17-9; 331772-18-0;
331772-19-1; 331772-20-4;
331772-21-5; 331772-22-6;
331772-23-7; 331772-24-8;
331772-25-9; 331772-26-0;
331772-27-1; 331772-28-2;
331772-29-3; 331772-30-6;
331772-31-7; 331772-32-8;
331772-34-0; 331772-35-1;
331772-36-2; 331772-37-3;
331772-38-4; 331772-39-5;
331772-40-8; 331772-41-9;
331772-42-0; 331772-43-1;
331772-46-4; 331772-48-6;
331772-49-7; 331772-50-0;
331772-54-4; 331772-55-5;
331772-56-6; 331772-57-7;
331772-58-8; 331772-59-9;
331772-60-2; 331772-61-3;
331772-62-4; 331772-63-5;
331772-64-6; 331772-65-7;
331772-66-8; 331772-67-9;
331772-68-0; 331772-69-1;
331772-70-4; 331772-71-5;
331772-72-6; 331772-73-7;
331772-74-8; 331772-75-9;
331772-76-0; 331772-77-1;
331772-78-2; 331772-79-3;
331772-80-6; 331772-81-7;
331772-82-8; 331772-83-9;
331772-84-0; 331772-85-1;
331772-86-2; 331772-87-3;
331772-88-4; 331772-89-5;
331772-90-8; 331772-91-9;
331772-92-0; 331772-93-1;
331772-94-2; 331772-95-3;
331772-96-4; 331772-97-5;
331772-98-6; 331772-99-7;
331773-00-3; 331773-01-4;
331773-02-5; 331773-03-6;
331773-04-7; 331773-05-8;

331773-06-9; 331773-07-0;
331773-08-1; 331773-09-2;
331773-10-5; 331773-11-6;
331773-12-7; 331773-13-8;
331773-14-9; 331773-15-0;
331773-16-1; 331773-17-2;
331773-18-3; 331773-19-4;
331773-20-7; 331773-21-8;
331773-22-9; 331773-23-0;
331773-24-1; 331773-25-2;
331773-26-3; 331773-27-4;
331773-28-5; 331773-29-6;
331773-30-9; 331773-31-0;
331773-32-1; 331773-33-2;
331773-34-3; 331773-35-4;
331773-36-5; 331773-37-6;
331773-38-7; 331773-39-8;
331773-40-1; 331773-41-2;
331773-42-3; 331773-43-4;
331773-44-5; 331773-45-6;
331773-46-7; 331773-47-8;
331773-48-9; 331773-49-0;
331773-50-3; 331773-51-4;
331773-52-5; 331773-53-6;
331773-54-7; 331773-55-8;
331773-56-9; 331773-57-0;
331773-58-1; 331773-59-2;
331773-60-5; 331773-61-6;
331773-62-7; 331773-63-8;
331773-64-9; 331773-65-0;
331773-66-1; 331773-67-2;
331773-68-3; 331773-69-4;
331773-70-7; 331773-71-8;
331773-72-9; 331773-73-0;
331773-74-1; 331773-75-2;
331773-76-3; 331773-77-4;
331773-78-5; 331773-79-6;
331773-80-9; 331773-81-0;
331773-82-1; 331773-83-2;
331773-84-3; 331773-85-4;
331773-86-5; 331773-87-6;
331773-88-7; 331773-89-8;
331773-90-1; 331773-91-2;
331773-92-3; 331773-93-4;
331773-94-5; 331773-95-6;
331773-96-7; 331773-97-8;
331773-98-9; 331773-99-0;
331774-00-6; 331774-01-7;
331774-02-8; 331774-03-9;
331774-04-0; 331774-05-1;
331774-06-2; 331774-07-3;
331774-08-4; 331774-09-5;
331774-10-8; 331774-11-9;
331774-12-0; 331774-13-1;
331774-15-3; 331774-17-5;
331774-18-6; 331774-19-7;
331774-20-0; 331774-21-1;
331774-22-2; 331774-23-3;
331774-24-4; 331774-25-5;

331774-26-6; 331774-27-7;
331774-28-8; 331774-29-9;
331774-30-2; 331774-31-3;
331774-32-4; 331774-33-5;
331774-34-6; 331774-35-7;
331774-36-8; 331774-37-9;
331774-38-0; 331774-39-1;
331774-40-4; 331774-41-5;
331774-42-6; 331774-43-7;
331774-44-8; 331774-45-9;
331774-46-0; 331774-47-1;
331774-48-2; 331774-49-3;
331774-50-6; 331774-51-7;
331774-52-8; 331774-53-9;
331774-54-0; 331774-55-1;
331774-56-2; 331774-57-3;
331774-58-4; 331774-59-5;
331774-60-8; 331774-62-0;
331774-63-1; 331774-64-2;
331774-65-3; 331774-66-4;
331774-67-5; 331774-68-6;
331774-69-7; 331774-70-0;
331774-71-1; 331774-72-2;
331774-73-3; 331774-74-4;
331774-75-5; 331774-76-6;
331774-77-7; 331774-78-8;
331774-79-9; 331774-80-2;
331774-81-3; 331774-82-4;
331774-83-5; 331774-84-6;
331774-85-7; 331774-86-8;
331774-87-9; 331774-88-0;
331774-89-1; 331774-90-4;
331774-91-5; 331774-92-6;
331774-93-7; 331774-94-8;
331774-95-9; 331774-96-0;
331774-97-1; 331774-98-2;
331774-99-3; 331775-00-9;
331775-01-0; 331775-02-1;
331775-03-2; 331775-04-3;
331775-05-4; 331775-06-5;
331775-07-6; 331775-08-7;
331775-09-8; 331775-10-1;
331775-11-2; 331775-12-3;
331775-13-4; 331775-14-5;
331775-15-6; 331775-16-7;
331775-17-8; 331775-18-9;
331775-19-0; 331775-20-3;
331775-21-4; 331775-22-5;
331775-23-6; 331775-24-7;
331775-25-8; 331775-26-9;
331775-27-0; 331775-28-1;
331775-29-2; 331775-30-5;
331775-31-6; 331775-32-7;
331775-33-8; 331775-34-9;
331775-35-0; 331775-36-1;
331775-37-2; 331775-38-3;
331775-39-4; 331775-40-7;
331775-41-8; 331775-42-9;
331775-43-0; 331775-44-1;

REGISTRY NUMBER:

331775-45-2; 331775-46-3;
331775-50-9; 331775-51-0;
331775-52-1; 331775-53-2;
331775-54-3; 331775-56-5;
331775-57-6; 331775-58-7; 331775-59-8;
331775-60-1; 331775-61-2; 331775-62-3;
331775-63-4; 331775-64-5; 331775-65-6; 331775-66-7;
331775-67-8; 331775-68-9; 331775-69-0; 331775-70-3;
331775-71-4; 331775-72-5; 331775-73-6; 331775-75-8;
331775-76-9; 331775-77-0; 331775-78-1; 331775-79-2;
331775-80-5; 331775-81-6; 331775-82-7; 331775-83-8;
331775-84-9; 331775-85-0; 331775-86-1; 331775-87-2;
331775-88-3; 331775-89-4; 331775-90-7; 331775-91-8;
331775-92-9; 331775-93-0; 331775-94-1; 331775-95-2;
331775-96-3; 331775-97-4; 331775-98-5; 331775-99-6;
331776-00-2; 331776-01-3; 331776-02-4; 331776-03-5;
331776-04-6; 331776-05-7; 331776-06-8; 331776-07-9;
331776-08-0; 331776-09-1; 331776-10-4; 331776-11-5;
331776-12-6; 331776-13-7; 331776-14-8; 331776-15-9;
331776-16-0; 331776-17-1; 331776-18-2; 331776-19-3;
331776-20-6; 331776-21-7; 331776-22-8; 331776-23-9;
331776-24-0; 331776-25-1; 331776-26-2; 331776-27-3;
331776-28-4; 331776-29-5; 331776-30-8; 331776-31-9;
331776-32-0; 331776-33-1; 331776-34-2; 331776-35-3;
331776-36-4; 331776-37-5; 331776-38-6; 331776-39-7;
331776-40-0; 331776-41-1; 331776-42-2; 331776-43-3;
331776-44-4; 331810-24-3; 331825-58-2;
331825-60-6; 99-52-5; 111-39-7; 111-49-9;
111-95-5; 122-80-5; 127-69-5; 625-43-4; 651-06-9;
693-07-2; 729-99-7; 1576-43-8; 1576-44-9; 1948-92-1;
2058-49-3; 3881-20-7; 4476-28-2; 4892-89-1; 5471-90-9;
14763-60-1; 20173-04-0; 21035-59-6; 21539-47-9;
25236-64-0; 33331-99-6; 34750-64-6; 40306-32-9;
41239-40-1; 44565-47-1; 50274-85-6; 57165-06-7;
60923-28-6; 63765-79-7; 67579-87-7; 115132-84-8;
137709-66-1; 144870-96-2; 331776-53-5; 331776-55-7
; 331776-56-8; 331776-59-1;
331776-60-4; 331776-67-1; 331776-69-3;
331776-71-7; 331776-80-8

L21 ANSWER 19 OF 30 TOXCENTER COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:95460 TOXCENTER
COPYRIGHT: Copyright 2005 ACS
DOCUMENT NUMBER: CA13418252355M
TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors
AUTHOR(S): Mortlock, Andrew Austen; Keen, Nicholas John
CORPORATE SOURCE: ASSIGNEE: Astrazeneca UK Limited
PATENT INFORMATION: WO 2001021594 A1 29 Mar 2001
SOURCE: (2001) PCT Int. Appl., 101 pp.
CODEN: PIXXD2.
COUNTRY: SWEDEN
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2001:228864
LANGUAGE: English
ENTRY DATE: Entered STN: 20011116
Last Updated on STN: 20050823

ABSTRACT:

Title compds. (I) [wherein X = O, S, SO, SO₂, NH, or NR₈; R₈ = H or alkyl; Ra =

S.I.C.
Applicant's
PCT

(un)substituted 3-quinolinyl or Ph; R1-R4 = independently halo, CN, NO₂, alkylsulfanyl, N(OH)R12, or R14X1; R12 = H or alkyl; X1 = a direct bond, O, CH₂, OC(O), CO, S, SO, SO₂, or (un)substituted NHCO, CONH, SO₂NH, NHSO₂, or NH; R14 = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, 4-phenoxyaniline•HCl and 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline were refluxed in i-PrOH to yield II (86%). The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.069 μ M. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 2.89 μ M and reduced BrdU incorporation into cellular DNA by 50% at 3.68 μ M.

CLASSIFICATION CODE: 28-16

SUPPLEMENTARY TERMS: Miscellaneous Descriptors

quinazoline prepn aurora 2 kinase inhibitor; anticancer antiproliferative quinazoline prepn

REGISTRY NUMBER:

13790-39-1 (4-Chloro-6,7-dimethoxyquinazoline)
13794-72-4 (6,7-Dimethoxy-3,4-dihydroquinazolin-4-one)
16665-38-6 (2-(Hydroxymethyl)-4-methoxypyridine)
42508-74-7 (2-(Hydroxymethyl)-4-picoline)
108479-25-0 (Ethyl 3-methoxy-4-(3-morpholinopropoxy)benzoate)
162364-72-9 (4-Chloro-6-methoxy-7-benzyloxyquinazoline)
179687-94-6 (3-Fluoro-4-(2-pyridylmethoxy)aniline)
179687-96-8 (3-Methyl-4-[(4-methoxy-2-pyridyl)methoxy]aniline)
179687-97-9 (3-Methyl-4-[(6-methyl-2-pyridyl)methoxy]aniline)
179688-01-8 (7-Benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one)
179688-53-0 (6-Acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one)
179688-54-1 (4-Chloro-6-acetoxy-7-methoxyquinazoline hydrochloride)
196194-62-4 (6-Methoxy-7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one)
230955-75-6 (4-Chloro-6-acetoxy-7-methoxyquinazoline)
330999-74-1 (4-[4-(N-Boc-amino)anilino]-6-methoxy-7-(3-morpholinopropoxy)quinazoline dihydrochloride)
330999-75-2 (3-Methyl-4-[(4-methyl-2-pyridyl)methoxy]aniline)
330999-76-3 (2-[(4-Methyl-2-pyridyl)methoxy]-5-nitrotoluene)
330999-77-4 (2-[(4-Methoxy-2-pyridyl)methoxy]-5-nitrotoluene)
330999-78-5 (2-[(6-Methyl-2-pyridyl)methoxy]-5-nitrotoluene)
330999-79-6 (4-Chloro-6-methoxy-7-(2,2,2-trifluoroethoxy)quinazoline)
330999-80-9 (Ethyl 4-(2,2,2-trifluoroethoxy)-3-methoxybenzoate)
330999-81-0 (Ethyl 3-methoxy-4-(2,2,2-trifluoroethoxy)-6-nitrobenzoate)
330999-82-1 (Ethyl 3-methoxy-4-(2,2,2-trifluoroethoxy)-6-aminobenzoate)
330999-83-2 (6-Methoxy-7-(2,2,2-trifluoroethoxy)-3,4-dihydroquinazolin-4-one)
330999-84-3 (Ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-

nitrobenzoate)
330999-85-4 (Ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-aminobenzoate)
9026-43-1 (Serine/threonine kinase)
458560-40-2 (Protein kinase aurora 2)
59-51-8 (Methionine)
92-69-3 (4-Phenylphenol)
98-00-0 (Furfuryl alcohol)
98-98-6 (Picolinic acid)
101-53-1 (4-Hydroxydiphenylmethane)
101-59-7 (4-Amino-4'-nitrodiphenylsulfide)
101-79-1 (4-Amino-4'-chlorodiphenyl ether)
103-16-2 (4-Benzyloxyphenol)
103-63-9 (Phenethyl bromide)
104-13-2 (4-Butylaniline)
104-96-1 (4-Aminothioanisole)
108-47-4 (2,4-Lutidine)
109-70-6 (1-Bromo-3-chloropropane)
123-30-8 (4-Aminophenol)
139-59-3 (4-Phenoxyaniline)
369-34-6 (3,4-Difluoronitrobenzene)
455-88-9 (2-Fluoro-5-nitrotoluene)
540-37-4 (4-Iodoaniline)
540-38-5 (4-Iodophenol)
580-17-6 (3-Aminoquinoline)
586-98-1 (2-(Hydroxymethyl)pyridine)
607-12-5 (5-Chloro-2-hydroxybiphenyl)
617-05-0 (Ethyl vanillate)
623-47-2 (Ethyl propiolate)
636-98-6 (4-Iodonitrobenzene)
645-56-7 (4-Propylphenol)
831-82-3 (4-Phenoxyphenol)
1066-54-2 ((Trimethylsilyl)acetylene)
1073-72-9 (4-(Methylmercapto)phenol)
1122-71-0 (2-(Hydroxymethyl)-6-methylpyridine)
1135-12-2 (4-Aminodiphenylmethane)
1689-82-3 (4-Phenylazophenol)
2359-60-6 (1-(4-Aminophenyl)piperidine)
2713-33-9 (3,4-Difluorophenol)
2835-96-3 (4-Amino-2-methylphenol)
3916-44-7 (4-Hydroxy-4'-nitrobiphenyl)
4344-55-2 (4-Butoxyaniline)
5597-50-2 (Methyl 3-(4-hydroxyphenyl)propionate)
5653-40-7 (4,5-Dimethoxyanthranilic acid)
6959-47-3 (2-Picolyl chloride hydrochloride)
7357-67-7 (N-(3-Chloropropyl)morpholine)
17362-17-3 (3-(4-Hydroxyphenyl)propionitrile)
18979-50-5 (4-Propoxyphenol)
18979-53-8 (4-Pentyloxyphenol)
24900-79-6 ((4-Amino-2-chlorophenyl)-4-chlorophenyl ether)
25236-64-0 (2,2,2-Trifluoroethyl methanesulfonate)
29558-77-8 (4-Bromo-4'-hydroxybiphenyl)
33228-45-4 (4-Hexylaniline)
51388-20-6 (4-Benzyloxyaniline hydrochloride)
54457-84-0 ((4-Amino-2,6-dichlorophenyl)-4-chlorophenylsulfide)
60547-98-0 (2-Amino-4-benzyloxy-5-methoxybenzamide)
71026-66-9 (N-(tert-Butoxycarbonyl)-1,4-phenylenediamine)
129912-30-7 (4-Chloro-6,7-dimethoxyquinazoline)

hydrochloride)
168835-91-4 (4-(4-Iodoanilino)-6,7-dimethoxyquinazoline)
196195-13-8 (4-Chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline)
REGISTRY NUMBER: 29681-43-4; 35283-10-4; 179688-28-9; 330999-86-5;
330999-53-6; 330999-66-1; 183322-25-0; 179246-62-9;
179688-83-6; 183319-34-8; 330999-28-5; 330999-29-6;
330999-30-9; 330999-31-0; 330999-32-1; 330999-33-2;
330999-34-3; 330999-35-4; 330999-36-5; 330999-37-6;
330999-38-7; 330999-39-8; 330999-40-1; 330999-41-2;
330999-42-3; 330999-43-4; 330999-44-5; 330999-45-6;
330999-46-7; 330999-47-8; 330999-48-9; 330999-49-0;
330999-50-3; 330999-51-4; 330999-52-5; 330999-54-7;
330999-55-8; 330999-56-9; 330999-57-0; 330999-58-1;
330999-59-2; 330999-60-5; 330999-61-6; 330999-62-7;
330999-63-8; 330999-64-9; 330999-65-0; 330999-67-2;
330999-68-3; 330999-69-4; 330999-70-7; 330999-71-8;
330999-72-9; 2524-67-6; 4760-58-1; 35283-08-0;
188829-39-2; 330999-73-0

L21 ANSWER 20 OF 30 TOXCENTER COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:181880 TOXCENTER
COPYRIGHT: Copyright 2005 ACS
DOCUMENT NUMBER: CA12509114665A
TITLE: Preparation of quinoline and quinazoline protein tyrosine
kinase inhibitors
AUTHOR(S): Hudson, Alan Thomas; Vile, Sadie; Barraclough, Paul;
Franzmann, Karl Witold; McKeown, Stephen Carl; Page,
Martin John
CORPORATE SOURCE: ASSIGNEE: Wellcome Foundation Limited
PATENT INFORMATION: WO 969294 A1 28 Mar 1996
SOURCE: (1996) PCT Int. Appl., 139 pp.
CODEN: PIXXD2.
COUNTRY: UNITED KINGDOM
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 1996:462220
LANGUAGE: English
ENTRY DATE: Entered STN: 20011116
Last Updated on STN: 20020730

ABSTRACT:
The title compds. [I; X = N, CH; Y = W(CH₂), (CH₂)W, W; W = O, S(O)m,
(un)substituted NH; R₁ = NH₂, H, halogen, OH, NO₂, CO₂H, CF₃, CF₃O, ureido,
etc.; R₄ = H, OH, halogen, alkyl, alkoxy, alkylthio, CN, NO₂, CF₃, etc.; n =
1-3; R₅ = H, halogen, CF₃, alkyl, alkoxy; R₆ = substituted hydrocarbyl, etc.],
which are protein tyrosine kinase inhibitors, are prepared Thus,
4-chloroquinoline was reacted with 4-methoxyaniline in the presence of HCl,
producing 4-(4-phenoxyanilino)quinoline hydrochloride, m.p. 216-218°,
which demonstrated a IC₅₀ against p56lck protein tyrosine kinase of 5 µM.

CLASSIFICATION CODE: 28-16

SUPPLEMENTARY TERMS: Miscellaneous Descriptors
phenoxyanilinoquinoline prepn protein tyrosine kinase
inhibitor; antiatherosclerotic prepn quinazoline;
antitumor agent prepn quinazoline; antithrombotic prepn
quinazoline

REGISTRY NUMBER: 80449-02-1 (Protein tyrosine kinase)
62-55-5 (Ethanethioamide)
88-30-2 (4-Nitro-3-(trifluoromethyl)phenol)
98-00-0 (2-Furanmethanol)

99-28-5 (2,6-Dibromo-4-nitrophenol)
99-65-0 (1,3-Dinitrobenzene)
100-02-7 (4-Nitrophenol)
100-11-8 (4-Nitrobenzylbromide)
100-39-0 (Benzyl bromide)
100-44-7 (Benzyl chloride)
100-51-6 (Benzenemethanol)
101-79-1 (4-(4-Chlorophenoxy)aniline)
108-24-7 (Acetic anhydride)
108-95-2 (Phenol)
108-98-5 (Thiophenol)
139-59-3 (4-Phenoxyaniline)
350-46-9 (4-Fluoronitrobenzene)
400-74-8 (4-Fluoro-3-trifluoromethylnitrobenzene)
403-19-0 (2-Fluoro-4-nitrophenol)
446-48-0 (2-Fluorobenzyl bromide)
455-88-9 (2-Fluoro-5-nitrotoluene)
491-36-1 (4(1H)-Quinazolinone)
536-74-3 (Phenylacetylene)
540-37-4 (4-Iodoaniline)
578-51-8 (2-Bromobenzyl chloride)
619-08-9 (2-Chloro-4-nitrophenol)
636-72-6 (2-Thiophenemethanol)
697-73-4 (2,6-Difluorobenzyl chloride)
782-45-6 (4-Aminobenzanilide)
834-24-2 (4-Aminostilbene)
836-43-1 (4-Benzyloxybenzyl alcohol)
1135-12-2 (4-Aminodiphenylmethane)
1135-14-4 (4-(Phenylthio)aniline)
1137-41-3 (4-Aminobenzophenone)
1836-75-5 (4-(2,4-Dichlorophenoxy)nitrobenzene)
1849-36-1 (4-Nitrothiophenol)
2014-83-7 (2,6-Dichlorobenzyl chloride)
2359-60-6 (N-(4-Aminophenyl)piperidine)
2524-67-6 (N-(4-Aminophenyl)morpholine)
2550-36-9 (Cyclohexylmethyl bromide)
2581-34-2 (3-Methyl-4-nitrophenol)
3096-81-9 (4-Phenoxybenzonitrile)
3251-56-7 (2-Methoxy-4-nitrophenol)
3586-12-7 (3-Phenoxyaniline)
4295-06-1 (4-Chloro-2-methylquinoline)
4360-63-8 (2-Bromomethyl-1,3-dioxolane)
4412-91-3 (3-Furanmethanol)
6373-50-8 (4-Cyclohexylaniline)
7035-02-1 (2-Methoxybenzyl chloride)
17417-09-3 (2-Fluoro-5-nitrobenzonitrile)
22544-04-3 (3-Chloro-4-(2,4-dichlorophenoxy)nitrobenzene)
26697-35-8 (4-Benzyloxy-2-nitroaniline)
33884-43-4 (2-(2-Bromoethyl)-1,3-dioxane)
71637-34-8 (3-Thiophenemethanol)
76243-24-8 (4-Benzyloxy-3-fluoronitrobenzene)
175201-90-8 (4-(3-Aminophenyl)-2-methylpyrimidine)
14861-17-7 (4-(2,4-Dichlorophenoxy)aniline)
56966-58-6 (3-Chloro-4-(2,4-dichlorophenoxy)aniline)
179246-27-6 (2-(4-Nitrophenoxy)methyl)thiophene)
179246-59-4; 179246-80-1; 179247-03-1; 179247-09-7;
179247-14-4; 179248-74-9; 179248-75-0; 179248-76-1;
179248-77-2; 77725-90-7; 77729-07-8; 179246-07-2;
179246-08-3; 179246-18-5; 179246-52-7; 179246-53-8;

REGISTRY NUMBER:

179246-54-9; 179246-55-0; 179246-56-1; 179246-57-2;
179246-58-3; 179246-60-7; 179246-61-8; 179246-62-9;
179246-63-0; 179246-64-1; 179246-65-2; 179246-66-3;
179246-67-4; 179246-68-5; 179246-69-6; 179246-70-9;
179246-71-0; 179246-72-1; 179246-73-2; 179246-74-3;
179246-75-4; 179246-76-5; 179246-77-6; 179246-78-7;
179246-79-8; 179246-81-2; 179246-82-3; 179246-83-4;
179246-84-5; 179246-85-6; 179246-86-7; 179246-87-8;
179246-88-9; 179246-89-0; 179246-90-3; 179246-91-4;
179246-92-5; 179246-93-6; 179246-94-7; 179246-95-8;
179246-96-9; 179246-97-0; 179246-98-1; 179246-99-2;
179247-00-8; 179247-01-9; 179247-02-0; 179247-04-2;
179247-05-3; 179247-06-4; 179247-07-5; 179247-08-6;
179247-10-0; 179247-11-1; 179247-12-2; 179247-13-3;
179247-15-5; 179247-16-6; 179247-17-7; 179247-18-8;
179247-19-9; 179247-20-2; 179247-21-3; 179247-22-4;
179247-23-5; 179247-24-6; 179247-25-7; 179247-26-8;
179247-27-9; 179247-28-0; 179247-29-1; 179247-30-4;
179247-31-5; 179247-32-6; 179247-33-7; 179247-34-8;
179247-35-9; 179247-36-0; 179247-37-1; 179247-38-2;
179247-39-3; 179247-40-6; 179247-41-7;
179247-42-8; 179247-43-9; 179247-44-0;
179247-45-1; 179247-46-2; 179247-47-3; 179247-48-4;
179247-49-5; 179247-50-8; 179247-51-9; 179247-52-0;
179247-53-1; 179247-54-2; 179247-55-3; 179247-56-4;
179247-57-5; 179247-58-6; 179247-59-7; 179247-60-0;
179247-61-1; 179247-62-2; 179247-63-3; 179247-64-4;
179247-65-5; 179247-66-6; 179247-67-7; 179247-68-8;
179247-69-9; 179247-70-2; 179247-71-3; 179247-72-4;
179247-73-5; 179247-74-6; 179247-75-7; 179247-76-8;
179247-77-9; 179247-78-0; 179247-79-1; 179247-80-4;
179247-81-5; 179247-82-6; 179247-83-7; 179247-84-8;
179247-85-9; 179247-86-0; 179247-87-1; 179247-88-2;
179247-89-3; 179247-90-6; 179247-91-7; 179247-92-8;
179247-93-9; 179247-94-0; 179247-95-1; 179247-96-2;
179247-97-3; 179247-98-4; 179247-99-5; 179248-00-1;
179248-01-2; 179248-02-3; 179248-03-4; 179248-04-5;
179248-05-6; 179248-06-7; 179248-07-8; 179248-08-9;
179248-09-0; 179248-10-3; 179248-11-4; 179248-12-5;
179248-13-6; 179248-14-7; 179248-15-8; 179248-16-9;
179248-17-0; 179248-18-1; 179248-19-2; 179248-20-5;
179248-21-6; 179248-22-7; 179248-23-8; 179248-24-9;
179248-25-0; 179248-26-1; 179248-27-2; 179248-28-3;
179248-29-4; 179248-30-7; 179248-31-8; 179248-32-9;
179248-33-0; 179248-34-1; 179248-35-2; 179248-36-3;
179248-37-4; 179248-38-5; 179248-39-6; 179248-40-9;
179248-41-0; 179248-42-1; 179248-43-2; 179248-44-3;
179248-45-4; 179248-46-5; 179248-47-6; 179248-48-7;
179248-49-8; 179248-50-1; 179248-51-2; 179248-52-3;
179248-53-4; 179248-54-5; 179248-55-6; 179248-56-7;
179248-57-8; 179248-58-9; 179248-59-0; 179248-60-3;
179248-61-4; 179248-62-5; 179248-63-6; 179248-64-7;
179248-65-8; 179248-66-9; 179248-68-1; 179248-69-2;
179248-70-5; 179248-71-6; 179248-72-7; 179248-73-8;
179248-81-8; 72-14-0; 103-16-2; 446-32-2; 611-35-8;
616-79-5; 637-89-8; 712-97-0; 778-94-9; 1484-26-0;
3473-63-0; 5326-47-6; 5653-40-7; 6373-46-2; 6958-39-0;
6972-71-0; 13425-93-9; 16064-14-5; 16064-25-8; 16499-57-3
20197-71-1; 20872-93-9; 30519-03-0; 32084-59-6;

REGISTRY NUMBER:

57940-05-3; 58230-69-6; 60233-66-1; 76745-74-9;
 108711-21-3; 121180-51-6; 152305-23-2; 179246-09-4;
 179248-83-0; 713-41-7; 716-32-5; 721-00-6; 1591-38-4;
 1849-25-8; 2148-55-2; 2148-57-4; 2976-71-8; 3048-12-2;
 4792-60-3; 5190-68-1; 6943-17-5; 7253-22-7; 7703-38-0;
 13024-49-2; 13738-70-0; 13790-39-1; 15015-57-3;
 15089-77-7; 15382-71-5; 16064-08-7; 16499-56-2;
 16499-58-4; 16499-61-9; 16499-62-0; 16499-64-2;
 16499-65-3; 17272-83-2; 17625-83-1; 19815-16-8;
 19815-17-9; 22227-55-0; 22424-58-4; 24007-66-7;
 27691-43-6; 31867-90-0; 31867-91-1; 31867-92-2;
 35241-23-7; 35654-56-9; 38267-96-8; 38469-85-1;
 39062-69-6; 40680-63-5; 50377-49-6; 50424-28-7;
 50508-54-8; 55496-52-1; 57181-90-5; 59404-86-3;
 64431-77-2; 70338-47-5; 72700-23-3; 76253-28-6;
 76253-40-2; 91092-88-5; 98556-31-1; 98953-59-4;
 107622-80-0; 107922-43-0; 133209-49-1; 135106-52-4;
 155960-93-3; 155960-95-5; 155960-98-8; 162363-46-4;
 166955-01-7; 168268-00-6; 179246-10-7; 179246-11-8;
 179246-12-9; 179246-13-0; 179246-14-1; 179246-16-3;
 179246-17-4; 179246-19-6; 179246-20-9; 179246-21-0;
 179246-22-1; 179246-23-2; 179246-24-3; 179246-25-4;
 179246-26-5; 179246-29-8; 179246-30-1; 179246-31-2;
 179246-32-3; 179246-33-4; 179246-34-5; 179246-35-6;
 179246-36-7; 179246-37-8; 179246-38-9; 179246-39-0;
 179246-40-3; 179246-41-4; 179246-42-5; 179246-43-6;
 179246-44-7; 179246-45-8; 179246-46-9; 179246-47-0;
 179246-48-1; 179246-49-2; 179246-50-5; 179246-51-6;
 179248-67-0; 179248-78-3; 179248-79-4; 179248-80-7;
 179248-82-9

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, TOXCENTER, USPATFULL, BIOSIS, CAOLD' -
 CONTINUE? (Y)/N:y

L21 ANSWER 21 OF 30 USPATFULL on STN DUPLICATE 9
 ACCESSION NUMBER: 2003:306981 USPATFULL
 TITLE: Substituted anilino-quinoline compounds and use thereof
 INVENTOR(S): Cumming, John G., Macclesfield, UNITED KINGDOM
 PATENT ASSIGNEE(S): ASTRAZENECA AB (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003216417	A1	20031120
	US 6716847	B2	20040406
APPLICATION INFO.:	US 2003-441084	A1	20030520 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-787883, filed on 23 Mar 2001, GRANTED, Pat. No. US 6593333 A 371 of International Ser. No. WO 1999-GB3220, filed on 27 Sep 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-21338	19981001
	GB 1999-6564	19990323
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE
 NW, WASHINGTON, DC, 20004
 NUMBER OF CLAIMS: 13
 EXEMPLARY CLAIM: 1
 LINE COUNT: 3538

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns amide derivatives of Formula (I), wherein: G is N or CH; R^{sup.1} is a group such as hydroxy, halo, trifluoromethyl, C_{sub.1-6}alkyl and C_{sub.1-6}alkoxy; each of R^{sup.2} and R^{sup.3} is hydrogen, halo, C_{sub.1-6}alkyl, C_{sub.2-6}alkenyl or C_{sub.2-6}alkynyl; R^{sup.4} is a group such as hydrogen, hydroxy, C_{sub.1-6}alkyl, C_{sub.1-6}alkoxy and C_{sub.3-7}cycloalkyl, or R^{sup.4} is of the Formula (IC): --K-J, wherein J is aryl, heteroaryl or heterocyclyl and K is a bond or a group such as oxy and imino, R^{sup.5} is a group such as hydrogen, halo and trifluoromethyl; m is 1-3 and q is 0-4; or pharmaceutically acceptable salts or in vivo cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 263400-17-5P 263400-18-6P

(preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)

RN 263400-17-5 USPATFULL


CN 4-Pyridinecarboxamide, N-[3-[[6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-18-6 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[(6-hydroxy-7-methoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




IT 263399-67-3P 263399-68-4P 263399-70-8P
 263399-71-9P 263399-72-0P 263399-74-2P
 263399-75-3P 263399-76-4P 263399-77-5P
 263399-78-6P 263399-79-7P 263399-80-0P
 263399-81-1P 263399-82-2P 263399-83-3P
 263399-84-4P 263399-85-5P 263399-86-6P
 263399-87-7P 263399-88-8P 263399-89-9P
 263399-90-2P 263399-91-3P 263399-92-4P
 263399-93-5P 263399-94-6P 263399-95-7P
 263399-96-8P 263399-97-9P 263399-98-0P
 263399-99-1P 263400-00-6P 263400-01-7P
 263400-03-9P 263400-04-0P 263400-05-1P
 263400-06-2P 263400-07-3P 263400-08-4P
 263400-09-5P 263400-10-8P 263400-11-9P
 263400-12-0P 263400-13-1P 263400-19-7P
 263400-20-0P 263400-21-1P 263400-22-2P
 263400-23-3P 263400-25-5P 263400-26-6P
 263400-27-7P 263400-28-8P 263400-29-9P
 263400-30-2P 263400-31-3P 263400-32-4P
 263400-33-5P 263400-34-6P 263400-35-7P
 263400-36-8P 263400-37-9P 263400-38-0P
 263400-39-1P 263400-40-4P 263400-41-5P
 263400-42-6P 263400-43-7P 263400-44-8P
 263400-45-9P 263400-46-0P 263400-48-2P
 263400-50-6P 263400-51-7P 263400-52-8P
 263400-53-9P 263400-94-8P

(preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)


RN 263399-67-3 USPATFULL

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-68-4 USPATFULL
 CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,4-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-70-8 USPATFULL
 CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-71-9 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-72-0 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-74-2 USPATFULL


CN Benzamide, 4-cyano-N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-75-3 USPATFULL


CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263399-76-4 USPATFULL


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-77-5 USPATFULL


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263399-78-6 USPATFULL


CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-79-7 USPATFULL


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263399-80-0 USPATFULL


CN Acetamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-81-1 USPATFULL


CN Propanamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-82-2 USPATFULL


CN Acetamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-83-3 USPATFULL


CN Propanamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-84-4 USPATFULL


CN Acetamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-85-5 USPATFULL

CN Acetamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-86-6 USPATFULL
 CN Acetamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-87-7 USPATFULL
 CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-88-8 USPATFULL


CN 2-Furancarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-89-9 USPATFULL


CN 3-Pyridinecarboxamide, 6-chloro-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-90-2 USPATFULL


CN 5-Isioxazolecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-91-3 USPATFULL

CN Benzamide, 3-(dimethylamino)-N-[4-methyl-3-[(6,7,8-trimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 263399-92-4 USPATFULL

CN Carbamic acid, [5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 263399-93-5 USPATFULL


CN Benzamide, 4-cyano-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-94-6 USPATFULL

CN Benzamide, N-[2-fluoro-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 263399-95-7 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-96-8 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-97-9 USPATFULL


CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-98-0 USPATFULL


CN Benzamide, 4-cyano-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-99-1 USPATFULL


CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-00-6 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-01-7 USPATFULL


CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-03-9 USPATFULL

CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2,4-difluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-04-0 USPATFULL
 CN Benzamide, N-[4-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-05-1 USPATFULL
 CN Benzamide, 3-(dimethylamino)-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-06-2 USPATFULL


CN Acetamide, N-[4-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-07-3 USPATFULL


CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[3-(3-pyridinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-08-4 USPATFULL


CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-09-5 USPATFULL


CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-10-8 USPATFULL


CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 263400-11-9 USPATFULL

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 263400-12-0 USPATFULL
 CN 4-Pyridinecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-13-1 USPATFULL
 CN Benzamide, N-[2-fluoro-5-[(6,7,8-trimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-19-7 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(diethylamino)-2-oxoethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-20-0 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)-2-oxoethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-21-1 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)ethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-22-2 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(diethylamino)ethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-23-3 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-[bis(1-methylethyl)amino]ethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-25-5 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[3-(dimethylamino)propoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-26-6 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[3-(diethylamino)propoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-27-7 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)-2-methylpropoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-28-8 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-29-9 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-piperidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-30-2 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-31-3 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-32-4 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-33-5 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-34-6 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-35-7 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[(1-methyl-2-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-36-8 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[(1-methyl-3-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-37-9 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[(1-methyl-5-oxo-2-piperidinyl)methoxy]-4-quinazoliny]amino]-4-methylphenyl]-2-(4-morpholinyl)-(9CI) (CA INDEX NAME)




RN 263400-38-0 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(2-oxo-1-imidazolidinyl)ethoxy]-4-quinazoliny]amino]-4-methylphenyl]-2-(4-morpholinyl)-(9CI) (CA INDEX NAME)




RN 263400-39-1 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]-4-quinazoliny]amino]-4-methylphenyl]-2-(4-morpholinyl)-(9CI) (CA INDEX NAME)




RN 263400-40-4 USPATFULL

CN Benzamide, 4-cyano-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 263400-41-5 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-42-6 USPATFULL


CN 4-Pyridinecarboxamide, N-[3-[(7-fluoro-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 263400-43-7 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[3-(methylsulfonyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-44-8 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-45-9 USPATFULL


CN 2-Thiophenecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-46-0 USPATFULL


CN Cyclopropanecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-48-2 USPATFULL


CN Acetamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-50-6 USPATFULL

CN Carbamic acid, [5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 263400-51-7 USPATFULL

CN Benzamide, 4-cyano-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 263400-52-8 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6,7-dimethoxy-4-quinazolinyl]amino]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-53-9 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-94-8 USPATFULL

CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-
(9CI) (CA INDEX NAME)




IT 263400-86-8P 263400-87-9P

(preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors
of cytokine mediated disease)

RN 263400-86-8 USPATFULL


CN 4-Pyridinecarboxamide, N-[3-[(7-hydroxy-6-methoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-87-9 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-(phenylmethoxy)-4-

quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride
(9CI) (CA INDEX NAME)



● 2 HCl

L21 ANSWER 22 OF 30 USPATFULL on STN

ACCESSION NUMBER: 2003:190778 USPATFULL

TITLE: Substituted anilino-quinazoline (or quinoline) compounds and use thereof

INVENTOR(S): Cumming, John G, Macclesfield, UNITED KINGDOM

PATENT ASSIGNEE(S): Astrazeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6593333	B1	20030715
	WO 2000020402		20000413
APPLICATION INFO.:	US 2001-787883		20010323 (9)
	WO 1999-GB3220		19990927

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-21338	19981001
	GB 1999-6564	19990323

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Raymond, Richard L.

ASSISTANT EXAMINER: Truong, Tamthom N.

LEGAL REPRESENTATIVE: Morgan, Lewis & Bockius LLP

NUMBER OF CLAIMS: 12

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 3585

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB ##STR1##

The invention concerns amide derivatives of Formula (I), wherein: G is N or CH; R^{sup.1} is a group such as hydroxy, halo, trifluoromethyl, C_{sub.1-6}alkyl and C_{sub.1-6}alkoxy; each of R^{sup.2} and R^{sup.3} is hydrogen, halo, C_{sub.1-6}alkyl, C_{sub.2-6}alkenyl or C_{sub.2-6}alkynyl;

R.sup.4 is a group such as hydrogen, hydroxy, C.sub.1-6alkyl, C.sub.1-6alkoxy and C.sub.3-7cycloalkyl, or R.sup.4 is of the Formula (IC): --K--J, wherein J is aryl, heteroaryl or heterocyclyl and K is a bond or a group such as oxy and imino, R.sup.5 is a group such as hydrogen, halo and trifluoromethyl: m is 1-3 and q is 0-4; or pharmaceutically acceptable salts or in vivo cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 263400-17-5P 263400-18-6P

(preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)

RN 263400-17-5 USPATFULL


CN 4-Pyridinecarboxamide, N-[3-[[6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-18-6 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[(6-hydroxy-7-methoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




IT 263399-67-3P 263399-68-4P 263399-70-8P

263399-71-9P 263399-72-0P 263399-74-2P
263399-75-3P 263399-76-4P 263399-77-5P
263399-78-6P 263399-79-7P 263399-80-0P
263399-81-1P 263399-82-2P 263399-83-3P
263399-84-4P 263399-85-5P 263399-86-6P
263399-87-7P 263399-88-8P 263399-89-9P
263399-90-2P 263399-91-3P 263399-92-4P
263399-93-5P 263399-94-6P 263399-95-7P
263399-96-8P 263399-97-9P 263399-98-0P
263399-99-1P 263400-00-6P 263400-01-7P
263400-03-9P 263400-04-0P 263400-05-1P
263400-06-2P 263400-07-3P 263400-08-4P
263400-09-5P 263400-10-8P 263400-11-9P
263400-12-0P 263400-13-1P 263400-19-7P
263400-20-0P 263400-21-1P 263400-22-2P
263400-23-3P 263400-25-5P 263400-26-6P
263400-27-7P 263400-28-8P 263400-29-9P
263400-30-2P 263400-31-3P 263400-32-4P
263400-33-5P 263400-34-6P 263400-35-7P
263400-36-8P 263400-37-9P 263400-38-0P
263400-39-1P 263400-40-4P 263400-41-5P
263400-42-6P 263400-43-7P 263400-44-8P
263400-45-9P 263400-46-0P 263400-48-2P
263400-50-6P 263400-51-7P 263400-52-8P
263400-53-9P 263400-94-8P

(preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)

RN 263399-67-3 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-68-4 USPATFULL


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,4-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-70-8 USPATFULL


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-71-9 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-72-0 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-74-2 USPATFULL


CN Benzamide, 4-cyano-N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-75-3 USPATFULL


CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 263399-76-4 USPATFULL


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-77-5 USPATFULL


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 263399-78-6 USPATFULL


CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-79-7 USPATFULL


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 263399-80-0 USPATFULL


CN Acetamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-81-1 USPATFULL


CN Propanamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-82-2 USPATFULL


CN Acetamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-83-3 USPATFULL


CN Propanamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-84-4 USPATFULL

CN Acetamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-85-5 USPATFULL
 CN Acetamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-86-6 USPATFULL
 CN Acetamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-87-7 USPATFULL


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-88-8 USPATFULL


CN 2-Furancarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-89-9 USPATFULL


CN 3-Pyridinecarboxamide, 6-chloro-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-90-2 USPATFULL


CN 5-Isoxazolecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-91-3 USPATFULL

CN Benzamide, 3-(dimethylamino)-N-[4-methyl-3-[(6,7,8-trimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 263399-92-4 USPATFULL

CN Carbamic acid, [5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 263399-93-5 USPATFULL


CN Benzamide, 4-cyano-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-94-6 USPATFULL

CN Benzamide, N-[2-fluoro-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 263399-95-7 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-96-8 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-97-9 USPATFULL


CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-98-0 USPATFULL


CN Benzamide, 4-cyano-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-99-1 USPATFULL


CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-00-6 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-01-7 USPATFULL


CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-03-9 USPATFULL


CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2,4-difluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-04-0 USPATFULL


CN Benzamide, N-[4-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-05-1 USPATFULL


CN Benzamide, 3-(dimethylamino)-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-06-2 USPATFULL

CN Acetamide, N-[4-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-07-3 USPATFULL
 CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[3-(3-pyridinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 263400-08-4 USPATFULL
 CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-09-5 USPATFULL


CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-10-8 USPATFULL


CN Acetamide, N-[2-fluoro-5-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-11-9 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-12-0 USPATFULL


CN 4-Pyridinecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-13-1 USPATFULL


CN Benzamide, N-[2-fluoro-5-[(6,7,8-trimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-19-7 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(diethylamino)-2-oxoethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-20-0 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)-2-oxoethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-21-1 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)ethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-22-2 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(diethylamino)ethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-23-3 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-[bis(1-methylethyl)amino]ethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI)
(CA INDEX NAME)




RN 263400-25-5 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[3-(dimethylamino)propoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-26-6 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[3-(diethylamino)propoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-27-7 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)-2-methylpropoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI)
(CA INDEX NAME)



RN 263400-28-8 USPATFULL


CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-29-9 USPATFULL


CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-piperidiny)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

NAME)




RN 263400-30-2 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-31-3 USPATFULL


CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-32-4 USPATFULL


CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-33-5 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-34-6 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-35-7 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[(1-methyl-2-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-(9CI) (CA INDEX NAME)




RN 263400-36-8 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[(1-methyl-3-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-(9CI) (CA INDEX NAME)




RN 263400-37-9 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[(1-methyl-5-oxo-2-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-(9CI) (CA INDEX NAME)




RN 263400-38-0 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(2-oxo-1-imidazolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-39-1 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-40-4 USPATFULL

CN Benzamide, 4-cyano-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 263400-41-5 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-42-6 USPATFULL


CN 4-Pyridinecarboxamide, N-[3-[(7-fluoro-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 263400-43-7 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[3-(methylsulfonyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-44-8 USPATFULL


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-45-9 USPATFULL


CN 2-Thiophenecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-46-0 USPATFULL


CN Cyclopropanecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263400-48-2 USPATFULL


CN Acetamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263400-50-6 USPATFULL

CN Carbamic acid, [5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 263400-51-7 USPATFULL

CN Benzamide, 4-cyano-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 263400-52-8 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-53-9 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-94-8 USPATFULL

CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]- (9CI) (CA INDEX NAME)




IT 263400-86-8P 263400-87-9P

(preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)


RN 263400-86-8 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[(7-hydroxy-6-methoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-87-9 USPATFULL

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L21 ANSWER 23 OF 30 USPATFULL on STN

ACCESSION NUMBER: 1998:124570 USPATFULL

TITLE: Aniline derivatives

INVENTOR(S): Brown, Dearg Sutherland, Macclesfield, United Kingdom
 Morris, Jeffrey James, Macclesfield, United Kingdom
 Thomas, Andrew Peter, Macclesfield, United Kingdom

PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 5821246 19981013
 WO 9615118 19960523
 APPLICATION INFO.: US 1997-836362 19970521 (8)
 WO 1995-GB2606 19951108
 19970512 PCT 371 date
 19970512 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-22866	19941112
	GB 1995-7308	19950407
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Grumbling, Matthew V.	
LEGAL REPRESENTATIVE:	Cushman Darby & Cushman Intellectual Property Group of Pillsbury Madison & Sutro, LLP	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1,2,3	
LINE COUNT:	4058	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns aniline derivatives of formula I ##STR1## wherein m is 1, 2 or 3, n is 0, 1, 2 or 3, Q is phenyl or naphthyl or a 5- or 6-membered heteroaryl moiety containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur, and X, R^{sup.1} and R^{sup.2} are defined in the claims; or pharmaceutical compositions containing them, and the methods of using the compounds as tyrosine kinase inhibitors and for the treatment of proliferative diseases such as cancer.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 179687-48-0P

(preparation of N-phenylquinazolinamines as tyrosine kinase inhibitors)

RN 179687-48-0 USPATFULL

CN Benzenesulfonamide, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L21 ANSWER 24 OF 30 USPATFULL on STN

ACCESSION NUMBER: 97:27169 USPATFULL
 TITLE: Quinazoline derivatives as anti-proliferative agents
 INVENTOR(S): Barker, Andrew J., Macclesfield, England
 PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5616582		19970401
APPLICATION INFO.:	US 1995-490666		19950615 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-284293, filed on 2 Aug 1994, now patented, Pat. No. US 5457105 which is a continuation of Ser. No. US 1993-5280, filed on 19 Jan 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-1095	19920120
	GB 1992-13572	19920626
	GB 1992-23735	19921112
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Grumbling, Matthew V.	
LEGAL REPRESENTATIVE:	Cushman Darby & Cushman Intellectual Property Group of Pillsbury Madison & Sutro, LLP	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3508	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns quinazoline derivatives of the formula I ##STR1## wherein m is 1, 2 or 3 and each R.sup.1 includes hydroxy, amino, carboxy, carbamoyl, ureido, (1-4C)alkoxycarbonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyl]carbamoyl, hydroxyamino, (1-4C)alkoxyamino, (2-4C)alkanoyloxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C)alkylenedioxy;

n is 1 or 2 and each R.sup.2 includes hydrogen, hydroxy, halogeno, trifluoromethyl, amino, nitro, cyano and (1-4C)alkyl; or a pharmaceutically-acceptable salt thereof;

processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of cancer.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 153437-74-2P 153437-75-3P

(preparation of, as tyrosine kinase-inhibiting anticancer agent)


RN 153437-74-2 USPATFULL

CN Acetamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 153437-75-3 USPATFULL

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



L21 ANSWER 25 OF 30 USPATFULL on STN

ACCESSION NUMBER: 95:90529 USPATFULL

TITLE: Quinazoline derivatives useful for treatment of neoplastic disease

INVENTOR(S): Barker, Andrew J., Macclesfield, England

PATENT ASSIGNEE(S): Zeneca Limited, London, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5457105		19951010
APPLICATION INFO.:	US 1994-284293		19940802 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-5280, filed on 19 Jan 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-1095	19920120
	GB 1992-13572	19920626
	GB 1992-23735	19921112

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Shah, Mukund J.
 ASSISTANT EXAMINER: Grumbling, Matthew V.
 LEGAL REPRESENTATIVE: Cushman Darby & Cushman
 NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1

LINE COUNT: 3702

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns quinazoline derivatives of the formula I ##STR1## wherein m is 1, 2 or 3 and each R^{sup.1} includes hydroxy, amino, carboxy, carbamoyl, ureido, (1-4C)alkoxycarbonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyl]carbamoyl, hydroxyamino, (1-4C)alkoxyamino, (2-4C)alkanoyloxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C)alkylenedioxy;

n is 1 or 2 and each R^{sup.2} includes hydrogen, hydroxy, halogeno, trifluoromethyl, amino, nitro, cyano and (1-4C)alkyl;

or a pharmaceutically-acceptable salt thereof;

processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of cancer.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 153437-74-2P 153437-75-3P

(preparation of, as tyrosine kinase-inhibiting anticancer agent)


RN 153437-74-2 USPATFULL

CN Acetamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl] - (9CI) (CA INDEX NAME)



RN 153437-75-3 USPATFULL

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl] - (9CI) (CA INDEX NAME)



original

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, TOXCENTER, USPATFULL, BIOSIS, CAOLD' -
CONTINUE? (Y)/N:y

L21 ANSWER 26 OF 30 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

ACCESSION NUMBER: 2005:301746 BIOSIS
DOCUMENT NUMBER: PREV200510095771
TITLE: Buhl and Aurora cooperate to maintain the spindle
checkpoint.
AUTHOR(S): Taylor, S. S. [Reprint Author]; Morrow, C. J.; Johnson, V.
L.; Ditchfield, C.
CORPORATE SOURCE: Univ Manchester, Fac Life Sci, Manchester, Lancs, UK
SOURCE: Molecular Biology of the Cell, (NOV 2004) Vol. 15, No.
Suppl. S, pp. 381A.
Meeting Info.: 44th Annual Meeting of the
American-Society-for-Cell-Biology. Washington, DC, USA.
December 04 -08, 2004. Amer Soc Cell Biol.
CODEN: MBCEEV. ISSN: 1059-1524.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 15 Aug 2005
Last Updated on STN: 15 Aug 2005
CONCEPT CODE: General biology - Symposia, transactions and proceedings
00520
Genetics - General 03502
Pathology - Therapy 12512
Pharmacology - General 22002
Neoplasms - Pathology, clinical aspects and systemic
effects 24004
Neoplasms - Therapeutic agents and therapy 24008

INDEX TERMS: Major Concepts
Pharmacology; Tumor Biology; Molecular Genetics
(Biochemistry and Molecular Biophysics)

INDEX TERMS: Parts, Structures, & Systems of Organisms
kinetochore; spindle checkpoint

INDEX TERMS: Diseases
tumor: neoplastic disease, drug therapy
Neoplasms (MeSH)

INDEX TERMS: Chemicals & Biochemicals
nocodazole: antineoplastic-drug; Bub1; Aurora kinase;
RNAi; anaphase promoting complex [APC]; BubR1; Aurora;
Cenp-E; ZM447439

INDEX TERMS: Miscellaneous Descriptors
mitotic arrest

ORGANISM: Classifier
Organisms 00500
Super Taxa
Organisms
Organism Name
organism (common)
Taxa Notes
Organisms

REGISTRY NUMBER: 31430-18-9 (nocodazole)
74812-49-0 (anaphase promoting complex)
74812-49-0 (APC)
128639-02-1 (Aurora)
331771-20-1 (ZM447439)

L21 ANSWER 27 OF 30 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

ACCESSION NUMBER: 2005:301097 BIOSIS
 DOCUMENT NUMBER: PREV200510095122
 TITLE: Aurora B contributes to the correction of merotelic kinetochore orientation before anaphase onset.
 AUTHOR(S): Cimini, D. [Reprint Author]; Salmon, E. D.
 CORPORATE SOURCE: Univ N Carolina, Chapel Hill, NC USA
 SOURCE: Molecular Biology of the Cell, (NOV 2004) Vol. 15, No. Suppl. S, pp. 264A.
 Meeting Info.: 44th Annual Meeting of the American-Society-for-Cell-Biology. Washington, DC, USA. December 04 -08, 2004. Amer Soc Cell Biol.
 CODEN: MBCEEV. ISSN: 1059-1524.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 15 Aug 2005
 Last Updated on STN: 15 Aug 2005
 CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
 Cytology - General 02502
 Cytology - Animal 02506
 Biochemistry studies - General 10060
 Biochemistry studies - Proteins, peptides and amino acids 10064
 INDEX TERMS: Major Concepts
 Biochemistry and Molecular Biophysics; Cell Biology
 INDEX TERMS: Parts, Structures, & Systems of Organisms
 microtubule; chromosome
 INDEX TERMS: Chemicals & Biochemicals
 H3 histone; aurora B; ZM447439
 INDEX TERMS: Methods & Equipment
 immunostaining: laboratory techniques, histology and cytology techniques, immunologic techniques; Western blot: electrophoretic techniques, immunologic techniques, laboratory techniques
 INDEX TERMS: Miscellaneous Descriptors
 anaphase
 ORGANISM: Classifier
 Macropodidae 86075
 Super Taxa
 Marsupialia; Mammalia; Vertebrata; Chordata; Animalia
 Organism Name
 PtK1 cell line (cell_line)
 Taxa Notes
 Animals, Chordates, Mammals, Marsupials, Nonhuman Vertebrates, Nonhuman Mammals, Vertebrates
 REGISTRY NUMBER: 331771-20-1 (ZM447439)

L21 ANSWER 28 OF 30 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2005:287790 BIOSIS
 DOCUMENT NUMBER: PREV200510076851
 TITLE: Bub1 and Aurora cooperate to maintain chromosome stability.
 AUTHOR(S): Taylor, S. [Reprint Author]
 CORPORATE SOURCE: Univ Manchester, Manchester, Lancs, UK
 SOURCE: British Journal of Cancer, (JUL 2004) Vol. 91, No. Suppl. 1, pp. S10.
 Meeting Info.: British Cancer Research Meeting 2004. Manchester, ENGLAND. June 27 -30, 2004.

DOCUMENT TYPE: CODEN: BJCAAI. ISSN: 0007-0920.
 Conference; (Meeting)
 Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE: Entered STN: 4 Aug 2005
 Last Updated on STN: 4 Aug 2005

CONCEPT CODE: General biology - Symposia, transactions and proceedings
 00520
 Genetics - General 03502
 Enzymes - General and comparative studies: coenzymes
 10802

INDEX TERMS: Major Concepts
 Molecular Genetics (Biochemistry and Molecular
 Biophysics); Enzymology (Biochemistry and Molecular
 Biophysics)

INDEX TERMS: Chemicals & Biochemicals
 RNAi; anaphase promoting complex; BubR1; Cenp-E; Aurora
 kinase: activity; kinensin: regulation; ZM447439: enzyme
 inhibitor-drug

INDEX TERMS: Miscellaneous Descriptors
 chromosome stability; mitotic progression

REGISTRY NUMBER: 74812-49-0 (anaphase promoting complex)
 331771-20-1 (ZM447439)

L21 ANSWER 29 OF 30 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
 STN

ACCESSION NUMBER: 2003:513823 BIOSIS

DOCUMENT NUMBER: PREV200300513203

TITLE: ZM447439, a novel Aurora kinase inhibitor, prevents
 chromosome alignment and compromises spindle checkpoint
 function in human cells.

AUTHOR(S): Ditchfield, Claire [Reprint Author]; Johnson, Victoria L.;
 Ellston, Rebecca; Haworth, Carolyn; Johnson, Trevor;
 Mortlock, Andrew; Heron, Nicola; Keen, Nick; Taylor,
 Stephen S.

CORPORATE SOURCE: University of Manchester, Manchester, UK

SOURCE: Proceedings of the American Association for Cancer Research
 Annual Meeting, (July 2003) Vol. 44, pp. 784. print.
 Meeting Info.: 94th Annual Meeting of the American
 Association for Cancer Research. Washington, DC, USA. July
 11-14, 2003.
 ISSN: 0197-016X.

DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 5 Nov 2003
 Last Updated on STN: 5 Nov 2003

CONCEPT CODE: General biology - Symposia, transactions and proceedings
 00520
 Genetics - General 03502
 Genetics - Human 03508
 Pathology - Therapy 12512
 Pharmacology - General 22002
 Pharmacology - Clinical pharmacology 22005
 Neoplasms - Pathology, clinical aspects and systemic
 effects 24004
 Neoplasms - Therapeutic agents and therapy 24008

INDEX TERMS: Major Concepts
 Genetics; Pharmacology; Tumor Biology

INDEX TERMS: Chemicals & Biochemicals
 ZM 447439: antineoplastic-drug, Aurora kinase inhibitor
 ORGANISM: Classifier
 Hominidae 86215
 Super Taxa
 Primates; Mammalia; Vertebrata; Chordata; Animalia
 Organism Name
 MCF-7 cell line (cell line): drug-induced chromosome
 alignment prevention, drug-induced spindle spindle
 checkpoint disruption, human breast cancer cell line,
 in-vitro model system
 U2OS cell line (cell line): drug-induced chromosome
 alignment prevention, drug-induced spindle checkpoint
 disruption, human osteosarcoma cell line, in-vitro model
 system
 Taxa Notes
 Animals, Chordates, Humans, Mammals, Primates,
 Vertebrates
 REGISTRY NUMBER: 331771-20-1 (ZM 447439)

L21 ANSWER 30 OF 30 CAOLD COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: CA57:12670a CAOLD

TITLE: azo dyes

AUTHOR NAME: Barker, Peter W.; Hunter, J. S.; Waite, F. A.

DOCUMENT TYPE: Patent

TITLE: dyes (azo)

PATENT ASSIGNEE: Imperial Chemical Industries Ltd.

DOCUMENT TYPE: Patent

PATENT NO.	KIND	DATE
-----	-----	----


PI GB 892323

INDEX TERM:	91183-12-9	92401-01-9	92457-86-8	92819-88-0	93112-20-0
	93169-10-9	93309-34-3	93690-02-9	95172-95-5	
	95705-31-0	95745-27-0	96295-52-2	96366-38-0	96458-72-9
	96466-92-1	96765-42-3	96868-79-0	97238-88-5	97318-16-6
	97636-29-8	97676-65-8	97836-11-8	98363-22-5	98483-77-3
	98483-78-4	98658-37-8	99995-48-9	99995-73-0	100271-32-7
	100351-54-0	100403-74-5	101812-65-1	101943-39-9	102111-29-5
	104949-02-2	105164-60-1	107801-35-4	111639-92-0	

IT 93309-34-3

RN 93309-34-3 CAOLD

CN Sulfamic acid, [p-[(2-chloro-4-quinazolinyl)amino]phenyl]- (7CI) (CA
 INDEX NAME)



AUTHOR Search in CAPLUS

(structure hits from the structure ^{search} are shown if they are present)

Truong 10_088814

10/18/2005

=> file caplus

FILE 'CAPLUS' ENTERED AT 09:44:49 ON 18 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Oct 2005 VOL 143 ISS 17

FILE LAST UPDATED: 17 Oct 2005 (20051017/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que nos L18

L1 STR
L2 5754 SEA FILE=REGISTRY SSS FUL L1
L4 STR
L6 716 SEA FILE=REGISTRY SUB=L2 SSS FUL L4
L7 19 SEA FILE=CAPLUS ABB=ON PLU=ON L6
L8 296 SEA FILE=CAPLUS ABB=ON PLU=ON KEEN N?/AU
L9 66 SEA FILE=CAPLUS ABB=ON PLU=ON MORTLOCK A?/AU
L10 391 SEA FILE=CAPLUS ABB=ON PLU=ON JUNG F?/AU
L11 74 SEA FILE=CAPLUS ABB=ON PLU=ON BREWSTER A?/AU
L13 14 SEA FILE=CAPLUS ABB=ON PLU=ON (L8 AND (L9 OR L10 OR L11)) OR
(L9 AND (L10 OR L11)) OR (L10 AND L11)
L18 14 SEA FILE=CAPLUS ABB=ON PLU=ON L13 OR (L13 AND L7)

14 answers

=> d ibib abs hitind hitstr L18 1-14

L18 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:955257 CAPLUS

TITLE: Progress in the development of selective inhibitors of Aurora Kinases

AUTHOR(S): Mortlock, Andrew A.; Keen, Nicholas J.; Jung, Frederic H.; Heron, Nicola M.; Foote, Kevin M.; Wilkinson, Robert W.; Green, Stephen

CORPORATE SOURCE: AstraZeneca, Macclesfield, SK10 4TG, UK

SOURCE: Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates) (2005), 5(8), 807-821

CODEN: CTMCCL; ISSN: 1568-0266

PUBLISHER: Bentham Science Publishers Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Errors in the mitotic process are thought to be one of the principal

sources of the genetic instability that hallmarks cancer. Unsurprisingly, many of the proteins that regulate mitosis are aberrantly expressed in tumor cells when compared to their normal counterparts. These may represent a good source of targets for the development of novel anticancer agents. The Aurora kinases represent one such family of mitotic regulators. In recent years there has been intense interest in both understanding the role of the Aurora kinases in cell cycle regulation and also in developing small mol. inhibitors as potential novel anti-cancer drugs. With several companies now starting to take Aurora kinase inhibitors into clin. development, the time is right to review the medicinal chemical contribution to developing the field, in particular to review the increasingly broad range of small mol. inhibitors with activity against this kinase family.

CC 7 (Enzymes)

REFERENCE COUNT: 141 THERE ARE 141 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:955256 CAPLUS

TITLE: Progress in the development of selective inhibitors of Aurora kinases. [Erratum to document cited in CA142:475149]

AUTHOR(S): Mortlock, Andrew; Keen, Nicholas J.

; Jung, Frederic H.; Heron, Nicola M.; Foote, Kevin M.; Wilkinson, Robert; Green, Stephen
CORPORATE SOURCE: Cancer and Infection Research Area (CIRA), AstraZeneca, Macclesfield, SK10 4TG, UK

SOURCE: Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates) (2005), 5(8), 805
CODEN: CTMCCL; ISSN: 1568-0266

PUBLISHER: Bentham Science Publishers Ltd.

DOCUMENT TYPE: Journal; General Review; Errata

LANGUAGE: English

AB A review. An erratum.

CC 1-0 (Pharmacology)

IT INDEXING IN PROGRESS

L18 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:318734 CAPLUS

DOCUMENT NUMBER: 142:475149

TITLE: Progress in the development of selective inhibitors of Aurora kinases

AUTHOR(S): Mortlock, Andrew; Keen, Nicholas J.

; Jung, Frederic H.; Heron, Nicola M.; Foote, Kevin M.; Wilkinson, Robert; Green, Stephen
CORPORATE SOURCE: Cancer and Infection Research Area (CIRA), AstraZeneca, Macclesfield, SK10 4TG, UK

SOURCE: Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates) (2005), 5(2), 199-213
CODEN: CTMCCL; ISSN: 1568-0266

PUBLISHER: Bentham Science Publishers Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Errors in the mitotic process are thought to be one of the principal sources of the genetic instability that hallmarks cancer. Unsurprisingly, many of the proteins that regulate mitosis are aberrantly expressed in tumor cells when compared to their normal counterparts. These may represent a good source of targets for the development of novel

anti-cancer agents. The Aurora kinases represent one such family of mitotic regulators. In recent years there was intense interest in both understanding the role of the Aurora kinases in cell cycle regulation and also in developing small mol. inhibitors as potential novel anti-cancer drugs. With several companies now starting to take Aurora kinase inhibitors into clin. development, the time is right to review the medicinal chemical contribution to developing the field, in particular to review the increasingly broad range of small mol. inhibitors with activity against this kinase family.

CC 1-0 (Pharmacology)

REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1154697 CAPLUS

DOCUMENT NUMBER: 142:93862

TITLE: Preparation of (triazolylamino)quinazoline derivatives as aurora kinase inhibitors

INVENTOR(S): Mortlock, Andrew Austen; Heron, Nicola Murdoch; Jung, Frederic Henri

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113324	A1	20041229	WO 2004-GB2564	20040614
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


PRIORITY APPLN. INFO.: EP 2003-291463 A 20030617

OTHER SOURCE(S): MARPAT 142:93862

GI



I



II

AB Title compds. represented by the formula I [wherein X = O or (alkyl)amino; R1, R3, R4 = independently H, halo or X1R11; R2 = H, halo, nitro, cyano, X2R12; X1-X2 = independently a direct bond, O, NH, (alkyl)amino, etc.; R11, R12 = independently H, (cyclo)alkyl, (cyclo)alkenyl, heterocyclyl, etc.; R5 = (un)substituted (hetero)aryl; and salts, esters or prodrugs thereof] were prepared as aurora kinase inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of 2-(4-amino-1H-1,2,3-triazol-1-yl)-N-(3-fluorophenyl)acetamide with 4-chloro-7-(3-chloropropoxy)-6-methoxyquinazoline. II showed 50% inhibition of enzyme activity at concentration of 0.1 μ M in vitro aurora-A kinase inhibition test, and the compds. of invention are generally active at 1 nM to 100 μ M in vitro cell proliferation assay and 1 nM to 10 μ M in vitro cell cycle anal. assay. Thus, I and their pharmaceutical compns. are useful as aurora kinase inhibitors for the treatment of proliferative diseases, such as cancer (no data).

IC ICM C07D403-12

ICS C07D403-14; C07D401-14; A61K031-517; A61K031-4192; A61P035-00

CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1059177 CAPLUS

DOCUMENT NUMBER: 142:38269

TITLE: Preparation of (3-((quinazolin-4-yl)amino)-1H-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer

INVENTOR(S): Mortlock, Andrew Austen; Heron, Nicola Murdoch; Jung, Frederic Henri; Pasquet, Georges Rene

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004105764	A1	20041209	WO 2004-GB2281	20040527
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: EP 2003-291314 A 20030602
OTHER SOURCE(S): MARPAT 142:38269
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Quinazoline derivs. I [X = O, NR6; R1-R4 = independently H, halo, X1R7; R5 = optionally substituted aryl, heteroaryl; R6 = H, C1-4 alkyl; X1 = bond, O, NH, N(C1-6 alkyl); R7 = H, optionally substituted heterocyclyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl] for use in the treatment of proliferative diseases such as cancer and in the preparation of medicaments for use in the treatment of proliferative diseases, and to processes for their preparation, as well as pharmaceutical compns. containing, them as active ingredient. Thus, coupling of chloroquinazoline II (preparation given) with aminopyrazole III (preparation given), followed by substitution with D-prolinol gave title compound IV.

IC ICM A61K031-517

ICS C07D403-14; C07D403-12; C01B025-26; A61P043-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:927198 CAPLUS

DOCUMENT NUMBER: 141:395569

TITLE: Quinazoline derivatives as aurora kinase inhibitors, process for their preparations, pharmaceutical compositions and uses in the treatment of proliferative diseases

INVENTOR(S): Heron, Nicola Murdoch; Pasquet, Georges Rene; Mortlock, Andrew Austen; Jung, Frederic Henri

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 300 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094410	A1	20041104	WO 2004-GB1614	20040414
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:


EP 2003-290951

A 20030416

OTHER SOURCE(S):

MARPAT 141:395569

GI



AB Quinazoline derivs. of formula I [wherein X = O, NH or N(alkyl); R1-R4 = H, halo or alkoxy; R2 = nitro, cyano, OPO3H2; R3 = phosphonooxyalkoxy; R5 = (un)substituted (hetero)aryl; R19 = H, alkyl, acyl, amide, ester, etc.; and salts, esters or prodrugs thereof] were prepared as aurora kinase inhibitors. Thus, II was synthesized in 95% yield by condensation of the corresponding 4-chloroquinazoline derivative (preparation given) with 4-aminopyrazole derivative (preparation given). Compds. I generally showed 50% inhibition activity at the concns. of 1-1000 nM against both aurora-A and aurora-B kinases, and were active in the in vitro cell proliferation assay and in the in vitro cell cycle anal. assay at the concns. of 1 nM to 100 μM and 1 nM to 10 μM, resp. Also disclosed are processes for the preps. of I, pharmaceutical compns. comprising I and uses of I for the treatment of proliferative diseases such as cancer.

IC ICM C07D403-12

ICS A61K031-517; A61P035-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 29, 63

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:566624 CAPLUS

DOCUMENT NUMBER: 141:123757

TITLE: Preparation of phosphonooxy quinazoline derivatives
and their pharmaceutical useINVENTOR(S): Heron, Nicola Murdoch; Jung, Frederic Henri;
Pasquet, Georges Rene; Mortlock, Andrew Austen

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 150 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058781	A1	20040715	WO 2003-GB5613	20031222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2511613	AA	20040715	CA 2003-2511613	20031222
EP 1578755	A1	20050928	EP 2003-782672	20031222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			EP 2002-293238	A 20021224
			EP 2003-291315	A 20030602
			WO 2003-GB5613	W 20031222

OTHER SOURCE(S): MARPAT 141:123757

GI



I

AB Preparation of phosphonoxy quinazoline derivs., I (A = 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; X = O, S, S(O), S(O)₂, organoamino; m = 0-3; Z = organoamino, phosphonoxy, (un)substituted C3-6 cycloalkyl, etc.; R3 = H, halo, cyano, nitro, C1-6 alkoxy, C1-6 alkyl, alkoxycarbonyl, organoamido, sulfonylamido, etc.; R4 = H, C1-4 alkyl, heteroaryl, heteroaryl C1-4 alkyl, aryl, etc.; R5 = H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, etc.; R6, R7 = H, halo, C1-4 alkyl, C3-6 cycloalkyl, hydroxy, C1-4 alkoxy, etc.), and compns. containing them, processes for their preparation and their use in therapy is described. Thus, reaction of N-(3-fluorophenyl)-2-{3-[(7-{3-[4-(hydroxymethyl)piperidin-1-yl]propoxy}-6-methoxyquinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide (preparation given) with di-tert-butyl-diethylphosphoramidite gave 70% di-tert-Bu {1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1Hpyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]piperidin-4-yl}methyl phosphate which on acidic hydrolysis gave 94% title compound, di-tert-Bu {1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1Hpyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]piperidin-4-yl}methyl dihydrogen phosphate. In vitro Aurora-A and Aurora-B kinase inhibition activity and cell proliferation and cycle anal. of the prepared compds. were determined

IC ICM C07F009-6512
ICS C07F009-6558; C07D401-14; C07D403-12; A61K031-661

CC 29-7 (Organometallic and Organometalloidal Compounds)
Section cross-reference(s): 1, 63

L18 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:339130 CAPLUS

DOCUMENT NUMBER: 139:143528

TITLE: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores

AUTHOR(S): Ditchfield, Claire; Johnson, Victoria L.; Tighe, Anthony; Ellston, Rebecca; Haworth, Carolyn; Johnson, Trevor; **Mortlock, Andrew; Keen, Nicholas**; Taylor, Stephen S.

CORPORATE SOURCE: School of Biological Sciences, University of Manchester, Manchester, M13 9PT, UK

SOURCE: Journal of Cell Biology (2003), 161(2), 267-280

CODEN: JCLBA3; ISSN: 0021-9525

PUBLISHER: Rockefeller University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The Aurora/Ipl1 family of protein kinases plays multiple roles in mitosis and cytokinesis. Here, we describe ZM447439, a novel selective Aurora kinase inhibitor. Cells treated with ZM447439 progress through interphase, enter mitosis normally, and assemble bipolar spindles. However, chromosome alignment, segregation, and cytokinesis all fail. Despite the presence of maloriented chromosomes, ZM447439-treated cells exit mitosis with normal kinetics, indicating that the spindle checkpoint is compromised. Indeed, ZM447439 prevents mitotic arrest after exposure to paclitaxel. RNA interference expts. suggest that these phenotypes are due to inhibition of Aurora B, not Aurora A or some other kinase. In the absence of Aurora B function, kinetochore localization of the spindle checkpoint components BubR1, Mad2, and Cenp-E is diminished. Furthermore, inhibition of Aurora B kinase activity prevents the rebinding of BubR1 to metaphase kinetochores after a reduction in centromeric tension. Aurora B kinase activity is also required for phosphorylation of BubR1 on entry into mitosis. Finally, we show that BubR1 is not only required for

spindle checkpoint function, but is also required for chromosome alignment. Together, these results suggest that by targeting checkpoint proteins to kinetochores, Aurora B couples chromosome alignment with anaphase onset.

CC 1-6 (Pharmacology)

IT 331771-20-1, ZM 447439

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores)


IT 331771-20-1, ZM 447439

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores)

RN 331771-20-1 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:10468 CAPLUS

DOCUMENT NUMBER: 136:85826

TITLE: Preparation of substituted quinazoline derivatives and their use as inhibitors of AURORA-2 kinase

INVENTOR(S): Mortlock, Andrew; Jung, Frederic

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 249 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000649	A1	20020103	WO 2001-SE1450	20010621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2412592 AA 20020103 CA 2001-2412592 20010621
 EP 1299381 A1 20030409 EP 2001-944061 20010621
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 BR 2001011754 A 20030429 BR 2001-11754 20010621
 JP 2004501914 T2 20040122 JP 2002-505773 20010621
 CN 1496364 A 20040512 CN 2001-814620 20010621
 EE 200200715 A 20040816 EE 2002-715 20010621
 NZ 522696 A 20040827 NZ 2001-522696 20010621
 ZA 2002009412 A 20040219 ZA 2002-9412 20021119
 BG 107376 A 20030930 BG 2002-107376 20021211
 NO 2002006010 A 20021213 NO 2002-6010 20021213
 US 2003187002 A1 20031002 US 2002-311916 20021216
 US 6919338 B2 20050719



PRIORITY APPLN. INFO.:

EP 2000-401842 A 20000628

WO 2001-SE1450 W 20010621

OTHER SOURCE(S): MARPAT 136:85826

GI



AB The title compds. [I; X = O, S, S:O, SO₂, NR; R = H, C1-6alkyl; R₁ = OCH₃, 3-(4-morpholinyl)propoxy, N-methylpiperidine-4-ylmethoxy, 3-(N-methylpiperazine-4-yl)propoxy, 3-(pyrrolidine-1-yl)propoxy, (CH₃)₂N(CH₂)₃O, etc.; Q = (un)substituted 5-membered heteroarom.], pharmaceutically acceptable salts, in vivo hydrolysable esters, and amides are prepared as AURORA-2 kinase inhibitors in warm blooded animals. The title compds. together with pharmaceutical compns. containing them are also described and claimed. Thus, the title compound II was prepared and tested in vitro for the ability to arrest MCF7 cells in specific phases of the cell

cycle.

IC ICM C07D403-12

ICS C07D409-12; C07D413-12; A61K031-505; A61P035-00

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:565012 CAPLUS

DOCUMENT NUMBER: 135:137521

TITLE: Preparation of 4-[N-(5-pyrimidyl)amino]quinolines as
inhibitors of aurora 2 kinaseINVENTOR(S): Mortlock, Andrew Austen; Jung, Frederic
Henri

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055116	A2	20010802	WO 2001-GB245	20010124
WO 2001055116	A3	20011227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1294709	A2	20030326	EP 2001-946855	20010124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003520855	T2	20030708	JP 2001-555058	20010124
US 2003105129	A1	20030605	US 2002-182454	20020726
PRIORITY APPLN. INFO.:			EP 2000-400228	A 20000128
			WO 2001-GB245	W 20010124

OTHER SOURCE(S): MARPAT 135:137521

GI



AB The title compds. [I; R5 = (un)substituted 6-membered aromatic ring containing at least one N atom; R1-R4 = halo, CN, NO₂, etc.; provided that at least one of R2 or R3 is other than hydrogen] which are inhibitors of aurora 2 kinase useful in treatment of proliferative disease such as cancer and in particular cancers such as colorectal or breast cancer where aurora 2 is upregulated, were prepared Thus, reacting 4-chloro-6-cyano-7-(3-morpholinopropoxy)quinoline with 2-(N-benzoyl)-2,5-diaminopyrimidine (preparation of both reactants given) afforded 59% I [R1, R4 = H; R2 = CN; R3 = 3-morpholinopropoxy; R5 = 2-(N-benzoylamino)pyrimidin-5-yl] which showed 50% inhibition of aurora 2 kinase activity at 0.0521 μ M in vitro.


IC ICM C07D215-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1


L18 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:228867 CAPLUS
DOCUMENT NUMBER: 134:266318
TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors
INVENTOR(S): **Mortlock, Andrew Austen; Keen, Nicholas John**
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021597	A1	20010329	WO 2000-GB3593	20000919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2384296	AA	20010329	CA 2000-2384296	20000919
BR 2000014137	A	20020521	BR 2000-14137	20000919
TR 200200717	T2	20020621	TR 2002-200200717	20000919
EP 1218355	A1	20020703	EP 2000-960850	20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509500	T2	20030311	JP 2001-524976	20000919
EE 200200118	A	20030415	EE 2002-118	20000919
AU 762697	B2	20030703	AU 2000-73019	20000919
BG 106526	A	20021031	BG 2002-106526	20020318
ZA 2002002232	A	20030619	ZA 2002-2232	20020319
NO 2002001400	A	20020506	NO 2002-1400	20020320
PRIORITY APPLN. INFO.:			GB 1999-22171	A 19990921
			WO 2000-GB3593	W 20000919
OTHER SOURCE(S):	MARPAT	134:266318		
GI				



I



II

proviso

AB Title compds. (I) [wherein X = O, S, SO, SO₂, NH, or NR₆; R₆ = H or alkyl; R₅ = (un)substituted 6-membered aromatic ring containing at least one N; R₁-R₄

=

independently halo, CN, NO₂, alkylsulfanyl, N(OH)R₇, or R₉X₁; R₇ = H or alkyl; X₁ = a direct bond, O, CH₂, OC(O), CO, S, SO, SO₂, or (un)substituted NHCO, CONH, SO₂NH, NHSO₂, or NH; R₉ = H or (un)substituted hydrocarbonyl, heterocyclyl, or alkoxy; and at least one of R₂ or R₃ is other than H; or a salt, ester, amide, or prodrug thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, 2-(N-benzoylamino)-5-aminopyrimidine and 4-chloro-6,7-dimethoxyquinazoline were coupled in i-PrOH to yield II (58%). The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.00785 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 1.7 μM and reduced BrdU incorporation into cellular DNA by 50% at 1.92-2.848 μM.

IC ICM C07D239-94

ICS C07D401-12; C07D403-12; A61K031-517; A61P035-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:228866 CAPLUS

DOCUMENT NUMBER: 134:266317

TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors

INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John; Jung, Frederic Henri; Brewster, Andrew George

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 306 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021596	A1	20010329	WO 2000-GB3580	20000918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				


HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


CA 2384291	AA	20010329	CA 2000-2384291	20000918
BR 2000014116	A	20020521	BR 2000-14116	20000918
EP 1218354	A1	20020703	EP 2000-960840	20000918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509499	T2	20030311	JP 2001-524975	20000918
EE 200200119	A	20030415	EE 2002-119	20000918
BG 106492	A	20030131	BG 2002-106492	20020307
ZA 2002002234	A	20030619	ZA 2002-2234	20020319
NO 2002001399	A	20020430	NO 2002-1399	20020320
PRIORITY APPLN. INFO.:			GB 1999-22154	A 19990921
			GB 1999-22170	A 19990921
			WO 2000-GB3580	W 20000918

OTHER SOURCE(S): MARPAT 134:266317

GI



I



II

AB Title compds. (I) [wherein X = O, S, SO, SO₂, NH, or NR₁₂; R₁₂ = H or alkyl; R₁-R₄ = independently halo, CN, NO₂, alkylsulfanyl, N(OH)R₁₃, or R₁₅X₁; R₁₃ = H or alkyl; X₁ = a direct bond, O, CH₂, OC(O), CO, CO₂, S, SO, SO₂, or (un)substituted NHCO, CONH, SO₂NH, NHSO₂, or NH; R₁₅ = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; R₅ = NHCO₂R₉, NHCOR₉, NHSO₂R₉, COR₉, CO₂R₉, SOR₉, SO₂OR₉, CONR₁₀R₁₁, SONR₁₀R₁₁, or SO₂NR₁₀R₁₁; R₉-R₁₁ = independently H or (un)substituted hydrocarbyl or

heterocyclyl; or R10 and R11 together with the N to which they are attached = (un)substituted heterocyclyl; R6 = H or (un)substituted hydrocarblyl or heterocyclyl; R7 and R8 = independently H, halo, alkyl, (di)alkoxy(methyl), alkanoyl, CF3, CN, NHY2, alkenyl, alkynyl, or (un)substituted Ph, PhCH2, or heterocyclyl; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, a 7-step sequence involving (1) alkylation of morpholine with 1-bromo-3-chloropropane (49%), (2) addition of Et vanillate to yield Et 3-methoxy-4-(3-morpholinopropoxy)benzoate (100%), (3) nitration (86%), (4) reduction to the amine using 10% Pd/C (100%), (5) cycloaddn. with formamide to form the quinazoline(68%), (6) chlorination to give 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (60%), and (7) amination with N-benzoyl-4-aminoaniline (58%) yielded II. The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration

of

0.0193 μ M. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 1.06 μ M and reduced BrdU incorporation into cellular DNA by 50% at 0.159-0.209 μ M.

IC

ICM C07D239-94

ICS A61K031-517; A61P035-00

CC

28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT

331770-21-9P 331771-20-1P 331775-74-7P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

IT

331772-11-3P 331772-14-6P 331772-33-9P

331772-44-2P 331772-45-3P 331772-47-5P

331772-51-1P 331772-52-2P 331772-53-3P

331774-61-9P 331775-47-4P 331775-48-5P

331775-49-6P 331775-55-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

IT

202475-67-0P 331770-22-0P 331770-23-1P

331770-24-2P 331770-25-3P 331770-26-4P

331770-27-5P 331770-28-6P 331770-29-7P

331770-30-0P 331770-31-1P 331770-32-2P

331770-33-3P 331770-34-4P 331770-35-5P

331770-36-6P 331770-37-7P 331770-38-8P

331770-39-9P 331770-40-2P 331770-41-3P

331770-42-4P 331770-43-5P 331770-44-6P

331770-45-7P 331770-46-8P 331770-47-9P

331770-48-0P 331770-49-1P 331770-50-4P

331770-51-5P 331770-52-6P 331770-53-7P

331770-54-8P 331770-55-9P 331770-56-0P

331770-57-1P 331770-58-2P 331770-59-3P

331770-60-6P 331770-61-7P 331770-62-8P

331770-63-9P 331770-64-0P 331770-65-1P

331770-66-2P 331770-67-3P 331770-68-4P

331770-69-5P 331770-70-8P 331770-71-9P

331770-72-0P 331770-73-1P 331770-74-2P

331770-75-3P 331770-76-4P 331770-77-5P
331770-78-6P 331770-79-7P 331770-80-0P
331770-81-1P 331770-82-2P 331770-83-3P
331770-84-4P 331770-85-5P 331770-86-6P
331770-87-7P 331770-88-8P 331770-89-9P
331770-90-2P 331770-91-3P 331770-92-4P
331770-93-5P 331770-94-6P 331770-95-7P
331770-96-8P 331770-97-9P 331770-98-0P
331770-99-1P 331771-00-7P 331771-01-8P
331771-02-9P 331771-03-0P 331771-04-1P
331771-05-2P 331771-06-3P 331771-07-4P
331771-08-5P 331771-09-6P 331771-10-9P
331771-11-0P 331771-12-1P 331771-13-2P
331771-14-3P 331771-15-4P 331771-16-5P
331771-17-6P 331771-18-7P 331771-19-8P 331771-21-2P
331771-22-3P 331771-23-4P 331771-24-5P
331771-25-6P 331771-26-7P 331771-27-8P
331771-28-9P 331771-29-0P 331771-30-3P
331771-31-4P 331771-32-5P 331771-33-6P
331771-34-7P 331771-35-8P 331771-36-9P
331771-37-0P 331771-38-1P 331771-39-2P
331771-40-5P 331771-41-6P 331771-42-7P
331771-43-8P 331771-44-9P 331771-45-0P
331771-46-1P 331771-47-2P 331771-48-3P
331771-49-4P 331771-50-7P 331771-51-8P
331771-52-9P 331771-53-0P 331771-54-1P
331771-55-2P 331771-56-3P 331771-57-4P
331771-58-5P 331771-59-6P 331771-60-9P
331771-61-0P 331771-62-1P 331771-63-2P
331771-64-3P 331771-65-4P 331771-66-5P
331771-67-6P 331771-68-7P 331771-69-8P
331771-70-1P 331771-71-2P 331771-72-3P
331771-73-4P 331771-74-5P 331771-75-6P
331771-76-7P 331771-77-8P 331771-78-9P
331771-79-0P 331771-80-3P 331771-81-4P
331771-82-5P 331771-83-6P 331771-84-7P
331771-85-8P 331771-86-9P 331771-87-0P
331771-88-1P 331771-89-2P 331771-90-5P
331771-91-6P 331771-92-7P 331771-93-8P
331771-94-9P 331771-95-0P 331771-96-1P
331771-97-2P 331771-98-3P 331771-99-4P
331772-00-0P 331772-01-1P 331772-02-2P
331772-03-3P 331772-04-4P 331772-05-5P
331772-06-6P 331772-07-7P 331772-08-8P
331772-09-9P 331772-10-2P 331772-12-4P
331772-13-5P 331772-15-7P 331772-16-8P
331772-17-9P 331772-18-0P 331772-19-1P
331772-20-4P 331772-21-5P 331772-22-6P
331772-23-7P 331772-24-8P 331772-25-9P
331772-26-0P 331772-27-1P 331772-28-2P
331772-29-3P 331772-30-6P 331772-31-7P
331772-32-8P 331772-34-0P 331772-35-1P
331772-36-2P 331772-37-3P 331772-38-4P
331772-39-5P 331772-40-8P 331772-41-9P
331772-42-0P 331772-43-1P 331772-46-4P
331772-48-6P 331772-49-7P 331772-50-0P
331772-54-4P 331772-55-5P 331772-56-6P
331772-57-7P 331772-58-8P 331772-59-9P
331772-60-2P 331772-61-3P 331772-62-4P

331772-63-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

IT 331772-64-6P 331772-65-7P 331772-66-8P
331772-67-9P 331772-68-0P 331772-69-1P
331772-70-4P 331772-71-5P 331772-72-6P
331772-73-7P 331772-74-8P 331772-75-9P
331772-76-0P 331772-77-1P 331772-78-2P
331772-79-3P 331772-80-6P 331772-81-7P
331772-82-8P 331772-83-9P 331772-84-0P
331772-85-1P 331772-86-2P 331772-87-3P
331772-88-4P 331772-89-5P 331772-90-8P
331772-91-9P 331772-92-0P 331772-93-1P
331772-94-2P 331772-95-3P 331772-96-4P
331772-97-5P 331772-98-6P 331772-99-7P
331773-00-3P 331773-01-4P 331773-02-5P
331773-03-6P 331773-04-7P 331773-05-8P
331773-06-9P 331773-07-0P 331773-08-1P
331773-09-2P 331773-10-5P 331773-11-6P
331773-12-7P 331773-13-8P 331773-14-9P
331773-15-0P 331773-16-1P 331773-17-2P
331773-18-3P 331773-19-4P 331773-20-7P
331773-21-8P 331773-22-9P 331773-23-0P
331773-24-1P 331773-25-2P 331773-26-3P
331773-27-4P 331773-28-5P 331773-29-6P
331773-30-9P 331773-31-0P 331773-32-1P
331773-33-2P 331773-34-3P 331773-35-4P
331773-36-5P 331773-37-6P 331773-38-7P
331773-39-8P 331773-40-1P 331773-41-2P
331773-42-3P 331773-43-4P 331773-44-5P
331773-45-6P 331773-46-7P 331773-47-8P
331773-48-9P 331773-49-0P 331773-50-3P
331773-51-4P 331773-52-5P 331773-53-6P
331773-54-7P 331773-55-8P 331773-56-9P
331773-57-0P 331773-58-1P 331773-59-2P
331773-60-5P 331773-61-6P 331773-62-7P
331773-63-8P 331773-64-9P 331773-65-0P
331773-66-1P 331773-67-2P 331773-68-3P
331773-69-4P 331773-70-7P 331773-71-8P
331773-72-9P 331773-73-0P 331773-74-1P
331773-75-2P 331773-76-3P 331773-77-4P
331773-78-5P 331773-79-6P 331773-80-9P
331773-81-0P 331773-82-1P 331773-83-2P
331773-84-3P 331773-85-4P 331773-86-5P
331773-87-6P 331773-88-7P 331773-89-8P
331773-90-1P 331773-91-2P 331773-92-3P
331773-93-4P 331773-94-5P 331773-95-6P
331773-96-7P 331773-97-8P 331773-98-9P
331773-99-0P 331774-00-6P 331774-01-7P
331774-02-8P 331774-03-9P 331774-04-0P
331774-05-1P 331774-06-2P 331774-07-3P
331774-08-4P 331774-09-5P 331774-10-8P
331774-11-9P 331774-12-0P 331774-13-1P
331774-15-3P 331774-17-5P 331774-18-6P
331774-19-7P 331774-20-0P 331774-21-1P
331774-22-2P 331774-23-3P 331774-24-4P

331774-25-5P 331774-26-6P 331774-27-7P
 331774-28-8P 331774-29-9P 331774-30-2P
 331774-31-3P 331774-32-4P 331774-33-5P
 331774-34-6P 331774-35-7P 331774-36-8P
 331774-37-9P 331774-38-0P 331774-39-1P
 331774-40-4P 331774-41-5P 331774-42-6P
 331774-43-7P 331774-44-8P 331774-45-9P
 331774-46-0P 331774-47-1P 331774-48-2P
 331774-49-3P 331774-50-6P 331774-51-7P
 331774-52-8P 331774-53-9P 331774-54-0P
 331774-55-1P 331774-56-2P 331774-57-3P
 331774-58-4P 331774-59-5P 331774-60-8P
 331774-62-0P 331774-63-1P 331774-64-2P
 331774-65-3P 331774-66-4P 331774-67-5P
 331774-68-6P 331774-69-7P 331774-70-0P
 331774-71-1P 331774-72-2P 331774-73-3P
 331774-74-4P 331774-75-5P 331774-76-6P
 331774-77-7P 331774-78-8P 331774-79-9P
 331774-80-2P 331774-81-3P 331774-82-4P
 331774-83-5P 331774-84-6P 331774-85-7P
 331774-86-8P 331774-87-9P 331774-88-0P
 331774-89-1P 331774-90-4P 331774-91-5P
 331774-92-6P 331774-93-7P 331774-94-8P
 331774-95-9P 331774-96-0P 331774-97-1P
 331774-98-2P 331774-99-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

IT 331775-00-9P 331775-01-0P 331775-02-1P
 331775-03-2P 331775-04-3P 331775-05-4P
 331775-06-5P 331775-07-6P 331775-08-7P
 331775-09-8P 331775-10-1P 331775-11-2P
 331775-12-3P 331775-13-4P 331775-14-5P
 331775-15-6P 331775-16-7P 331775-17-8P
 331775-18-9P 331775-19-0P 331775-20-3P
 331775-21-4P 331775-22-5P 331775-23-6P
 331775-24-7P 331775-25-8P 331775-26-9P
 331775-27-0P 331775-28-1P 331775-29-2P
 331775-30-5P 331775-31-6P 331775-32-7P
 331775-33-8P 331775-34-9P 331775-35-0P
 331775-36-1P 331775-37-2P 331775-38-3P
 331775-39-4P 331775-40-7P 331775-41-8P
 331775-42-9P 331775-43-0P 331775-44-1P
 331775-45-2P 331775-46-3P 331775-50-9P
 331775-51-0P 331775-52-1P 331775-53-2P
 331775-54-3P 331775-56-5P 331775-57-6P
 331775-58-7P 331775-59-8P 331775-60-1P 331775-61-2P
 331775-62-3P 331775-63-4P 331775-64-5P 331775-65-6P 331775-66-7P
 331775-67-8P 331775-68-9P 331775-69-0P 331775-70-3P 331775-71-4P
 331775-72-5P 331775-73-6P 331775-75-8P 331775-76-9P 331775-77-0P
 331775-78-1P 331775-79-2P 331775-80-5P 331775-81-6P 331775-82-7P
 331775-83-8P 331775-84-9P 331775-85-0P 331775-86-1P 331775-87-2P
 331775-88-3P 331775-89-4P 331775-90-7P 331775-91-8P 331775-92-9P
 331775-93-0P 331775-94-1P 331775-95-2P 331775-96-3P 331775-97-4P
 331775-98-5P 331775-99-6P 331776-00-2P 331776-01-3P 331776-02-4P
 331776-03-5P 331776-04-6P 331776-05-7P 331776-06-8P 331776-07-9P
 331776-08-0P 331776-09-1P 331776-10-4P 331776-11-5P 331776-12-6P

331776-13-7P 331776-14-8P 331776-15-9P 331776-16-0P 331776-17-1P
 331776-18-2P 331776-19-3P 331776-20-6P 331776-21-7P 331776-22-8P
 331776-23-9P 331776-24-0P 331776-25-1P 331776-26-2P 331776-27-3P
 331776-28-4P 331776-29-5P 331776-30-8P 331776-31-9P 331776-32-0P
 331776-33-1P 331776-34-2P 331776-35-3P 331776-36-4P 331776-37-5P
 331776-38-6P 331776-39-7P 331776-40-0P 331776-41-1P 331776-42-2P
 331776-43-3P 331776-44-4P 331810-24-3P 331825-58-2P

331825-60-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

IT 5930-93-8, 4-Nitropyrrole-2-carboxylic acid 6168-72-5,
 2-Amino-1-propanol 6284-84-0, cis-2,5-Dimethyl-piperazine 6291-85-6,
 3-Ethoxypropylamine 6303-58-8, 4-Phenoxybutyric acid 6304-89-8,
 3-Acetoxybenzoic acid 6338-70-1, Tetrahydro-3-thiophenamine 1,1-dioxide
 6482-24-2, 2-Bromoethyl methyl ether 6547-53-1, 4-Benzyloxyphenyl-acetic
 acid 6850-35-7, 3-Methylcyclohexylamine 6850-65-3,
 4-Aminocyclo-hexanol 6859-99-0, 3-Hydroxypiperidine 6959-48-4,
 3-Picolyl chloride hydrochloride 6964-21-2, 3-Thiopheneacetic acid
 7051-34-5, Cyclopropylmethyl bromide 7154-73-6, 1-(2-Aminoethyl)-
 pyrrolidine 7170-38-9, 3-Phenoxypropanoic acid 7304-32-7,
 2-Fluoro-5-nitrobenzoic acid 7311-63-9, 5-Bromothiophene-2-carboxylic
 acid 7531-52-4, L-Prolinamide 7663-77-6, 1-(3-Aminopropyl)-2-
 pyrrolidinone 10517-21-2, 5-Chloro indole-2-carboxylic acid
 13156-06-4, N-Isopropyl-3-hydroxyazetidine 13325-10-5, 4-Amino-1-butanol
 13364-16-4, 2-Methyl-pentylamine 13484-40-7, 1-(2-
 Methoxyethyl)piperazine 13831-31-7, Acetoxyacetyl chloride 13889-98-0,
 N-Acetyl piperazine 14003-16-8, 5-Methyl-2-furanmethanamine
 14290-86-9, (E)-4-Fluorocinnamic acid 14763-60-1 16397-19-6,
 2-Amino-1-hexanol 16499-88-0, 3-Butoxypropyl-amine 16874-33-2,
 Tetrahydro-2-furoic acid 16957-70-3, trans-2-Methylpent-2-enoic acid
 17247-58-4, Cyclobutylmethyl bromide 17420-30-3, 2-Cyano-4-nitroaniline
 18278-34-7, 4-Hydroxy-2-methoxybenzaldehyde 18542-42-2,
 2-(Methylthio)ethylamine 18600-42-5, 4-Nitrobenzylamine hydrochloride
 19815-17-9, 4-Chloro-7-nitroquinazoline 19961-27-4, N-Ethyl
 isopropylamine 19968-85-5, 1-Aminomethyl-1-cyclohexanol hydrochloride
 20173-04-0 20327-23-5, N-Cyclopropyl piperazine 21035-59-6
 21211-22-3, 3-Chlorobenzothiophene-2-carboxylic acid 21539-47-9
 23356-96-9, (S)-2-Pyrrolidinemethanol 25236-64-0 25850-22-0,
 4-Amino-2,2-dimethyltetrahydropyran 25952-53-8, 1-(3-
 Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 26116-12-1,
 2-(Aminomethyl)-1-ethylpyrrolidine 26371-07-3, 1-Piperidine propanoic
 acid 26690-80-2, N-(tert-Butoxycarbonyl)-ethanolamine 26734-09-8,
 3-Amino-2,2-dimethyl-1-propanol 27578-60-5, 2-Piperidino-ethylamine
 27631-29-4, 2,4-Dichloro-6,7-dimethoxyquinazoline 27757-85-3,
 Thiophene-2-methylamine 30433-91-1, 2-Thiophene ethylamine 30964-00-2,
 6-Heptynoic acid 31230-17-8, 3-Amino-5-methylpyrazole 32852-81-6,
 3-Phenoxyphenylacetic acid 33208-99-0, L-Alaninamide hydrochloride
 33331-99-6 34698-41-4, 1-Aminoindan 34750-64-6 35794-11-7,
 3,5-Dimethyl-piperidine 36489-03-9, 2-(Ethylthio)ethylamine
 37143-54-7, 2-Amino-1-methoxypropane 38196-09-7, 3-(4-Hydroxy-3-
 nitrophenyl)propanoic acid 39178-35-3, Isonicotinoyl chloride
 hydrochloride 39546-32-2, Isonipecotamide 40306-32-9 40499-83-0,
 3-Hydroxy pyrrolidine 41239-40-1 42514-50-1, 3-Amino-3-methyl-1-
 butanol 44565-47-1 45347-82-8, 3-Hydroxy azetidine 50274-85-6
 51387-90-7, 2-(2-Aminoethyl)-1-methylpyrrolidine 52671-64-4,
 3-Chloro-4-aminophenol hydrochloride 53293-00-8, 5-Hexynoic acid

54872-83-2, 1-Piperidinepropanoyl chloride 57165-06-7 58859-46-4,
Ethyl-4-amino-1-piperidinecarboxylate 60547-98-0, 2-Amino-4-benzyloxy-5-
methoxybenzamide 60923-28-6 62937-45-5, D-Prolinamide 63765-79-7
64021-83-6, N,N'-Dimethyl-3-aminopyrrolidine 64415-15-2,
4-Aminosulphonyl-1-hydroxy-2-naphthoic acid 67515-55-3,
4-Fluoro-3-(trifluoromethyl)benzoic acid 67579-87-7 67801-07-4,
(E)-3-(Trifluoromethyl)-cinnamic acid 68453-63-4, 1-(3-Hydroxypropyl)-
4,5-dihydroimidazole 70987-78-9, (2S)-(+)-Glycidyl tosylate
71026-66-9, N-(t-Butoxycarbonyl)-4-aminoaniline 72934-37-3,
1-(4-Chlorophenyl)-cyclopropane carboxylic acid 73579-08-5,
1-Methyl-4-(methylamino)piperidine 74141-12-1, E-3-(Tributylstannyl)-2-
propen-1-ol 81018-64-6, Thiazoline-2-carboxylic acid 81029-08-5,
4-(Methylsulphonyl)-3-nitrobenzoic acid 85068-28-6, 2,6-Difluorophenyl-
acetic acid 89895-06-7, 4-Acetyl piperidine hydrochloride 103057-44-9,
N-(tert-Butoxycarbonyl)-3-hydroxypyrrolidine 104587-51-1,
(2S,4R)-2-(Hydroxymethyl)-4-hydroxypyrrolidine 105184-38-1,
3,5-Difluorophenyl-acetic acid 115132-84-8 133659-14-0,
2-Chloro-3-methoxythiophene-4-carboxylic acid 137709-66-1 141699-57-2,
N-(tert-Butoxycarbonyl)-3-hydroxypyrrolidine methanesulphonate
143128-39-6, 4-Amino-2-chloro-4'-fluorobenzophenone 144870-96-2
162364-72-9, 4-Chloro-6-methoxy-7-benzyloxyquinazoline 162848-23-9,
2-Bromo-3-methoxythiophene-4-carboxylic acid 179688-29-0,
6,7-Di(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one 205194-33-8,
4-(3-Hydroxypropyl)-thiomorpholine-1,1-dioxide 220141-72-0,
3,4,5-Trifluorobenzyl bromide 220896-01-5, 7-Benzyloxy-3,4-
dihydroquinazolin-4-thione 330999-50-3, 4-(4-Aminoanilino)-6,7-
dimethoxyquinazoline 330999-74-1, 4-(4-(N-Boc-amino)anilino)-6-
methoxy-7-(3-morpholinopropoxy)quinazoline dihydrochloride 330999-79-6,
4-Chloro-6-methoxy-7-(2,2,2-trifluoroethoxy)quinazoline 330999-80-9,
Ethyl 4-(2,2,2-trifluoroethoxy)-3-methoxybenzoate 331734-30-6,
3-Aminotetrahydrothiophene-S,S-dioxide dihydrochloride 331776-45-5,
(E)-2,3,4-Trifluorocinnamic acid 331776-49-9, N-(4-Amino-2-
(trifluoromethyl)phenyl)benzamide 331776-52-4,
4-(4-(N-Boc-amino)anilino)-6-methoxy-7-(2,2,2-trifluoroethoxy)quinazoline
331776-53-5 331776-55-7 331776-56-8
331776-57-9, 4-(4-(N-Benzoyl)amino)anilino)-6-methoxy-7-
hydroxyquinazoline trifluoroacetate 331776-58-0,
4-(4-(N-Benzoyl)amino)anilino)-6-methoxy-7-benzyloxyquinazoline
trifluoroacetate 331776-59-1 331776-60-4
331776-61-5, 4-(4-(N-Benzoyl)amino)anilino)-6-methoxy-7-(4-
piperidinoxy)quinazoline 331776-62-6, 4-(Methylthio)-6-methoxy-7-((4,5-
dihydro-2-imidazolyl)methoxy)quinazoline 331776-63-7,
4-(Methylthio)-6-methoxy-7-hydroxyquinazoline 331776-65-9,
4-(4-(N-Benzoyl)amino)anilino)-6-methoxy-7-(2-bromoethoxy)quinazoline
331776-66-0, 3-(Aminomethyl)-thiophene dihydrochloride 331776-67-1
331776-68-2, (R)-4-(4-(N-Benzoyl)amino)anilino)-6-methoxy-7-
(glycidyl)quinazoline 331776-69-3 331776-71-7
331776-79-5, 4-(4-(N-Benzoyl)amino)anilino)-7-nitroquinazoline
331776-80-8 331776-81-9, 4-(Methylthio)-7-nitroquinazoline
331776-85-3, 4-Amino-2,4'-difluorobenzophenone 331776-89-7,
4-(4-Carboxyphenyl)-6-methoxy-7-(3-morpholinopropoxy)quinazoline
331776-90-0, 4-(4-Carboxyanilino)-6-methoxy-7-(3-
morpholinopropoxy)quinazoline dihydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of 4-substituted quinazoline aurora 2 kinase
inhibitors for treatment of cancer and other proliferative diseases)

IT 331770-21-9P 331771-20-1P


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
effector, except adverse); BSU (Biological study, unclassified); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)

(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for
treatment of cancer and other proliferative diseases)


RN 331770-21-9 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA
INDEX NAME)



RN 331771-20-1 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




IT 331772-11-3P 331772-14-6P 331772-33-9P
331772-44-2P 331772-45-3P 331772-47-5P
331772-51-1P 331772-52-2P 331772-53-3P
331774-61-9P 331775-47-4P 331775-48-5P
331775-49-6P 331775-55-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)

(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for
treatment of cancer and other proliferative diseases)


RN 331772-11-3 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331772-14-6 CAPLUS

CN Benzamide, N-[4-[(6-hydroxy-7-methoxy-4-quinazolinyl)amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331772-33-9 CAPLUS

CN Carbamic acid, [2-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331772-44-2 CAPLUS

CN Benzamide, N-[4-[[7-(2-hydroxyethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-45-3 CAPLUS

CN Benzamide, N-[4-[[7-(3-chloropropoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-47-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331772-51-1 CAPLUS

CN Benzamide, N-[4-[[7-(2-aminoethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331772-52-2 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(3-pyrrolidinyloxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-53-3 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(2-pyrrolidinylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-61-9 CAPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[3-(methylamino)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331775-47-4 CAPLUS

CN 2-Propenoic acid, 3-[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331775-48-5 CAPLUS


CN 2-Propenoic acid, 3-[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331775-49-6 CAPLUS

CN Benzamide, N-[4-[[7-(3-hydroxy-1-propenyl)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331775-55-4 CAPLUS

CN Benzamide, N-[4-[(7-amino-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




IT 331770-22-0P 331770-23-1P 331770-24-2P
331770-25-3P 331770-26-4P 331770-27-5P
331770-28-6P 331770-29-7P 331770-30-0P
331770-31-1P 331770-32-2P 331770-33-3P
331770-34-4P 331770-35-5P 331770-36-6P
331770-37-7P 331770-38-8P 331770-39-9P
331770-40-2P 331770-41-3P 331770-42-4P
331770-43-5P 331770-44-6P 331770-45-7P
331770-46-8P 331770-47-9P 331770-48-0P
331770-49-1P 331770-50-4P 331770-51-5P
331770-52-6P 331770-53-7P 331770-54-8P
331770-55-9P 331770-56-0P 331770-57-1P
331770-58-2P 331770-59-3P 331770-60-6P
331770-61-7P 331770-62-8P 331770-63-9P
331770-64-0P 331770-65-1P 331770-66-2P
331770-67-3P 331770-68-4P 331770-69-5P
331770-70-8P 331770-71-9P 331770-72-0P
331770-73-1P 331770-74-2P 331770-75-3P
331770-76-4P 331770-77-5P 331770-78-6P
331770-79-7P 331770-80-0P 331770-81-1P
331770-82-2P 331770-83-3P 331770-84-4P
331770-85-5P 331770-86-6P 331770-87-7P
331770-88-8P 331770-89-9P 331770-90-2P
331770-91-3P 331770-92-4P 331770-93-5P
331770-94-6P 331770-95-7P 331770-96-8P
331770-97-9P 331770-98-0P 331770-99-1P
331771-00-7P 331771-01-8P 331771-02-9P
331771-03-0P 331771-04-1P 331771-05-2P
331771-06-3P 331771-07-4P 331771-08-5P
331771-09-6P 331771-10-9P 331771-11-0P
331771-12-1P 331771-13-2P 331771-14-3P
331771-15-4P 331771-16-5P 331771-17-6P
331771-21-2P 331771-22-3P 331771-23-4P
331771-24-5P 331771-25-6P 331771-26-7P
331771-27-8P 331771-28-9P 331771-29-0P
331771-30-3P 331771-31-4P 331771-32-5P
331771-33-6P 331771-34-7P 331771-35-8P
331771-36-9P 331771-37-0P 331771-38-1P

331771-39-2P 331771-40-5P 331771-41-6P
331771-42-7P 331771-43-8P 331771-44-9P
331771-45-0P 331771-46-1P 331771-47-2P
331771-48-3P 331771-49-4P 331771-50-7P
331771-51-8P 331771-52-9P 331771-53-0P
331771-54-1P 331771-55-2P 331771-56-3P
331771-57-4P 331771-58-5P 331771-59-6P
331771-60-9P 331771-61-0P 331771-62-1P
331771-63-2P 331771-64-3P 331771-65-4P
331771-66-5P 331771-67-6P 331771-68-7P
331771-69-8P 331771-70-1P 331771-71-2P
331771-72-3P 331771-73-4P 331771-74-5P
331771-75-6P 331771-76-7P 331771-77-8P
331771-78-9P 331771-79-0P 331771-80-3P
331771-81-4P 331771-82-5P 331771-83-6P
331771-84-7P 331771-85-8P 331771-86-9P
331771-87-0P 331771-88-1P 331771-89-2P
331771-90-5P 331771-91-6P 331771-92-7P
331771-93-8P 331771-94-9P 331771-95-0P
331771-96-1P 331771-97-2P 331771-98-3P
331771-99-4P 331772-00-0P 331772-01-1P
331772-02-2P 331772-03-3P 331772-04-4P
331772-05-5P 331772-06-6P 331772-07-7P
331772-08-8P 331772-09-9P 331772-10-2P
331772-12-4P 331772-13-5P 331772-15-7P
331772-16-8P 331772-17-9P 331772-18-0P
331772-19-1P 331772-20-4P 331772-21-5P
331772-22-6P 331772-23-7P 331772-24-8P
331772-25-9P 331772-26-0P 331772-27-1P
331772-28-2P 331772-29-3P 331772-30-6P
331772-31-7P 331772-32-8P 331772-34-0P
331772-35-1P 331772-36-2P 331772-37-3P
331772-38-4P 331772-39-5P 331772-40-8P
331772-41-9P 331772-42-0P 331772-43-1P
331772-46-4P 331772-48-6P 331772-49-7P
331772-50-0P 331772-54-4P 331772-55-5P
331772-56-6P 331772-57-7P 331772-58-8P
331772-59-9P 331772-60-2P 331772-61-3P
331772-62-4P 331772-63-5P 331772-64-6P
331772-65-7P 331772-66-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 331770-22-0 CAPLUS


CN 2-Furancarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)



RN 331770-23-1 CAPLUS


CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-phenyl-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331770-24-2 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 331770-25-3 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,4-difluoro-
(9CI) (CA INDEX NAME)



RN 331770-26-4 CAPLUS


CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4,5-dimethoxy-
2-nitro- (9CI) (CA INDEX NAME)



RN 331770-27-5 CAPLUS

CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,4-dinitro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331770-28-6 CAPLUS

CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 331770-29-7 CAPLUS


CN Cyclopentanecarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331770-30-0 CAPLUS


CN 4-Pentenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methyl-
(9CI) (CA INDEX NAME)

RN 331770-31-1 CAPLUS

CN Acetamide, 2-cyano-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)


RN 331770-32-2 CAPLUS

CN Octanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA
INDEX NAME)




RN 331770-33-3 CAPLUS

CN Propanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(methylthio)- (9CI) (CA INDEX NAME)




RN 331770-34-4 CAPLUS

CN Propanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-ethoxy- (9CI) (CA INDEX NAME)




RN 331770-35-5 CAPLUS

CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methyl-
(9CI) (CA INDEX NAME)


RN 331770-36-6 CAPLUS

CN Pyrazinecarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 331770-37-7 CAPLUS


CN 3-Furancarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)



RN 331770-38-8 CAPLUS
 CN Benzamide, 3-cyano-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl] -
 (9CI) (CA INDEX NAME)




RN 331770-39-9 CAPLUS
 CN Benzamide, 4-(acetyloxy)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl] -
 (9CI) (CA INDEX NAME)




RN 331770-40-2 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-methoxy-2-nitro- (9CI) (CA INDEX NAME)




RN 331770-41-3 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 331770-42-4 CAPLUS

CN Benzamide, 3-(acetyloxy)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331770-43-5 CAPLUS

CN 2-Naphthalenecarboxamide, 4-(aminosulfonyl)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-1-hydroxy- (9CI) (CA INDEX NAME)




RN 331770-44-6 CAPLUS

CN 2-Pyridinecarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 331770-45-7 CAPLUS

CN 2-Quinolinecarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 331770-46-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 331770-47-9 CAPLUS


CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-fluoro-5-nitro- (9CI) (CA INDEX NAME)



RN 331770-48-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 331770-49-1 CAPLUS
 CN 3-Pyridinecarboxamide, 2-chloro-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331770-50-4 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-fluoro-
(9CI) (CA INDEX NAME)




RN 331770-51-5 CAPLUS


CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,3-difluoro-
(9CI) (CA INDEX NAME)



RN 331770-52-6 CAPLUS
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,5-difluoro-
 (9CI) (CA INDEX NAME)




RN 331770-53-7 CAPLUS
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,3-dimethoxy-
 (9CI) (CA INDEX NAME)




RN 331770-54-8 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-hydroxy-3,5-dimethoxy- (9CI) (CA INDEX NAME)



RN 331770-55-9 CAPLUS


CN Benzoic acid, 2-chloro-4-[[[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 331770-56-0 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-(methylsulfonyl)-3-nitro- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 331770-57-1 CAPLUS
CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methoxy-3-nitro- (9CI) (CA INDEX NAME)




RN 331770-58-2 CAPLUS
CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(2-nitrophenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331770-59-3 CAPLUS
CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(3-nitrophenyl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331770-60-6 CAPLUS

CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)aminophenyl]-3-(4-nitrophenyl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331770-61-7 CAPLUS

CN 2-Propenamide, 3-(4-chlorophenyl)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)aminophenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331770-62-8 CAPLUS

CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(2,3,4-trifluorophenyl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331770-63-9 CAPLUS

CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-[3-(trifluoromethyl)phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331770-64-0 CAPLUS


CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(4-fluorophenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331770-65-1 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(4-fluorophenyl)-, (2E)- (9CI) (CA INDEX NAME)




RN 331770-66-2 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 331770-67-3 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 331770-68-4 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,5-dinitro-
(9CI) (CA INDEX NAME)



RN 331770-69-5 CAPLUS


CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-
(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 331770-70-8 CAPLUS

CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 331770-71-9 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 331770-72-0 CAPLUS
CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 331770-73-1 CAPLUS
 CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


i-Pr

RN 331770-74-2 CAPLUS
 CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)



RN 331770-75-3 CAPLUS


CN Propanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-phenoxy-
(9CI) (CA INDEX NAME)




RN 331770-76-4 CAPLUS

CN Benzenepropanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,4-
dimethoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331770-77-5 CAPLUS
 CN Benzenebutanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methoxy-γ-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 331770-78-6 CAPLUS
 CN Butanamide, 4-chloro-N-[4-[(6,7-dimethoxy-4-quinazolinyl)aminolphenyl]-(9CI) (CA INDEX NAME)




RN 331770-79-7 CAPLUS

CN Butanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-phenoxy-
(9CI) (CA INDEX NAME)




RN 331770-80-0 CAPLUS


CN Benzenebutanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)



RN 331770-81-1 CAPLUS


CN Benzenepentanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
8-oxo- (9CI) (CA INDEX NAME)

RN 331770-82-2 CAPLUS

CN 10-Undecenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI)
(CA INDEX NAME)


RN 331770-83-3 CAPLUS

CN 2-Pentenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methyl-
(9CI) (CA INDEX NAME)




RN 331770-84-4 CAPLUS

CN 2-Thiopheneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl) amino]phenyl] -
(9CI) (CA INDEX NAME)



RN 331770-85-5 CAPLUS


CN 3-Thiopheneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl) amino]phenyl] -
(9CI) (CA INDEX NAME)




RN 331770-86-6 CAPLUS

CN Benzenepropanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-hydroxy-3-nitro- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 331770-87-7 CAPLUS
 CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 331770-88-8 CAPLUS
 CN [1,1'-Biphenyl]-4-acetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


Ph

RN 331770-89-9 CAPLUS
 CN 1,3-Benzodioxole-5-acetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331770-90-2 CAPLUS

CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 331770-91-3 CAPLUS

CN Benzeneacetamide, 4-butoxy-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-A


PAGE 2-A




RN 331770-92-4 CAPLUS
CN Pentanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methyl-
(9CI) (CA INDEX NAME)



RN 331770-93-5 CAPLUS
CN 5-Hexynamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI)
(CA INDEX NAME)




RN 331770-94-6 CAPLUS
CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-
phenoxy- (9CI) (CA INDEX NAME)




RN 331770-95-7 CAPLUS

CN 3-Thiophenecarboxamide, 5-bromo-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 331770-96-8 CAPLUS


CN 3-Thiophenecarboxamide, 5-chloro-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 331770-97-9 CAPLUS

CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-ethoxy-3-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331770-98-0 CAPLUS
CN Benzeneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 331770-99-1 CAPLUS
CN 2-Thiophenebutanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-00-7 CAPLUS
 CN 6-Heptynamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI)
 (CA INDEX NAME)




RN 331771-01-8 CAPLUS
 CN Cyclopropanecarboxamide, 1-(4-chlorophenyl)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-02-9 CAPLUS

CN Cyclopentaneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 331771-03-0 CAPLUS

CN Cyclopentanepropanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)



RN 331771-04-1 CAPLUS


CN Cyclohexaneacetamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 331771-05-2 CAPLUS

CN Cyclohexanepropanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 331771-06-3 CAPLUS
 CN Cyclohexanebutanamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl] -
 (9CI) (CA INDEX NAME)



RN 331771-07-4 CAPLUS


CN 2-Propenamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methyl-3-phenyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331771-08-5 CAPLUS


CN Benzamide, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-09-6 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenyl] -
(9CI) (CA INDEX NAME)


RN 331771-10-9 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-3-methylphenyl] -
(9CI) (CA INDEX NAME)

RN 331771-11-0 CAPLUS


CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methoxyphenyl] -
(9CI) (CA INDEX NAME)

RN 331771-12-1 CAPLUS

CN Benzamide, N-[2-cyano-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl] -
(9CI) (CA INDEX NAME)


RN 331771-13-2 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-3-(trifluoromethyl)phenyl] - (9CI) (CA INDEX NAME)




RN 331771-14-3 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methylphenyl] - (9CI) (CA INDEX NAME)




RN 331771-15-4 CAPLUS

CN Benzamide, N-[2-cyano-4-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331771-16-5 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 331771-17-6 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 331771-21-2 CAPLUS

CN Carbamic acid, [4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331771-22-3 CAPLUS

CN Benzamide, 2-chloro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 331771-23-4 CAPLUS

CN Acetamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-24-5 CAPLUS

CN Octanamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331771-25-6 CAPLUS

CN 2-Furancarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331771-26-7 CAPLUS

CN 3-Furancarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331771-27-8 CAPLUS

CN 2-Thiopheneacetamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331771-28-9 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-29-0 CAPLUS

CN Benzamide, 2,4-difluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-30-3 CAPLUS
 CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-(methylsulfonyl)-3-nitro- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 331771-31-4 CAPLUS
CN 5-Hexynamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-32-5 CAPLUS
CN Benzamide, 2-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 331771-33-6 CAPLUS
CN Benzamide, 3-methoxy-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 331771-34-7 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 331771-35-8 CAPLUS

CN Pyrazinecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 331771-36-9 CAPLUS

CN 6-Heptynamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-37-0 CAPLUS

CN Cyclopentanecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-38-1 CAPLUS

CN Cyclohexaneacetamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]aminophenyl]- (9CI) (CA INDEX NAME)




RN 331771-39-2 CAPLUS

CN Benzamide, 4-methoxy-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]aminophenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-40-5 CAPLUS

CN 2-Furancarboxamide, tetrahydro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331771-41-6 CAPLUS

CN 2-Pyridinecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 331771-42-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331771-43-8 CAPLUS

CN 2-Propenamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-3-(4-nitrophenyl)-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B


—NO₂

RN 331771-44-9 CAPLUS
 CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2,4-dinitro- (9CI) (CA INDEX NAME)




RN 331771-45-0 CAPLUS

CN Benzamide, 3-(acetyloxy)-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-46-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 331771-47-2 CAPLUS

CN Cyclobutanecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-48-3 CAPLUS

CN Benzamide, 2-methoxy-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-49-4 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-50-7 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 331771-51-8 CAPLUS

CN Cyclohexanecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-52-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 331771-53-0 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-methyl-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-54-1 CAPLUS

CN Benzamide, 4-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-55-2 CAPLUS

CN 3-Thiopheneacetamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331771-56-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, 3-chloro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 331771-57-4 CAPLUS


CN 1H-Indole-2-carboxamide, 5-chloro-N- [4- [[6-methoxy-7- [3- (4-morpholinyl)propoxy] -4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331771-58-5 CAPLUS

CN 1-Piperidinepropanamide, N- [4- [[6-methoxy-7- [3- (4-morpholinyl)propoxy] -4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 331771-59-6 CAPLUS
 CN 1,3-Benzodioxole-5-carboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-60-9 CAPLUS

CN 3-Butynamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331771-61-0 CAPLUS

CN Benzamide, 3-cyano-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331771-62-1 CAPLUS

CN Propanamide, 3-(acetylamino)-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-63-2 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 331771-64-3 CAPLUS

CN Benzamide, 3-chloro-4-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-65-4 CAPLUS

CN Benzamide, 4-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 331771-66-5 CAPLUS

CN Benzamide, 4-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-67-6 CAPLUS


CN 2-Thiophenecarboxamide, 5-bromo-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-68-7 CAPLUS
 CN Benzamide, 4-methoxy-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-69-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 331771-70-1 CAPLUS

CN 2-Furancarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 331771-71-2 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 331771-72-3 CAPLUS
 CN 2-Propenamide, 3-(3-chlorophenyl)-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331771-73-4 CAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-74-5 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-75-6 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 331771-76-7 CAPLUS

CN Benzamide, 2-chloro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331771-77-8 CAPLUS

CN Benzamide, 2-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331771-78-9 CAPLUS

CN Benzamide, 2,5-dichloro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-79-0 CAPLUS

CN Benzamide, 3-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-80-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-81-4 CAPLUS

CN 2-Furancarboxamide, 5-bromo-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-82-5 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-methyl-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-83-6 CAPLUS

CN Benzamide, 3-chloro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-84-7 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-85-8 CAPLUS

CN Benzamide, 2-chloro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 331771-86-9 CAPLUS

CN Cyclopentanecarboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-87-0 CAPLUS

CN Cyclohexaneacetamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-88-1 CAPLUS

CN Benzamide, 4-methoxy-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-89-2 CAPLUS

CN Octanamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-90-5 CAPLUS

CN 2-Furancarboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-91-6 CAPLUS

CN 3-Furancarboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-92-7 CAPLUS

CN 2-Thiopheneacetamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-93-8 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-94-9 CAPLUS

CN 2-Furancarboxamide, tetrahydro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-95-0 CAPLUS

CN 2-Pyridinecarboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-96-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-97-2 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-2,4-dinitro- (9CI) (CA INDEX NAME)




RN 331771-98-3 CAPLUS

CN Benzamide, 2,4-difluoro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-99-4 CAPLUS

CN 5-Hexynamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-00-0 CAPLUS
 CN 3-Thiopheneacetamide, tetrahydro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331772-01-1 CAPLUS

CN Propanamide, 3-methoxy-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-02-2 CAPLUS

CN Benzamide, 2-fluoro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 331772-03-3 CAPLUS

CN Benzamide, 3-methoxy-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 331772-04-4 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 331772-05-5 CAPLUS

CN Pyrazinecarboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 331772-06-6 CAPLUS

CN 6-Heptynamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-07-7 CAPLUS

CN Benzamide, 3-(acetyloxy)-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-08-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 331772-09-9 CAPLUS

CN Benzamide, N-[4-[[6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-10-2 CAPLUS

CN Benzamide, N-[4-[[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 331772-12-4 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-13-5 CAPLUS

CN Benzamide, N-[4-[[6,7-dimethoxy-2-(4-morpholinyl)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-15-7 CAPLUS

CN Benzamide, N-[4-[(7-hydroxy-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-16-8 CAPLUS

CN Benzamide, N-[4-[[7-methoxy-6-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-17-9 CAPLUS

CN Benzamide, N-[4-[[7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-18-0 CAPLUS

CN Benzamide, N-[4-[[6-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-19-1 CAPLUS

CN Benzamide, N-[4-[[7-methoxy-6-[3-(methylsulfonyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-20-4 CAPLUS

CN Benzamide, N-[4-[[7-methoxy-6-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-21-5 CAPLUS

CN Benzamide, N-[4-[[6-[2-(dimethylamino)ethoxy]-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-22-6 CAPLUS

CN Benzamide, N-[4-[[7-methoxy-6-(3-pyridinylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-23-7 CAPLUS

CN Benzamide, N-[4-[[7-methoxy-6-(2-methoxyethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-24-8 CAPLUS

CN Benzamide, N-[4-[[6-[3-(dimethylamino)propoxy]-7-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331772-25-9 CAPLUS

CN Benzamide, N-[4-[[7-methoxy-6-(phenylmethoxy)-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331772-26-0 CAPLUS

CN Benzamide, N-[4-[[6-(2-hydroxyethoxy)-7-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331772-27-1 CAPLUS

CN Benzamide, N-[4-[[7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-28-2 CAPLUS

CN Benzamide, N-[4-[[7-[3-(dimethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-29-3 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-30-6 CAPLUS

CN Benzamide, N-[4-[[7-[2-(dimethylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-31-7 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-32-8 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(methylsulfonyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-34-0 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(3-pyridinylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-35-1 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331772-36-2 CAPLUS

CN Benzamide, N-[4-[[7-(acetyloxy)-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331772-37-3 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(3,4,5-trifluorophenyl)methoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-38-4 CAPLUS


CN Benzamide, N-[4-[[7-[3-(2,3-dihydro-1H-pyrrol-1-yl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-39-5 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[[(2Z)-4-(1-pyrrolidinyl)-2-butenyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331772-40-8 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[[(2E)-4-(1-pyrrolidinyl)-2-butenyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331772-41-9 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[[(2Z)-4-(1-piperidiny)-2-butenyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331772-42-0 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[[(2E)-4-(4-morpholinyl)-2-butenyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331772-43-1 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[[(2E)-4-(4-methyl-1-piperazinyl)-2-butenyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331772-46-4 CAPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[(2S)-oxiranylmethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331772-48-6 CAPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[[1-(1-methylethyl)-3-azetidinyloxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-49-7 CAPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[(2R)-oxiranylmethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-50-0 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(2,2,2-trifluoroethoxy)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-54-4 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(4-piperidinylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-55-5 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(1-methyl-2-pyrrolidinyl)methoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-56-6 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(1-methyl-3-pyrrolidinyl)methoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-57-7 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(1-methyl-3-pyrrolidinyl)oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-58-8 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[(2-methoxyethyl)methylamino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-59-9 CAPLUS

CN Benzamide, N-[4-[[7-[3-(acetylmethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-60-2 CAPLUS

CN Benzamide, N-[4-[[7-[3-[[[(dimethylamino)carbonyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-61-3 CAPLUS

CN Benzamide, N-[4-[[7-[[1-(2-hydroxyethyl)-3-pyrrolidinyl]oxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-62-4 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[1-(2-methoxyethyl)-3-pyrrolidinyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-63-5 CAPLUS

CN Benzamide, N-[4-[[7-[[1-(cyanomethyl)-3-pyrrolidinyl]oxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-64-6 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[1-(2-methoxyethyl)-4-piperidinyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-65-7 CAPLUS

CN Benzamide, N-[4-[[7-[[1-(cyanomethyl)-4-piperidinyloxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-66-8 CAPLUS

CN Benzamide, N-[4-[[7-[[1-(cyclopropylmethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT 331772-67-9P 331772-68-0P 331772-69-1P
 331772-70-4P 331772-71-5P 331772-72-6P
 331772-73-7P 331772-74-8P 331772-75-9P
 331772-76-0P 331772-77-1P 331772-78-2P
 331772-79-3P 331772-80-6P 331772-81-7P
 331772-82-8P 331772-83-9P 331772-84-0P
 331772-85-1P 331772-86-2P 331772-87-3P
 331772-88-4P 331772-89-5P 331772-90-8P
 331772-91-9P 331772-92-0P 331772-93-1P
 331772-94-2P 331772-95-3P 331772-96-4P


331772-97-5P 331772-98-6P 331772-99-7P
331773-00-3P 331773-01-4P 331773-02-5P
331773-03-6P 331773-04-7P 331773-05-8P
331773-06-9P 331773-07-0P 331773-08-1P
331773-09-2P 331773-10-5P 331773-11-6P
331773-12-7P 331773-13-8P 331773-14-9P
331773-15-0P 331773-16-1P 331773-17-2P
331773-18-3P 331773-19-4P 331773-20-7P
331773-21-8P 331773-22-9P 331773-23-0P
331773-24-1P 331773-25-2P 331773-26-3P
331773-27-4P 331773-28-5P 331773-29-6P
331773-30-9P 331773-31-0P 331773-32-1P
331773-33-2P 331773-34-3P 331773-35-4P
331773-36-5P 331773-37-6P 331773-38-7P
331773-39-8P 331773-40-1P 331773-41-2P
331773-42-3P 331773-43-4P 331773-44-5P
331773-45-6P 331773-46-7P 331773-47-8P
331773-48-9P 331773-49-0P 331773-50-3P
331773-51-4P 331773-52-5P 331773-53-6P
331773-54-7P 331773-55-8P 331773-56-9P
331773-57-0P 331773-58-1P 331773-59-2P
331773-60-5P 331773-61-6P 331773-62-7P
331773-63-8P 331773-64-9P 331773-65-0P
331773-66-1P 331773-67-2P 331773-68-3P
331773-69-4P 331773-70-7P 331773-71-8P
331773-72-9P 331773-73-0P 331773-74-1P
331773-75-2P 331773-76-3P 331773-77-4P
331773-78-5P 331773-79-6P 331773-80-9P
331773-81-0P 331773-82-1P 331773-83-2P
331773-84-3P 331773-85-4P 331773-86-5P
331773-87-6P 331773-88-7P 331773-89-8P
331773-90-1P 331773-91-2P 331773-92-3P
331773-93-4P 331773-94-5P 331773-95-6P
331773-96-7P 331773-97-8P 331773-98-9P
331773-99-0P 331774-00-6P 331774-01-7P
331774-02-8P 331774-03-9P 331774-04-0P
331774-05-1P 331774-06-2P 331774-07-3P
331774-08-4P 331774-09-5P 331774-10-8P
331774-11-9P 331774-12-0P 331774-13-1P
331774-15-3P 331774-17-5P 331774-18-6P
331774-19-7P 331774-20-0P 331774-21-1P
331774-22-2P 331774-23-3P 331774-24-4P
331774-25-5P 331774-26-6P 331774-27-7P
331774-28-8P 331774-29-9P 331774-30-2P
331774-31-3P 331774-32-4P 331774-33-5P
331774-34-6P 331774-35-7P 331774-36-8P
331774-37-9P 331774-38-0P 331774-39-1P
331774-40-4P 331774-41-5P 331774-42-6P
331774-43-7P 331774-44-8P 331774-45-9P
331774-46-0P 331774-47-1P 331774-48-2P
331774-49-3P 331774-50-6P 331774-51-7P
331774-52-8P 331774-53-9P 331774-54-0P
331774-55-1P 331774-56-2P 331774-57-3P
331774-58-4P 331774-59-5P 331774-60-8P
331774-62-0P 331774-63-1P 331774-64-2P
331774-65-3P 331774-66-4P 331774-67-5P
331774-68-6P 331774-69-7P 331774-70-0P
331774-71-1P 331774-72-2P 331774-73-3P
331774-74-4P 331774-75-5P 331774-76-6P

331774-77-7P 331774-78-8P 331774-79-9P
 331774-80-2P 331774-81-3P 331774-82-4P
 331774-83-5P 331774-84-6P 331774-85-7P
 331774-86-8P 331774-87-9P 331774-88-0P
 331774-89-1P 331774-90-4P 331774-91-5P
 331774-92-6P 331774-93-7P 331774-94-8P
 331774-95-9P 331774-96-0P 331774-97-1P
 331774-98-2P 331774-99-3P 331775-00-9P
 331775-01-0P 331775-02-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)


RN 331772-67-9 CAPLUS

CN Benzamide, N-[4-[[7-[[1-(cyclobutylmethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-68-0 CAPLUS

CN Benzamide, N-[4-[[7-[[1-(2-hydroxyethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-69-1 CAPLUS

CN Benzamide, N-[4-[[7-[[1-[2-(ethylthio)ethyl]-2-pyrrolidiny]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331772-70-4 CAPLUS

CN Benzamide, N-[4-[[7-[[1-(cyclopropylmethyl)-4-piperidiny]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331772-71-5 CAPLUS

CN Benzamide, N-[4-[[7-[[1-(2-hydroxyethyl)-4-piperidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-72-6 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[1-(2-methoxyethyl)-4-piperidinyl]methoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-73-7 CAPLUS

CN Benzamide, N-[4-[[7-[[1-(cyanomethyl)-4-piperidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-74-8 CAPLUS

CN Benzamide, N-[4-[[7-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-75-9 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(2-thienylmethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-76-0 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-(acetamino)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-77-1 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-[bis(1-methylethyl)amino]ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-78-2 CAPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[2-[[2-(methylthio)ethyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-79-3 CAPLUS


CN Benzamide, N-[4-[[7-[2-[[[(1S)-2-amino-1-methyl-2-oxoethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-80-6 CAPLUS

CN Benzamide, N-[4-[[7-[2-(cyclopropylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-81-7 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(cyclopropylmethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-82-8 CAPLUS

CN Benzamide, N-[4-[[7-[2-(cyclobutylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-83-9 CAPLUS

CN Benzamide, N-[4-[[7-[2-(cyclopentylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-84-0 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[3-(1H-imidazol-1-yl)propyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-85-1 CAPLUS

CN Benzamide, N-[4-[[7-[2-(cyclohexylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-86-2 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(4-hydroxycyclohexyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-87-3 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(cyclohexylmethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-88-4 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI)
(CA INDEX NAME)




RN 331772-89-5 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)



RN 331772-90-8 CAPLUS


CN Benzamide, N-[4-[[7-[2-[[1,1-bis(hydroxymethyl)propyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-91-9 CAPLUS


CN Benzamide, N-[4-[[7-[2-[[[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-92-0 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[[(1-ethyl-2-pyrrolidinyl)methyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-93-1 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-94-2 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[[[tetrahydro-2-furanyl)methyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331772-95-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl] - (9CI) (CA INDEX NAME)




RN 331772-96-4 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[[2-(4-morpholinyl)ethyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-97-5 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[[3-(4-morpholinyl)propyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-98-6 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[[2-(1-piperidiny)ethyl]amino]ethoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-99-7 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[[2-(1-pyrrolidiny)ethyl]amino]ethoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-00-3 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxy-1,1-dimethylpentyl)amino]ethoxy]-6-methoxy-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-01-4 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxy-1,1-dimethylethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-02-5 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(3-hydroxy-1,1-dimethylpropyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-03-6 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(1-methylethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-04-7 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxy-1-methylethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-05-8 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[1-(hydroxymethyl)propyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331773-06-9 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(2,3-dihydroxypropyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331773-07-0 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-(dimethylamino)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-08-1 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-(diethylamino)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-09-2 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(2-methoxyethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-10-5 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-(2-hydroxyethoxy)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-11-6 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-12-7 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-mercaptoethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-13-8 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-(ethylthio)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-14-9 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(3-ethoxypropyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-15-0 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(3-butoxypropyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-16-1 CAPLUS

CN Benzamide, N- [4- [[7- [2- [(3-hydroxypropyl) amino] ethoxy] -6-methoxy-4-quinazoliny] amino] phenyl] - (9CI) (CA INDEX NAME)




RN 331773-17-2 CAPLUS

CN Benzamide, N- [4- [[7- [2- [(5-hydroxypentyl) amino] ethoxy] -6-methoxy-4-quinazoliny] amino] phenyl] - (9CI) (CA INDEX NAME)




RN 331773-18-3 CAPLUS

CN Benzamide, N- [4- [[6-methoxy-7- [2- [(2-methoxy-1-methylethyl) amino] ethoxy] -4-quinazoliny] amino] phenyl] - (9CI) (CA INDEX NAME)




RN 331773-19-4 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(4-hydroxybutyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-20-7 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(5-methyl-1H-pyrazol-3-yl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-21-8 CAPLUS

CN Benzamide, N- [4- [[6-methoxy-7- [2- [[3- (4-methyl-1-piperazinyl)propyl]amino]ethoxy] -4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331773-22-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4- [[2- [[4- [[4- (benzoylamino)phenyl]amino] -6-methoxy-7-quinazolinyl]oxy]ethyl]amino] -, ethyl ester (9CI) (CA INDEX NAME)




RN 331773-23-0 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-(dibutylamino)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-24-1 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-(dipropylamino)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-25-2 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-(2-hydroxycyclohexyl)methyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-26-3 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[[2-(2-thienyl)ethyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-27-4 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[1-(hydroxymethyl)pentyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-28-5 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[4-hydroxy-1-(methylthio)butyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-29-6 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-30-9 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[[5-methyl-2-furanyl)methyl]amino]ethoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-31-0 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(tetrahydro-1,1-dioxido-3-thienyl)amino]ethoxy]-4-quinazoliny]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-32-1 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(3-hydroxy-2,2-dimethylpropyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-33-2 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(3-thienylmethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-34-3 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(4-thiomorpholinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-35-4 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxyethyl)[2-(4-morpholinylethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-36-5 CAPLUS

CN Benzamide, N-[4-[[7-[2-[bis(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-37-6 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(1-piperidinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-38-7 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(4-pyridinylmethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-39-8 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-40-1 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(methylamino)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-41-2 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[methyl(methylsulfonyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-42-3 CAPLUS

CN Benzamide, N-[4-[[7-[2-(diethylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-43-4 CAPLUS

CN Benzamide, N-[4-[[7-[2-(hexahydro-1H-azepin-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-44-5 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxyethyl)methylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331773-45-6 CAPLUS

CN Benzamide, N-[4-[[7-[2-(2,5-dihydro-1H-pyrrol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331773-46-7 CAPLUS

CN Benzamide, N-[4-[[7-[2-[[2-(dimethylamino)ethyl]methylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-47-8 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-48-9 CAPLUS


CN Benzamide, N-[4-[[7-[2-(4-cyclopropyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 331773-49-0 CAPLUS


CN Benzamide, N-[4-[[7-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331773-50-3 CAPLUS

CN Benzamide, N-[4-[[7-[2-(4-hydroxy-1-piperidinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-51-4 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-52-5 CAPLUS

CN Benzamide, N-[4-[[7-[2-[4-(3-hydroxypropyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-53-6 CAPLUS

CN Benzamide, N-[4-[[7-[2-[ethyl(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-54-7 CAPLUS

CN Benzamide, N-[4-[[7-[2-(3-hydroxy-1-pyrrolidinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-55-8 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-cyanoethyl)methylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-56-9 CAPLUS

CN Benzamide, N-[4-[[7-(2-[1,4'-bipiperidin]-1'-ylethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-57-0 CAPLUS

CN Benzamide, N-[4-[[7-[2-(3,5-dimethyl-4-morpholinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331773-58-1 CAPLUS

CN Benzamide, N-[4-[[7-[2-(4-acetyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331773-59-2 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(methyl-2-propenylamino)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-60-5 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(2-methyl-1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-61-6 CAPLUS

CN Benzamide, N-[4-[[7-[2-[ethyl(1-methylethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331773-62-7 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-cyanoethyl)ethylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331773-63-8 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(methyl(2-methylpropyl)amino)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-64-9 CAPLUS

CN Benzamide, N-[4-[[7-[2-(4-ethyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-65-0 CAPLUS

CN Benzamide, N-[4-[[7-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-66-1 CAPLUS

CN 2-Thiazolidinecarboxylic acid, 3-[2-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 331773-67-2 CAPLUS

CN Benzamide, N-[4-[[7-[2-[4-(2-hydroxyethyl)-1-piperidiny]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-68-3 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[methyl(3-pyridinylmethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-69-4 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[methyl(2-pyridinylmethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-70-7 CAPLUS

CN Benzamide, N-[4-[[7-[2-(2,5-dimethyl-1-pyrrolidinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-71-8 CAPLUS

CN Benzamide, N-[4-[[7-[2-(3,6-dihydro-1(2H)-pyridinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-72-9 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(4-methyl-1-piperidinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


RN 331773-75-2 CAPLUS

CN Benzamide, N-[4-[[7-[2-(2-ethyl-4,5-dihydro-1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-76-3 CAPLUS

CN Benzamide, N-[4-[[7-[2-(4,5-dihydro-1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-77-4 CAPLUS


CN Benzamide, N-[4-[[7-[3-[[2-(acetylamino)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-78-5 CAPLUS


CN Benzamide, N-[4-[[7-[3-[[[(1S)-2-amino-1-methyl-2-oxoethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331773-79-6 CAPLUS

CN Benzamide, N-[4-[[7-[3-(cyclopropylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-80-9 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(cyclopropylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-81-0 CAPLUS

CN Benzamide, N-[4-[[7-[3-(cyclobutylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-82-1 CAPLUS

CN Benzamide, N-[4-[[7-[3-(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-83-2 CAPLUS

CN Benzamide, N-[4-[[7-[3-[[3-(1H-imidazol-1-yl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331773-84-3 CAPLUS

CN Benzamide, N-[4-[[7-[3-(cyclohexylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331773-85-4 CAPLUS

CN Benzamide, N-[4-[[[7-[3-[(4-hydroxycyclohexyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-86-5 CAPLUS

CN Benzamide, N-[4-[[[7-[3-[(cyclohexylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-87-6 CAPLUS

CN Benzamide, N-[4-[[7-[3-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI)
(CA INDEX NAME)




RN 331773-88-7 CAPLUS

CN Benzamide, N-[4-[[7-[3-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)



RN 331773-89-8 CAPLUS


CN Benzamide, N-[4-[[7-[[3-[[1,1-bis(hydroxymethyl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-90-1 CAPLUS


CN Benzamide, N-[4-[[7-[[3-[[1S)-1-(hydroxymethyl)-3-methylbutyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331773-91-2 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[[[(tetrahydro-2-furanyl)methyl]amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-92-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 331773-93-4 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[[2-(4-morpholinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-94-5 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-95-6 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-96-7 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[(1-methylethyl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-97-8 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(2-hydroxy-1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-98-9 CAPLUS

CN Benzamide, N-[4-[[7-[3-[[1-(hydroxymethyl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-99-0 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(2,3-dihydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-00-6 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[(2-methoxyethyl)amino]propoxy]-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331774-01-7 CAPLUS

CN Benzamide, N-[4-[[7-[3-[[2-(2-hydroxyethoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331774-02-8 CAPLUS

CN Benzamide, N- [4- [[7- [3- [(2-mercaptoethyl) amino] propoxy] -6-methoxy-4-quinazolinyl] amino] phenyl] - (9CI) (CA INDEX NAME)




RN 331774-03-9 CAPLUS

CN Benzamide, N-[4-[[7-[3-[[2-(ethylthio)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-04-0 CAPLUS

CN Benzamide, N-[4-[[7-[3-[[3-(diethylamino)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331774-05-1 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(3-ethoxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331774-06-2 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(3-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)



RN 331774-07-3 CAPLUS


CN Benzamide, N-[4-[[7-[3-[(5-hydroxypentyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-08-4 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-09-5 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[(5-methyl-1H-pyrazol-3-yl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-10-8 CAPLUS

CN Benzamide, N-[4-[[7-[3-[[2-hydroxycyclohexyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-11-9 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(1-hydroxyhexyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-12-0 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[[[(5-methyl-2-furanyl)methyl]amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-13-1 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-15-3 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[(3-thienylmethyl)amino]propoxy]-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331774-17-5 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331774-18-6 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[(2-thienylmethyl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-19-7 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-20-0 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331774-21-1 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331774-22-2 CAPLUS

CN Benzamide, N-[4-[[7-[3-(diethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331774-23-3 CAPLUS

CN Benzamide, N-[4-[[7-[3-bis(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-24-4 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-methyl(1-methyl-3-pyrrolidinyl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-25-5 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[methyl(2-(methylamino)-2-oxoethyl)amino]propoxy]-4-quinazolinyl]aminophenyl]- (9CI) (CA INDEX NAME)




RN 331774-26-6 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(2-oxo-1-piperazinyl)propoxy]-4-quinazolinyl]aminophenyl]- (9CI) (CA INDEX NAME)




RN 331774-27-7 CAPLUS

CN Benzamide, N- [4- [[6-methoxy-7- [3- [(tetrahydro-4-hydroxy-3-furanyl) amino]propoxy] -4-quinazolinyl] amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331774-28-8 CAPLUS

CN Benzamide, N- [4- [[6-methoxy-7- [3- (4-methyl-1-piperidinyl)propoxy] -4-quinazolinyl] amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331774-29-9 CAPLUS

CN Benzamide, N-[4-[[7-[3-(3,5-dimethyl-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-30-2 CAPLUS

CN Pentitol, 1,5-anhydro-2-[[3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]methylamino]-2,4-dideoxy-3-C-methyl- (9CI) (CA INDEX NAME)



RN 331774-31-3 CAPLUS


CN Benzamide, N-[4-[[7-[3-(2-cyclopenten-1-ylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-32-4 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(2S,4R)-4-hydroxy-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-33-5 CAPLUS


CN threo-Pentitol, 1,5-anhydro-3-[[3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]methylamino]-2,3-dideoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 331774-34-6 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(cyclobutylmethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-35-7 CAPLUS

CN Benzamide, N-[4-[[7-[3-(3-hydroxy-1-azetidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-36-8 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(2-cyanoethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-37-9 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[methyl[2-(4-morpholinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331774-38-0 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[4-(2-methoxyethyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331774-39-1 CAPLUS

CN Benzamide, N-[4-[[7-[3-(3,5-dimethyl-4-morpholinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-40-4 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-thiomorpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-41-5 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(2-methyl-1-piperidinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-42-6 CAPLUS

CN Benzamide, N-[4-[[7-[3-(2,6-dimethyl-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-43-7 CAPLUS

CN Benzamide, N-[4-[[7-[3-[2-(hydroxymethyl)-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-44-8 CAPLUS

CN Benzamide, N-[4-[[7-[3-(3-hydroxy-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-45-9 CAPLUS

CN Benzamide, N-[4-[[7-[3-(2,5-dihydro-1H-pyrrol-1-yl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 331774-46-0 CAPLUS


CN Benzamide, N-[4-[[7-[3-[bis(2-methoxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 331774-47-1 CAPLUS
 CN Benzamide, N-[4-[[7-[3-(4-hydroxy-1-piperidiny)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-48-2 CAPLUS
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[4-(1-methylethyl)-1-piperaziny]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-49-3 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[methyl[(tetrahydro-2-furanyl)methyl]amino]propoxy]-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)



RN 331774-50-6 CAPLUS


CN Benzamide, N-[4-[[7-[3-(4-acetyl-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)



RN 331774-51-7 CAPLUS


CN Benzamide, N-[4-[[7-[3-[(3R)-3-hydroxy-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-52-8 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[methyl(1-methyl-4-piperidinyl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-53-9 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]propoxy]-4-quinazolinyl]aminophenyl]- (9CI) (CA INDEX NAME)




RN 331774-54-0 CAPLUS

CN Benzamide, N-[4-[[7-[3-(hexahydro-4-methyl-1H-azepin-1-yl)propoxy]-6-methoxy-4-quinazolinyl]aminophenyl]- (9CI) (CA INDEX NAME)




RN 331774-55-1 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-56-2 CAPLUS

CN Benzamide, N-[4-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-57-3 CAPLUS


CN Benzamide, N-[4-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 331774-58-4 CAPLUS


CN Benzamide, N-[4-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-59-5 CAPLUS


CN Benzamide, N-[4-[[7-[3-[3-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-60-8 CAPLUS


CN Benzamide, N-[4-[[7-[3-[(2R,5R)-2,5-dimethyl-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 331774-62-0 CAPLUS
 CN Benzamide, N-[4-[[7-[(2R)-3-[[2-(dimethylamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-63-1 CAPLUS
 CN Benzamide, N-[4-[[7-[(2S)-3-[[2-(diethylamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-64-2 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[2-(2-hydroxyethoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-65-3 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-66-4 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-[[2-(ethylthio)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-67-5 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-[[3-(diethylamino)propyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-68-6 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-[(3-ethoxypropyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-69-7 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(3-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-70-0 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(5-hydroxypentyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-71-1 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(4-hydroxybutyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-72-2 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(5-methyl-1H-pyrazol-3-yl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-73-3 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[[1-(hydroxycyclohexyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-74-4 CAPLUS

CN Benzamide, N- [4- [[7- [(2R)-2-hydroxy-3- [[2- (2-thienyl) ethyl] amino] propoxy] - 6-methoxy-4-quinazolinyl] amino] phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-75-5 CAPLUS


CN Benzamide, N- [4- [[7- [(2R)-2-hydroxy-3- [[1- (hydroxymethyl) pentyl] amino] propoxy] - 6-methoxy-4-quinazolinyl] amino] phenyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-76-6 CAPLUS
CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-77-7 CAPLUS
CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[5-methyl-2-furanyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-78-8 CAPLUS
CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-79-9 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(3-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-80-2 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[(2,3-dihydroxypropyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-81-3 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-(cyclobutylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-82-4 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-83-5 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[3-(1H-imidazol-1-yl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-84-6 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-(cyclohexylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-85-7 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-[(cyclohexylmethyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-86-8 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 331774-87-9 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-88-0 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-[[1,1-bis(hydroxymethyl)propyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-89-1 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-[[1-ethyl-2-pyrrolidinyl)methyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-90-4 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[tetrahydro-2-furyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-91-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(2R)-3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-92-6 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[2-(4-morpholinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-93-7 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 331774-94-8 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-95-9 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-96-0 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-hydroxy-1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-97-1 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-(cyclopropylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-98-2 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-99-3 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-[[2-(acetylamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-00-9 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[2-(methylthio)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-01-0 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[2-(1-piperidinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-02-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2S)-3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 331775-03-2P 331775-04-3P 331775-05-4P
 331775-06-5P 331775-07-6P 331775-08-7P
 331775-09-8P 331775-10-1P 331775-11-2P
 331775-12-3P 331775-13-4P 331775-14-5P
 331775-15-6P 331775-16-7P 331775-17-8P
 331775-18-9P 331775-19-0P 331775-20-3P
 331775-21-4P 331775-22-5P 331775-23-6P
 331775-24-7P 331775-25-8P 331775-26-9P
 331775-27-0P 331775-28-1P 331775-29-2P
 331775-30-5P 331775-31-6P 331775-32-7P
 331775-33-8P 331775-34-9P 331775-35-0P
 331775-36-1P 331775-37-2P 331775-38-3P
 331775-39-4P 331775-40-7P 331775-41-8P
 331775-42-9P 331775-43-0P 331775-44-1P
 331775-45-2P 331775-46-3P 331775-50-9P
 331775-51-0P 331775-52-1P 331775-53-2P
 331775-54-3P 331775-56-5P 331775-57-6P
 331775-58-7P 331775-60-1P 331810-24-3P
 331825-58-2P 331825-60-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 331775-03-2 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-04-3 CAPLUS

CN Benzamide, N- [4- [[7- [(2S)-2-hydroxy-3- [[(1R)-1-(hydroxymethyl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-05-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2R)-3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-06-5 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]] - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 331775-07-6 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[[[(1R)-1-(hydroxymethyl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-08-7 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[[2-(dimethylamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-09-8 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[2-(2-hydroxyethoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-10-1 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-11-2 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[[2-(ethylthio)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-12-3 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[[3-(diethylamino)propyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-13-4 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[(3-ethoxypropyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]aminophenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-14-5 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(3-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]aminophenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-15-6 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(5-hydroxypentyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-16-7 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(4-hydroxybutyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-17-8 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(5-methyl-1H-pyrazol-3-yl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-18-9 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(1-hydroxycyclohexyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-19-0 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[2-(2-thienyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-20-3 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[1-(hydroxymethyl)pentyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-21-4 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-22-5 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[5-methyl-2-furanyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-23-6 CAPLUS

CN Benzamide, N- [4- [[7- [(2S)-2-hydroxy-3- [(3-hydroxy-2,2-dimethylpropyl)amino]propoxy] -6-methoxy-4-quinazolinyl] amino] phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-24-7 CAPLUS

CN Benzamide, N- [4- [[7- [(2R)-2-hydroxy-3- [(3-thienylmethyl)amino]propoxy] -6-methoxy-4-quinazolinyl] amino] phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-25-8 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-(cyclobutylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-26-9 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-27-0 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-(cyclohexylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-28-1 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[(cyclohexylmethyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-29-2 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-30-5 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[[1,1-bis(hydroxymethyl)propyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-31-6 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[[[1-ethyl-2-pyrrolidinyl]methyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-32-7 CAPLUS

CN Benzamide, N- [4- [[7- [(2S)-2-hydroxy-3- [[(tetrahydro-2-furanyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-33-8 CAPLUS

CN 4-Piperidinecarboxamide, 1- [(2S)-3- [[4- [[4- (benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-34-9 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[2-(4-morpholinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-35-0 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-36-1 CAPLUS

CN Benzamide, N- [4- [[7- [(2S)-2-hydroxy-3- [(3-hydroxy-1,1-dimethylpropyl) amino] propoxy] -6-methoxy-4-quinazolinyl] amino] phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-37-2 CAPLUS


CN Benzamide, N- [4- [[7- [(2S)-2-hydroxy-3- [(1-methylethyl) amino] propoxy] -6-methoxy-4-quinazolinyl] amino] phenyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-38-3 CAPLUS
CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-hydroxy-1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 331775-39-4 CAPLUS
CN Benzamide, N-[4-[[7-[(2S)-3-(cyclopropylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331775-40-7 CAPLUS
CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-41-8 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[[2-(acetylamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-42-9 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[[2-(methylthio)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-43-0 CAPLUS


CN Benzamide, N-[4-[[7-[(2R)-3-[bis(2-hydroxyethyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-44-1 CAPLUS

CN Phosphoric acid, 2-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 331775-45-2 CAPLUS

CN Phosphoric acid, 2-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 331775-46-3 CAPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[2-(phosphonoethoxy)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331775-50-9 CAPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[(1E)-3-oxo-3-(1-piperidinyl)-1-propenyl]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331775-51-0 CAPLUS


CN Benzamide, N-[4-[[7-(3-hydroxypropyl)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331775-52-1 CAPLUS

CN Benzamide, N-[4-[[7-[(1E)-3-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-3-oxo-1-propenyl]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 331775-53-2 CAPLUS
CN Benzamide, N-[4-[[7-(3-hydroxy-3-methyl-1-butynyl)-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)



RN 331775-54-3 CAPLUS
CN Benzamide, N-[4-[[7-(3-hydroxy-1-propynyl)-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331775-56-5 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[[4-(benzoylamino)phenyl]amino]-7-quinazolinyl] - (9CI) (CA INDEX NAME)




RN 331775-57-6 CAPLUS

CN 1-Piperidinepropanamide, N-[4-[[4-(benzoylamino)phenyl]amino]-7-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 331775-58-7 CAPLUS

CN Benzamide, N-[4-[[7-[[[(acetyloxy)acetyl]amino]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331775-60-1 CAPLUS


CN Methanesulfonamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 331810-24-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331825-58-2 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(4-hydroxycyclohexyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331825-60-6 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(4-hydroxycyclohexyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 330999-74-1, 4-(4-(N-Boc-amino)anilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline dihydrochloride 331776-52-4, 4-(4-(N-Boc-amino)anilino)-6-methoxy-7-(2,2,2-trifluoroethoxy)quinazoline 331776-55-7 331776-56-8 331776-57-9, 4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-hydroxyquinazoline trifluoroacetate 331776-58-0, 4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-benzyloxyquinazoline trifluoroacetate 331776-59-1 331776-60-4 331776-61-5, 4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-(4-piperidinoxy)quinazoline 331776-65-9, 4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-(2-bromoethoxy)quinazoline 331776-68-2, (R)-4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-(glycidyl)quinazoline 331776-69-3 331776-71-7 331776-79-5, 4-((4-(N-Benzoyl)amino)anilino)-7-nitroquinazoline
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 330999-74-1 CAPLUS


CN Carbamic acid, [4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, 1,1-dimethylethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 331776-52-4 CAPLUS

CN Carbamic acid, [4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 331776-55-7 CAPLUS


CN Benzamide, N-[4-[[6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 331776-56-8 CAPLUS

CN Benzamide, N-[4-[(6-hydroxy-7-methoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 331776-57-9 CAPLUS
 CN Benzamide, N-[4-[(7-hydroxy-6-methoxy-4-quinazolinyl)amino]phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 331772-15-7
 CMF C22 H18 N4 O3



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 331776-58-0 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 331772-11-3


CMF C29 H24 N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 331776-59-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331776-60-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331776-61-5 CAPLUS

CN Benzamide, N-[4-[[[6-methoxy-7-(4-piperidinyloxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331776-65-9 CAPLUS


CN Benzamide, N-[4-[[7-(2-bromoethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 331776-68-2 CAPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[(2R)-oxiranylmethyl]-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331776-69-3 CAPLUS

CN Phosphonic acid, [2-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 331776-71-7 CAPLUS

CN Methanesulfonic acid, trifluoro-, 4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl ester (9CI) (CA INDEX NAME)



RN 331776-79-5 CAPLUS

CN Benzamide, N-[4-[(7-nitro-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:228865 CAPLUS

DOCUMENT NUMBER: 134:266316

TITLE: Preparation of quinazoline derivatives, method of preparation and use in inhibiting aurora 2 kinase

INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021595	A1	20010329	WO 2000-GB3562	20000918
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2384284	AA	20010329	CA 2000-2384284	20000918
BR 2000014136	A	20020521	BR 2000-14136	20000918
EP 1218357	A1	20020703	EP 2000-962682	20000918
EP 1218357	B1	20050406		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003509498	T2	20030311	JP 2001-524974	20000918
EE 200200148	A	20030415	EE 2002-148	20000918
AT 292628	E	20050415	AT 2000-962682	20000918
ZA 2002001831	A	20030605	ZA 2002-1831	20020305
NO 2002001395	A	20020515	NO 2002-1395	20020320
BG 106535	A	20021229	BG 2002-106535	20020320

PRIORITY APPLN. INFO.:

GB 1999-22173

A 19990921

WO 2000-GB3562

W 20000918

OTHER SOURCE(S):

MARPAT 134:266316

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB I or a salt, ester, amide or prodrug thereof, a method for the preparation of I and the use of the claimed compds. for inhibiting aurora 2 kinase are claimed. These compds. are useful in the treatment of cancer. In I: X is O, or S, S(O) or S(O)₂ or NR₁₀ where R₁₀ is H or C₁-6 alkyl. R₅ is OR₁₁, NR₁₂R₁₃ or SR₁₁ where R₁₁, R₁₂ and R₁₃ are independently optionally substituted hydrocarbyl or optionally substituted heterocyclic groups, and R₁₂ and R₁₃ may addnl. form together with the N atom to which they are attached, an optionally substituted aromatic or nonarom. heterocyclic ring which may contain further heteroatoms. R₆ and R₇ are independently H or hydrocarbyl. R₈ and R₉ are independently H, halo, C₁-4 alkyl, C₁-4 alkoxy, C₁-4 alkoxyethyl, di(C₁-4alkoxy)methyl, C₁-4 alkanoyl, trifluoromethyl, cyano, amino, C₂-5 alkenyl, C₂-5 alkynyl, a Ph group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or nonarom. and may be saturated (linked via a ring C or N atom) or unsatd. (linked via a ring C atom), and which Ph, benzyl or heterocyclic group may bear on one or more ring C atoms up to 5 substituents selected from hydroxy, halo, C₁-3 alkyl, C₁-3 alkoxy, C₁-3 alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C₂-4 alkanoyl, C₁-4 alkanoylamino, C₁-4 alkoxyethyl, C₁-4 alkylthio, C₁-4 alkylsulfinyl, C₁-4 alkylsulfonyl, carbamoyl, N-C₁-4alkylcarbamoyl, N,N-di(C₁-4alkyl)carbamoyl, aminosulfonyl, N-C₁-4alkylaminosulfonyl, N,N-di(C₁-4alkyl)aminosulfonyl, C₁-4 alkylsulfonylamino, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halo, C₁-3 alkyl, C₁-3 alkoxy, C₁-3 alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C₁-4alkoxyethyl. R₁, R₂, R₃, R₄ are independently halo, cyano, nitro, C₁-3 alkylthio, -N(OH)R₁₄ (R₁₄ is H, or C₁-3 alkyl), or R₁₆X₁- (X₁ represents a direct bond, -O-, -CH₂-, -OC(O)-, -C(O)-, -S-, -SO-, -SO₂-, -NR₁₇C(O)-, -C(O)NR₁₈-, -SO₂NR₁₉-, -NR₂₀SO₂- or -NR₂₁- (R₁₇, R₁₈, R₁₉, R₂₀ and R₂₁ each independently represents H, C₁-3 alkyl or C₁-3alkoxyethyl), and R₁₆ is H, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy). A method for preparing I comprises reacting II where X, R₈ and R₉ are as defined above, R_{1'}, R_{2'}, R_{3'}, R_{4'} are groups R₁, R₂, R₃, R₄ as defined above resp., or precursors thereof; and R₅ is a leaving group, with HCR₆:CR₇C(O)R_{5'}, where R₆ and R₇ are as defined above, R_{5'} is a group R₅ as defined above or a precursor group therefore; and thereafter if desired or necessary, converting any precursor groups R_{1'}, R_{2'}, R_{3'}, R_{4'} or R_{5'} to groups R₁, R₂, R₃, R₄ or R₅ resp., or changing a group R₅ to a different such group. The compds. of the invention inhibit the serine/threonine kinase activity of the aurora 2 kinase and thus inhibit the cell cycle and cell proliferation. Procedures for assessing these properties are described and test results are given for (E)-4-[4-(2-(3-methylcyclohexylaminocarbonyl)ethenyl)anilino]-6,7-dimethoxyquinazoline.

IC

ICM C07D239-94

ICS A61K031-517; A61P035-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:228864 CAPLUS

DOCUMENT NUMBER: 134:252355

TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors

INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021594	A1	20010329	WO 2000-GB3556	20000918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2384282	AA	20010329	CA 2000-2384282	20000918
BR 2000014133	A	20020611	BR 2000-14133	20000918
TR 200200749	T2	20020621	TR 2002-200200749	20000918
EP 1218356	A1	20020703	EP 2000-962677	20000918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509497	T2	20030311	JP 2001-524973	20000918
EE 200200149	A	20030415	EE 2002-149	20000918
AU 763242	B2	20030717	AU 2000-74325	20000918
ZA 2002001833	A	20030605	ZA 2002-1833	20020305
BG 106491	A	20021229	BG 2002-106491	20020307
NO 2002001401	A	20020521	NO 2002-1401	20020320
PRIORITY APPLN. INFO.:			GB 1999-22152	A 19990921
			GB 1999-22156	A 19990921
			GB 1999-22159	A 19990921
			WO 2000-GB3556	W 20000918
OTHER SOURCE(S):			MARPAT 134:252355	
GI				



AB Title compds. (I) [wherein X = O, S, SO, SO₂, NH, or NR₈; R₈ = H or alkyl; Ra = (un)substituted 3-quinolinyl or Ph; R₁-R₄ = independently halo, CN, NO₂, alkylsulfanyl, N(OH)R₁₂, or R₁₄X₁; R₁₂ = H or alkyl; X₁ = a direct bond, O, CH₂, OC(O), CO, S, SO, SO₂, or (un)substituted NHCO, CONH, SO₂NH, NHSO₂, or NH; R₁₄ = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, 4-phenoxyaniline•HCl and 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline were refluxed in i-PrOH to yield II (86%). The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.069 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 2.89 μM and reduced BrdU incorporation into cellular DNA by 50% at 3.68 μM.

IC ICM C07D239-94

ICS C07D401-12; A61P035-00; A61K031-517

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT 13790-39-1P, 4-Chloro-6,7-dimethoxyquinazoline 13794-72-4P, 6,7-Dimethoxy-3,4-dihydroquinazolin-4-one 16665-38-6P, 2-(Hydroxymethyl)-4-methoxypyridine 29681-43-4P 35283-10-4P 42508-74-7P, 2-(Hydroxymethyl)-4-picoline 108479-25-0P, Ethyl 3-methoxy-4-(3-morpholinopropoxy)benzoate 162364-72-9P, 4-Chloro-6-methoxy-7-benzyloxyquinazoline 179687-94-6P, 3-Fluoro-4-(2-pyridylmethoxy)aniline 179687-96-8P, 3-Methyl-4-[(4-methoxy-2-pyridyl)methoxy]aniline 179687-97-9P, 3-Methyl-4-[(6-methyl-2-pyridyl)methoxy]aniline 179688-01-8P, 7-Benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one 179688-28-9P 179688-53-0P, 6-Acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one 179688-54-1P, 4-Chloro-6-acetoxy-7-methoxyquinazoline hydrochloride 196194-62-4P, 6-Methoxy-7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one 230955-75-6P, 4-Chloro-6-acetoxy-7-methoxyquinazoline 330999-74-1P, 4-[4-(N-Boc-amino)anilino]-6-methoxy-7-(3-morpholinopropoxy)quinazoline dihydrochloride 330999-75-2P, 3-Methyl-4-[(4-methyl-2-pyridyl)methoxy]aniline 330999-76-3P, 2-[(4-Methyl-2-pyridyl)methoxy]-5-nitrotoluene 330999-77-4P, 2-[(4-Methoxy-2-pyridyl)methoxy]-5-nitrotoluene 330999-78-5P, 2-[(6-Methyl-2-pyridyl)methoxy]-5-nitrotoluene 330999-79-6P, 4-Chloro-6-methoxy-7-(2,2,2-trifluoroethoxy)quinazoline 330999-80-9P, Ethyl 4-(2,2,2-

trifluoroethoxy)-3-methoxybenzoate 330999-81-0P, Ethyl
 3-methoxy-4-(2,2,2-trifluoroethoxy)-6-nitrobenzoate 330999-82-1P, Ethyl
 3-methoxy-4-(2,2,2-trifluoroethoxy)-6-aminobenzoate 330999-83-2P,
 6-Methoxy-7-(2,2,2-trifluoroethoxy)-3,4-dihydroquinazolin-4-one
 330999-84-3P, Ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-nitrobenzoate
 330999-85-4P, Ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-aminobenzoate
 330999-86-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of 4-substituted quinazoline aurora 2 kinase
 inhibitors for treatment of cancer and other proliferative diseases)


IT 330999-74-1P, 4-[4-(N-Boc-amino)anilino]-6-methoxy-7-(3-
 morpholinopropoxy)quinazoline dihydrochloride

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of 4-substituted quinazoline aurora 2 kinase
 inhibitors for treatment of cancer and other proliferative diseases)

RN 330999-74-1 CAPLUS

CN Carbamic acid, [4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-
 quinazolinyl]amino]phenyl]-, 1,1-dimethylethyl ester, dihydrochloride
 (9CI) (CA INDEX NAME)



● 2 HCl

REFERENCE COUNT:

12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

THIS PAGE BLANK (USPTO)

Search history

Truong 10_088814

10/18/2005

> d his full

(FILE 'HOME' ENTERED AT 09:15:52 ON 18 OCT 2005)

FILE 'REGISTRY' ENTERED AT 09:15:58 ON 18 OCT 2005

D SAV
ACT TRU854STRA/A

L1 STR
L2 5754 SEA SSS FUL L1

ACT TRU854RNS/A

L3 141 SEA ABB=ON PLU=ON (101-53-1/BI OR 101-59-7/BI OR 101-79-1/BI
OR 103-16-2/BI OR 103-63-9/BI OR 104-13-2/BI OR 104-96-1/BI OR
1066-54-2/BI OR 1073-72-9/BI OR 108-47-4/BI OR 108479-25-0/BI
OR 109-70-6/BI OR 1122-71-0/BI OR 1135-12-2/BI OR 123-30-8/BI
OR 129912-30-7/BI OR 13790-39-1/BI OR 13794-72-4/BI OR
139-59-3/BI OR 162364-72-9/BI OR 16665-38-6/BI OR 168835-91-4/B
I OR 1689-82-3/BI OR 17362-17-3/BI OR 179246-62-9/BI OR
179687-94-6/BI OR 179687-96-8/BI OR 179687-97-9/BI OR 179688-01
-8/BI OR 179688-28-9/BI OR 179688-53-0/BI OR 179688-54-1/BI OR
179688-83-6/BI OR 183319-34-8/BI OR 183322-25-0/BI OR 188829-39
-2/BI OR 18979-50-5/BI OR 18979-53-8/BI OR 196194-62-4/BI OR
196195-13-8/BI OR 230955-75-6/BI OR 2359-60-6/BI OR 24900-79-6/
BI OR 25236-64-0/BI OR 2524-67-6/BI OR 2713-33-9/BI OR
2835-96-3/BI OR 29558-77-8/BI OR 29681-43-4/BI OR 330999-28-5/B
I OR 330999-29-6/BI OR 330999-30-9/BI OR 330999-31-0/BI OR
330999-32-1/BI OR 330999-33-2/BI OR 330999-34-3/BI OR 330999-35
-4/BI OR 330999-36-5/BI OR 330999-37-6/BI OR 330999-38-7/BI OR
330999-39-8/BI OR 330999-40-1/BI OR 330999-41-2/BI OR 330999-42
-3/BI OR 330999-43-4/BI OR 330999-44-5/BI OR 330999-45-6/BI OR
330999-46-7/BI OR 330999-47-8/BI OR 330999-48-9/BI OR 330999-49
-0/BI OR 330999-50-3/BI OR 330999-51-4/BI OR 330999-52-5/BI OR
330999-53-6/BI OR 330999-54-7/BI OR 330999-55-8/BI OR 330999-56
-9/BI OR 330999-57-0/BI OR 330999-58-1/BI OR 330999-59-2/BI OR
330999-60-5/BI OR 330999-61-6/BI OR 330999-62-7/BI OR 330999-63
-8/BI OR 330999-64-9/BI OR 330999-65-0/BI OR 330999-66-1/BI OR
330999-67-2/BI OR 330999-68-3/BI OR 330999-69-4/BI OR 330999-70
-7/BI OR 330999-71-8/BI OR 330999-72-9/BI OR 330999-73-0/BI OR
330999-74-1/BI OR 330999-75-2/BI OR 330999-76-3/BI OR 330999-77
-4/BI OR 330999-78-5/BI OR 330999-79-6/BI OR 330999-80-9/BI OR
330999-81-

L4 STRUCTURE UPLOADED
L5 36 SEA SUB=L2 SSS SAM L4
D SCA
L6 716 SEA SUB=L2 SSS FUL L4
SAVE L6 TRU814STRE/A

FILE 'CAPLUS' ENTERED AT 09:20:58 ON 18 OCT 2005

L7 19 SEA ABB=ON PLU=ON L6
D SCA TI
E KEEN N/AU
L8 296 SEA ABB=ON PLU=ON KEEN N?/AU
L9 66 SEA ABB=ON PLU=ON MORTLOCK A?/AU
L10 391 SEA ABB=ON PLU=ON JUNG F?/AU
L11 74 SEA ABB=ON PLU=ON BREWSTER A?/AU
L12 1 SEA ABB=ON PLU=ON L8 AND L9 AND L10 AND L11

THIS PAGE BLANK (USPTO)

L13 14 SEA ABB=ON PLU=ON (L8 AND (L9 OR L10 OR L11)) OR (L9 AND
(L10 OR L11)) OR (L10 AND L11)
D SCA TI L12

L14 16 SEA ABB=ON PLU=ON L7 NOT L13

FILE 'CAPLUS' ENTERED AT 09:33:32 ON 18 OCT 2005
D QUE L13

FILE 'REGISTRY' ENTERED AT 09:34:57 ON 18 OCT 2005

L15 ANALYZE PLU=ON L6 1-716 LC : 9 TERMS
D

FILE 'TOXCENTER, USPATFULL, USPAT2, CASREACT, BIOSIS, CAOLD' ENTERED AT
09:39:52 ON 18 OCT 2005

L16 30 SEA ABB=ON PLU=ON L6

FILE 'CAPLUS' ENTERED AT 09:41:03 ON 18 OCT 2005

L17 1 SEA ABB=ON PLU=ON L13 AND L12

FILE 'CAPLUS' ENTERED AT 09:41:26 ON 18 OCT 2005
D QUE L13

L18 14 SEA ABB=ON PLU=ON L13 OR (L13 AND L7)

FILE 'REGISTRY' ENTERED AT 09:44:36 ON 18 OCT 2005

FILE 'CAPLUS' ENTERED AT 09:44:49 ON 18 OCT 2005
D QUE NOS L18
D IBIB ABS HITIND HITSTR L18 1-14

FILE 'REGISTRY' ENTERED AT 09:52:30 ON 18 OCT 2005

FILE 'CAPLUS' ENTERED AT 09:52:39 ON 18 OCT 2005
D STAT QUE L7

FILE 'TOXCENTER, USPATFULL, USPAT2, CASREACT, BIOSIS, CAOLD' ENTERED AT
09:53:38 ON 18 OCT 2005
D STAT QUE NOS L16

FILE 'CAPLUS, TOXCENTER, USPATFULL, USPAT2, CASREACT, BIOSIS, CAOLD'
ENTERED AT 09:54:53 ON 18 OCT 2005

L19 30 DUP REM L7 L16 (19 DUPLICATES REMOVED)
ANSWERS '1-19' FROM FILE CAPLUS
ANSWER '20' FROM FILE TOXCENTER
ANSWERS '21-25' FROM FILE USPATFULL
ANSWERS '26-29' FROM FILE BIOSIS
ANSWER '30' FROM FILE CAOLD

L20 26 SEA ABB=ON PLU=ON L19 NOT L13

FILE 'REGISTRY' ENTERED AT 09:57:17 ON 18 OCT 2005

FILE 'CAPLUS' ENTERED AT 09:57:26 ON 18 OCT 2005

FILE 'REGISTRY' ENTERED AT 09:57:32 ON 18 OCT 2005

FILE 'CAPLUS' ENTERED AT 09:57:34 ON 18 OCT 2005
D STAT QUE L14

FILE 'TOXCENTER, USPATFULL, USPAT2, CASREACT, BIOSIS, CAOLD' ENTERED AT
09:58:40 ON 18 OCT 2005

THIS PAGE BLANK (USPTO)

D STAT QUE NOS L16

FILE 'CAPLUS, TOXCENTER, USPATFULL, USPAT2, CASREACT, BIOSIS, CAOLD'
ENTERED AT 10:02:26 ON 18 OCT 2005

L21 30 DUP REM L14 L16 (16 DUPLICATES REMOVED)
ANSWERS '1-16' FROM FILE CAPLUS
ANSWERS '17-20' FROM FILE TOXCENTER
ANSWERS '21-25' FROM FILE USPATFULL
ANSWERS '26-29' FROM FILE BIOSIS
ANSWER '30' FROM FILE CAOLD

FILE 'STNGUIDE' ENTERED AT 10:02:46 ON 18 OCT 2005

FILE 'CAPLUS, TOXCENTER, USPATFULL, BIOSIS, CAOLD' ENTERED AT 10:04:35 ON
18 OCT 2005

D IBIB ABS HITSTR L21 1-16

FILE 'STNGUIDE' ENTERED AT 10:04:49 ON 18 OCT 2005

FILE 'CAPLUS, TOXCENTER, USPATFULL, BIOSIS, CAOLD' ENTERED AT 10:04:53 ON
18 OCT 2005

D IALL L21 17-20

FILE 'STNGUIDE' ENTERED AT 10:04:54 ON 18 OCT 2005

FILE 'CAPLUS, TOXCENTER, USPATFULL, BIOSIS, CAOLD' ENTERED AT 10:05:01 ON
18 OCT 2005

D IBIB ABS HITSTR L21 21-25

FILE 'STNGUIDE' ENTERED AT 10:05:10 ON 18 OCT 2005

FILE 'CAPLUS, TOXCENTER, USPATFULL, BIOSIS, CAOLD' ENTERED AT 10:05:13 ON
18 OCT 2005

D IALL 26-30

FILE 'STNGUIDE' ENTERED AT 10:05:13 ON 18 OCT 2005

FILE 'CAPLUS, TOXCENTER, USPATFULL, BIOSIS, CAOLD' ENTERED AT 10:06:13 ON
18 OCT 2005

D HITSTR L21 30

FILE 'STNGUIDE' ENTERED AT 10:06:16 ON 18 OCT 2005

FILE 'CAPLUS, TOXCENTER, USPATFULL, BIOSIS, CAOLD' ENTERED AT 10:09:33 ON
18 OCT 2005

D IALL HITSTR L21 26-30

FILE 'STNGUIDE' ENTERED AT 10:09:33 ON 18 OCT 2005

FILE 'STNGUIDE' ENTERED AT 10:10:22 ON 18 OCT 2005

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 OCT 2005 HIGHEST RN 865410-76-0

THIS PAGE BLANK (USPTO)

DICTIONARY FILE UPDATES: 17 OCT 2005 HIGHEST RN 865410-76-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE CAPLUS

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 Oct 2005 VOL 143 ISS 17
FILE LAST UPDATED: 17 Oct 2005 (20051017/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE TOXCENTER

FILE COVERS 1907 TO 11 Oct 2005 (20051011/ED)

This file contains CAS Registry Numbers for easy and accurate substance
identification.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TOXCENTER has been enhanced with new files segments and search fields.
See HELP CONTENT for more information.

THIS PAGE BLANK (USPTO)

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary. See <http://www.nlm.nih.gov/mesh/> and http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html for a description of changes.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 13 Oct 2005 (20051013/PD)
FILE LAST UPDATED: 13 Oct 2005 (20051013/ED)
HIGHEST GRANTED PATENT NUMBER: US6954941
HIGHEST APPLICATION PUBLICATION NUMBER: US2005229280
CA INDEXING IS CURRENT THROUGH 13 Oct 2005 (20051013/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 13 Oct 2005 (20051013/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPAT2

FILE COVERS 2001 TO PUBLICATION DATE: 13 Oct 2005 (20051013/PD)
FILE LAST UPDATED: 13 Oct 2005 (20051013/ED)
HIGHEST GRANTED PATENT NUMBER: US2005054189
HIGHEST APPLICATION PUBLICATION NUMBER: US2005229256
CA INDEXING IS CURRENT THROUGH 13 Oct 2005 (20051013/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 13 Oct 2005 (20051013/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2005

USPAT2 is a companion file to USPATFULL. USPAT2 contains full text of the latest US publications, starting in 2001, for the inventions covered in USPATFULL. USPATFULL contains full text of the original published US patents from 1971 to date and the original applications from 2001. In addition, a USPATFULL record for an invention contains a complete list of publications that may be searched in standard search fields, e.g., /PN, /PK, etc.

USPATFULL and USPAT2 can be accessed and searched together through

THIS PAGE BLANK (USPTO)

the new cluster USPATALL. Type FILE USPATALL to enter this cluster.

Use USPATALL when searching terms such as patent assignees, classifications, or claims, that may potentially change from the earliest to the latest publication.

FILE CASREACT

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 16 Oct 2005 VOL 143 ISS 16

New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
*****
*
*      CASREACT now has more than 9.2 million reactions
*
*****
```

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 12 October 2005 (20051012/ED)

FILE RELOADED: 19 October 2003.

FILE CAOLD

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Oct 14, 2005 (20051014/UP).

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)